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Abstract 
 
This dissertation is comprised of 4 distinct projects, all of which related to the 
pathogenesis of lung fibrosis in mice or humans.  We tested whether Pseudomonas aeruginosa, 
or Influenza A, (H1N1) could augment bleomycin-induced fibrosis, yet found neither of these 
agents had the exacerbating effects of murine gamma-herpesvirus (γHV-68). γHV-68 augmented 
fibrosis by uniquely causing epithelial cell apoptosis. 
We also explored the role the matricellular protein, periostin, played in augmenting lung 
fibrosis when produced in circulating fibrocytes. We demonstrated fibrocytes act via paracrine 
actions rather than differentiation to lung fibroblasts.  Wild-type (WT) fibroblasts were treated 
with conditioned medium from fibrocytes from bleomycin-treated WT or periostin
-/-
 mice. We 
saw less α-smooth muscle actin expression in cells treated with medium from periostin-/- 
fibrocytes. In vitro analysis demonstrated co-regulation of mesenchymal activation by TGFβ and 
periostin and indicated beta 1 integrin as a potential receptor for periostin on fibrocytes.  
Furthermore, periostin influenced production of connective tissue growth factor from fibrocytes.  
Treatment of WT lung mesenchymal cells with periostin led to increased X-linked 
inhibitor of apoptosis (XIAP) protein expression. TGF-β1 and bleomycin treatments increased 
XIAP and cellular IAP (cIAP) 1 and 2 in murine lungs and mesenchymal cells.  Functional 
blockade of XIAP and the cIAPs with AT-406, an orally bioavailable, inhibitor of apoptosis 
(IAP) antagonist abrogated bleomycin-induced lung fibrosis when given both prophylactically 
and therapeutically.  Surprisingly, we compared fibrosis in XIAP deficient mice (XIAP
-/y
) and 
 xv 
littermate controls but found no difference.  XIAP
-/y
 mesenchymal cells had increased resistance 
to Fas-mediated apoptosis, but AT-406 treatment restored sensitivity to Fas-mediated apoptosis 
in XIAP
-/y
 mesenchymal cells in vitro and increased apoptosis of mesenchymal cells in vivo 
indicating that the increased apoptosis resistance in XIAP
-/y
 mesenchymal cells was the result of 
increased cIAP expression.  These results highlight the potential usefulness of AT-406 as a 
treatment for lung fibrosis in vivo. 
Biomarkers in human idiopathic pulmonary fibrosis (IPF) would be clinically valuable. 
We used an unbiased proteomic approach to identify a six-analyte index, scaled 0 to 11, based on 
markers of immune function, proteolysis and angiogenesis [high levels of ficolin-2 (FCN2), 
cathepsin-S (Cath-S), legumain (LGMN) and soluble vascular endothelial growth factor receptor 
2 (VEGFsR2), but low levels of inducible T cell costimulator (ICOS) or trypsin 3 (TRY3)] that 
predicted better progression-free survival over 80 weeks in IPF when measured using aptamers 
in plasma near time of diagnosis.  This index could be useful for clinical decision making in IPF. 
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Chapter 1: Background and Introduction 
 
The work reported in this dissertation covered four distinct projects which all related to 
the pathogenesis of lung fibrosis.   In particular, this work explored bacterial and viral infections 
for their ability to exacerbate murine models of lung fibrosis, the ability of the matricellular 
protein, periostin, to influence fibrosis, particularly when secreted from circulating fibrocytes, 
and determined that therapeutic targeting of inhibitor of apoptosis proteins can have benefit in 
the murine model of bleomycin-induced fibrosis.  Finally, biomarkers in patients with IPF were 
studied in an attempt to define pathological pathways for further exploration.  The following 
sections briefly outline the background material related to all of these projects, and highlight 
much of what is known and not known about the pathogenesis of lung fibrosis. 
 
General Background on Pulmonary Fibrosis  
 
Idiopathic Pulmonary Fibrosis (IPF): Epidemiology, Diagnosis, Pathogenesis and Treatment  
IPF is a chronic and progressive lung disorder characterized by aberrant deposition of 
extracellular matrix (ECM) leading to extensive lung remodeling (1). IPF accounts for about 
20% of all cases of interstitial lung disease (ILD) and is the most frequent and severe disease 
among the idiopathic interstitial pneumonias.  It has no known cause and currently has no cure 
but is characterized by inflammation and fibrosis (2). 
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Epidemiology 
IPF has a poor prognosis with a 20% 5 year survival rate (3). The available registry data 
suggests IPF accounts for 17-37% of all ILD diagnoses (4, 5). Understanding IPF epidemiology 
is hindered by the diverse definition of IPF including cases diagnosed before the 2000 consensus 
statement on IPF(6).   Past studies have used both diagnostic and death registries as well as 
surveys of clinicians with varying degree of specialties and the results are not easily comparable.  
Research thus far shows that prevalence and incidence of IPF is increasing worldwide, 
and is now similar to other conditions such as stomach, liver, testicular, and cervical cancer (7).  
For example, a study collecting data from US Medicare beneficiaries 65 years or older between 
2001 and 2011 showed the overall range and incidence of IPF to be between 200 and 500 cases 
per 100,000 in the population, with incidence remaining stable at 93.7 cases per 100,000/year but 
the prevalence appeared to be on the rise (8). In the United Kingdom, a study retrieving cases 
from a longitudinal primary care database first reported incidence of the disease as 4.6 per 
100,000/year between 1993 and 2003 (9). However, a higher incidence of 7.4 per 100,000/year 
was reported in a follow-up study using data between 2000 and 2009 (10).  There have also been 
some epidemiologic studies in Asian communities. A Japanese study reported prevalence and 
incidence of IPF to be 10.0 and 2.23 per 100,000/year respectively (11). Most of the data 
reported was done predominantly in males and the increased frequency with increasing age was 
also confirmed in these studies.  
Overall, the data summarized here suggest an increasing prevalence and stable or 
increasing incidence of IPF in western countries. Further analysis of the data analyzing sex and 
age showed higher prevalence and incidence rates among men, increasing with age and shorter 
survival time after diagnosis (8). 
 3 
 
Diagnosis 
IPF mainly occurs in adults 60 years or older and is more prevalent in men (12).  The 
predominant symptom early in the disease is shortness of breath during activity; however, during 
advanced disease this also occurs at rest. The prognosis of IPF is poor, with median survival rate 
of 3-5 years from the time of diagnosis (13). The diagnosis of IPF requires the presence of a 
typical radiologic and pathologic pattern called usual interstitial pneumonia (UIP) (12). 
Radiographically, UIP is characterized by subplueral, basal-predominant, reticular abnormalities 
and the histology shows patchy involvement of the lung parenchyma showing fibrosis and 
honeycombing in a predominantly subplueral/paraseptal distribution as well as the presence of 
fibroblastic foci (12).  
In the absence of a definite UIP pattern on high-resolution computed tomography 
(HRCT), (Figure 1) and after exclusion of systemic disease causing fibrosis, a diagnosis of IPF 
is possible with a surgical lung biospsy. Bronchoalveolar lavage can also be a useful tool to 
exclude other fibrotic lung diseases presenting with UIP pattern, such a hypersensitivity 
pneumonitis (14). A major challenge in achieving an accurate diagnosis of IPF involves cases 
where a surgical lung biopsy is needed, because the risk sometimes outweighs the benefits, 
especially when the disease is more advanced or in older persons. 
In recent years, a new technique using flexible cryoprobes has been developed to use in 
bronchoscopic lung biopsy. In patients with suspected diffuse parenchymal lung disease, 
bronchoscopy cryobiopsy is a minimally invasive approach to obtain lung tissue with high 
diagnostic yield (15, 16). It has been demonstrated that the accuracy of the diagnosis of IPF 
increases with multidisciplinary discussion among pulmonologists, radiologists and pathologists 
experienced in the diagnosis of ILD (12). Undoubtedly, the definition of radiological UIP as 
 4 
reported in the current guidelines is not without flaws but as new and more targeted therapies are 
being developed, tools for stratification of patients are necessary to be able to personalize 
treatments to those patients who could benefit the most as well as help with better diagnosis. 
 
 
Figure 1: High Resolution Axial CT images of Normal and IPF lungs 
Arrow indicates UIP predominant basal abnormalities with sub-pleural honeycombing (adapted 
from www.PILOTforIPF.org) 
 
 
Pathogenesis and Treatment 
IPF is a fatal lung disease. The natural history is variable and unpredictable. Most 
patients with IPF demonstrate a gradual worsening of lung function over several years; however, 
some patients remain relatively stable or decline rapidly. Patients may also experience episodes 
of acute respiratory worsening despite previous stability (17, 18) (Figure 2). The paradigm about 
disease pathogenesis has shifted from the idea that IPF is a result of chronic inflammation to a 
paradigm of disordered fibroblast proliferation and alveolar epithelial cell dysfunction (19). The 
inflammatory response in IPF is thought to closely resemble a Th2-type immune response. There 
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are eosinophils, mast cells and increased amounts of the Th2 cytokines, interleukin 4 and 
interleukin-13 (20-24).  
In murine models of lung disease, animals with a Th2 response were more prone to 
pulmonary fibrosis following lung injury than those with a predominantly Th1 response (22, 25, 
26). However, the current model regarding the pathogenesis of IPF implies aberrant fibrosis as a 
consequence of recurrent injury to alveolar epithelial cells in a susceptible host (27, 28). The 
excessive deposition of ECM with irreversible lung remodeling and honeycombing is likely to be 
the result of many processes.  
Gene polymorphisms and transcriptional changes are linked to the inability of epithelial 
cells to respond appropriately to repetitive insults such as infections, chronic aspiration, tobacco, 
or mechanical stress (29). Abnormal telomere shortening, as well as epigenetic mechanisms 
involving DNA methylation, histone tail modification, and dysregulation of microRNA 
expression take place in aging lungs leading to loss of epithelial integrity and epithelial 
senescence (27). In an attempt to restore functional integrity, the injured Type II alveolar 
epithelial cells (AECs) aberrantly release cytokines and growth factors, matrix 
metalloproteinases (MMPs), matricellular proteins and pro-coagulant mediators, which promote 
the recruitment and activation of apoptosis-resistant fibroblasts, the key players in fibrotic tissue 
remodeling (27, 30).  
There is no proven pharmacologic cure for IPF. The results of the PANTHER-IPF trial, a 
randomized, three-arm trial of prednisone, azathioprine, and N-acetylcysteine (NAC) in 
combination, NAC alone or placebo, showed no effect of NAC monotherapy on the rate of 
change in forced vital capacity (FVC) in patients with IPF over a 60-week period (31).  Sadly, 
the triple arm therapy actually showed worse outcomes for patients and the triple-arm therapy 
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was stopped early(32).  The efficacy of two approved anti-fibrotic therapies, pirfenidone 
(Esbriet) and nintedanib (OFEV), in slowing progression of IPF was confirmed by the Phase III 
ASCEND trial (33) and the twin Phase III INPULSIS-1 and -2 trials (34), respectively. Based on 
the results from these trials, in patients with IPF and mild or moderate impairment in FVC, both 
pirfenidone and nintedanib improved FVC by approximately 50% in 1 year, with acceptable 
safety profiles. This led to the approval of both medications for treatment for IPF in the United 
States in 2014 and to approval of nintedanib in Europe at the beginning of 2015.  
The recently updated ATS/ERS/JRS/ALAT clinical practice guideline gives conditional 
recommendations for use of nintedanib and pirfenidone in the majority of patients with IPF (35).  
However, neither of these treatments can actually halt IPF progression, and to do that, we need a 
better understanding of the disease pathogenesis.   The following sections will describe some of 
the different cell types, cytokines and chemokines that contribute to the pathogenesis and 
progression of the disease.  
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Figure 2: The natural history of IPF.  (Adapted from (36)).  
The disease is very rapid is some patients (Accelerated), some patients show relative stability 
with episodes of acute worsening (acute exacerbations) and most patients present with a slow 
progression that eventually results in chronic respiratory failure.  Patients who develop infections 
generally have a disease course that mimics acute exacerbations of unknown cause. 
 
Immune Responses in the Elderly 
Changes in the immune response during aging include predisposition for increased 
production of proinflammatory mediators by macrophages (37). Preclinical studies in mice have 
shown that aged animals have an exaggerated lung inflammatory response to inhaled particles 
and ozone compared to young mice (38). Bronchoalveolar lavage fluid (BALF) from young and 
old healthy patients showed increased numbers of neutrophils in the lungs of older individuals 
suggesting that low-grade inflammation exists in the airspaces of normal, healthy older adults 
(39, 40). Shrinking T cell repertoire is a well-recognized phenomenon in humans and animals 
(39). Normal aging is associated with a shift in T lymphocytes from a predominantly Th1 
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phenotype to a Th2 phenotype that is evident in sickly older individuals. The well recognized 
increased susceptibility to respiratory infection and decreased efficacy of vaccination in older 
people are consequences of the aging immune system (41). Th2 cytokines promote expression of 
profibrotic factors and Th2-biased animals are susceptible to lung injury and fibrosis (42). 
Humans with chronic fibrotic lung disease also demonstrate a Th2-biased phenotype (43, 44). 
 
Aging and Lung Fibrosis 
IPF is an age-related disease. The incidence and prevalence of IPF increases almost 
exponentially with each decade of life with the majority of patients older than 60 years with a 
mean age of 66 years at the time of diagnosis (45).  Aging is characterized by progressive loss of 
functional integrity leading to increased susceptibility to diseases and death. Recently nine 
pivotal hallmarks of aging were described; genomic instability, telomere shortening, epigenetic 
alterations, loss of proteastasis, mitochondrial dysfunction, cellular senescence, stem cell 
exhaustion and altered intercellular communication (46). How these pathways contribute to the 
development of IPF is still unclear. The aging process is normally accompanied by accumulation 
of nuclear and mitochondrial DNA damage (47, 48). There is strong evidence supporting 
microsatellite DNA instability and loss of heterozygosity in IPF (49). Similarly, abnormal 
shortening of telomeres, which are highly susceptible to age-related deterioration, impaired 
autophagy, dysfunctional mitochondria, excessive reactive oxygen species (ROS) production and 
mitochondrial-mediated AEC apoptosis have all been described in IPF (50-52). Cell cycle arrest 
coupled to a variety of phenotypic changes is common in the alveolar epithelium of IPF lungs as 
well (51).  
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Likewise, immunosenescence, an age-related decline of immunocompetence 
characterized by expansion of CD4+CD8- T cells and the presence of autoantibodies was 
observed in some IPF patients (53, 54). Based on these data, one concept regarding the 
pathogenesis of IPF suggests that the following changes are critical for the development of 
disease: 1) excessive and unresolved ER stress and mitochondrial dysfunction enhance an 
apoptotic response in the AECs and 2) abnormal changes in the telomeres result in an inability to 
regenerate normal epithelium. It is also possible that immunosenescence increases the likelihood 
of infection-related exacerbation in aged individuals. 
Most of the preclinical animal models of lung fibrosis use young mice, however in an age-
related model of persistent fibrosis, data suggest that in response to lung injury, myofibroblasts 
from young mice manifest transient senescence and apoptosis susceptibility that permits fibrosis 
resolution. Alternatively, in the context of aging, myofibroblasts acquire a sustained senescent 
and apoptosis resistant phenotype that impairs the resolution of fibrosis (55). The authors also 
demonstrated that established fibrosis in the lungs of aged mice was at least partially reversed by 
administration of GKT137831, a small molecule NOx1/NOx4 dual inhibitor similar to the effects 
of NOx4-targeted siRNA (55). 
 A more recent study compared the development of lung pathology in both young and aged 
mice (2 months and 18 months of age, respectively) after pulmonary injury and proposed a 
mechanism to explain the increased prevalence of IPF and persistent fibrosis in older patients 
(55). Both groups of mice showed similar levels of collagen deposition 3 weeks after injury, 
which demonstrated that the initial fibrogenic healing response was intact and of similar 
magnitude for the young and aged mice. After the primary fibrotic response, the older mice 
presented an impaired capacity for fibrosis resolution as they failed to return to normal body 
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weight and still had myofibroblasts present in the fibrotic regions 2 months after the initial injury. 
Tissue samples from mice with pulmonary fibrosis expressed higher levels of NOx4, an enzyme 
involved in producing hydrogen peroxide. Additionally, the antioxidant transcription factor Nrf2 
was only present at low levels in the fibroblastic foci, but most of the protein was localized in the 
cytoplasm and was deficient in the nucleus of senescent cells suggesting that an imbalance in the 
expression of NOx4 and Nrf2 was promoting the production and maintenance of ROS-mediated 
damage in the aged mice (55).  
Overall these results indicated that with increased age, myofibroblasts that developed in 
response to an injury persist for an excessive amount of time because they do not undergo 
apoptosis. Instead the altered homeostasis of NOx4/Nrf2 allows oxidative damage to induce the 
persistence of myofibroblasts and prevent the clearance of these cells and their associated ECM 
proteins.  
ECM changes have important implications in the aging lung. In aging, the collagen 
content of the ECM increases (56), along with decreases in elastin fibers (57). The exact 
mechanism of how the age-dependent changes in ECM components affect lung repair is still 
unclear, but it is known that the expression of fibronectin is increased in clinical and 
experimental models of fibrosis (58, 59) which in turn suggests an association with the repair 
process. Fibronectin production increases early in the injured lung and this augmentation 
coincides with fibroblast proliferation. The activation and proliferation of fibroblasts are 
responsible for the excessive synthesis and deposition of collagen proteins (60), and in this 
regard, it is interesting that our data suggest periostin production is enhanced in aged mice (see 
Chapter 3). Changes in cell-fibronectin interactions may also contribute to the abnormal tissue 
remodeling by stimulating the proliferation of fibroblasts (61), myofibroblast differentiation (59) 
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and epithelial to mesenchymal transition (EMT), or by simply just facilitating the deposition of 
other ECM components such as collagens (60).  
Other components of the ECM that might have implications in the aging lung are the 
expression of matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitor of 
metalloproteinases (TIMPs). Studies comparing young and old mice showed a significant 
increase in MMP2, MMP9 and Timp2 mRNA expression in old lungs. MMP9 activity was 
enhanced in the old lungs with low expression of Timp-1, its inhibitor (62).  The increase in 
MMP expression could lead to increased susceptibility to injury, leading to increased leukocyte 
migration and more tissue damage in the injured lung.  Overall these observations indicate that 
aging leads to changes in the composition of the ECM that might play a role in the lung repair 
process. 
 
Relevant Background Information for Chapters 2 and 3: 
 
Murine Models of Fibrosis 
A number of murine models of fibrosis have been developed. No current model replicates 
all the manifestations of the human disease; however, investigations using murine models of 
fibrosis have led to the identification of many potential therapeutic targets that are believed to be 
important. 
Bleomycin 
The most common and best-characterized animal model of fibrosis involves a single 
intratracheal (i.t.) or intranasal (i.n.) administration of bleomycin to the lung. Bleomycin was 
originally isolated from the fungus Streptomyces verticillatus (63). Bleomycin has been shown to 
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induce lung injury and fibrosis in a number of experimental animals including mice, rat, hamster, 
rabbits, guinea pigs, dogs and primates over a range of doses via intraperitoneal (i.p.), 
intravenous (i.v.), subcutaneous (s.c.) or i.t. delivery (64). A single i.t. administration of 
bleomycin causes lung injury and resultant fibrosis in rodents (65-68). I.t. delivery of bleomycin 
results in direct damage to AECs, followed by inflammatory cell infiltration, collagen deposition 
and parenchymal consolidation (69-72). 
In this model, the development of fibrosis can be seen both histologically and biochemically 
by 14 days post-bleomycin administration. Peak responses are observed around days 21-28 (72-
76). By 30 days post bleomycin, the changes were more heterogeneous (72) (67, 68, 75). 
Collagen deposition post-bleomycin treatment is measured by both histological and biochemical 
techniques (Figure 3).  Most notably thru the accumulation of hydroxyproline, a component of 
collagen in the lung that serves as a read-out for whole lung collagen content (77). The 
mechanism of bleomycin-induced lung fibrosis is not entirely clear but likely involves oxidative 
damage, deficiency of the deactivating enzyme bleomycin hydrolase, genetic susceptibility and 
elaboration of inflammatory cytokines (78). The fibrotic response is strain-dependent; C57BL/6 
mice are more susceptible to bleomycin compared to Balb/c mice (76, 79). Cytokines such as 
interleukin-1 (IL-1), chemoattractant protein-1(MCP-1), platelet-derived growth factor (PDGF) 
and  transforming growth factor beta (TGF) are released from alveolar macrophages in animal 
models of bleomycin toxicity, resulting in fibrosis(80). Damage and activation of AECs may 
result in the release of cytokines and growth factors that stimulate proliferation of myofibroblasts 
and secretion of ECM proteins leading to fibrosis. Specifically, TGF, PDGF receptor alpha 
(PDGFRα) and tumor necrosis factor alpha (TNFα) are believed to stimulate the transformation, 
proliferation and accumulation of fibroblasts, which leads to the deposition of ECM (81-83). 
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There was increased PDGFRα in epithelial cells and macrophages in the lungs of patients with 
IPF (84).  Studies in bleomycin-induced lung fibrosis indicate that some fibroblasts in fibrosis 
may be formed from bone marrow progenitors as well as from epithelial cells through EMT (85). 
Given the heterogeneity of the human disease among patients, investigating whether the 
bleomycin model accurately reflects disease mechanisms for all IPF patients or specific subsets 
will be important for translating findings from this model to the appropriate patient population. 
The bleomycin model is well characterized and has clinical relevance but a clear disadvantage is 
that it is self-limiting in mice as reflected in the temporal and spatial heterogeneity (86). 
Bleomycin treatment was shown to provide symptomatic relief to patients with craniofacial 
venous malformations and lymphangiomas (87). However, as a therapy, bleomycin treatment is 
limited because of the potential for life threatening interstitial pulmonary fibrosis or pneumonia 
and hypersensitivity pneumonitis (78, 88, 89). BALF studies in patients with bleomycin-induced 
pneumonitis have the presence of polymorphonuclear alveolitis (90). 
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 Figure 3: Characteristic pathology seen with bleomycin.  
A: hematoxylin and eosin (H&E) staining of a paraffin-embedded section of untreated lung. B: 
H&E section prepared from a CBA/J mouse on day 14 post-intratracheal injection of bleomycin 
sulfate (0.02 U). Interstitial thickening, inflammation, alveolar collapse, and cystic air spaces are 
all noted. C: Trichrome staining of a lung section from a C57Bl/6 mouse on day 21 post-0.025 
units of bleomycin sulfate. The blue staining represents collagen deposition. (Adapted from (86)) 
 
Fluorescein isothiocyanate (FITC) 
Roberts and colleagues originally described this model of pulmonary fibrosis in Balb/c 
mice in 1995 (91). Intratracheal administration of FITC at 0.007mg per gram body weight/mice 
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dissolved in phosphate buffered saline (PBS) resulted in infiltration of mononuclear cells and 
neutrophils in the lung interstitium. The response to FITC is persistent; anti-FITC specific 
antibodies were detected in FITC treated mice from day 7 to 6 week’s post-FITC treatment. By 5 
months post-FITC, patchy focal destruction of normal lung architecture with interstitial fibrosis 
was noted (91).  
Christensen and colleagues further characterized this model and demonstrated that both 
C57BL/6 and Balb/c mice were susceptible to FITC-induced fibrosis, with Balb/c mice showing 
a greater degree of fibrosis to the dose tested (92). Similar to findings in the bleomycin model, 
FITC was demonstrated to induce fibrosis by day 21 in a number of wild type and transgenic 
strains of mice (92). Further investigations with the FITC model of fibrosis demonstrated that 
like bleomycin, the fibrotic response to FITC is chemokine receptor 2 (CCR2)-dependent (93). 
Production of chemokine (C-C motif) ligand 12 (CCL12) and CCL2 (94) in the injured lung 
resulted in the recruitment of CCR2 expressing circulating fibrocytes (25) augmenting the 
fibrosis. IL-13 was also produced in response to FITC, which was essential for the fibrotic 
response (95). One clear advantage of the FITC model is the ability to visualize the areas of lung 
deposition by immunofluorescence (91, 92) (Figure 4). Another advantage of this model is that 
the fibrotic response lasts for at least 6 months and is not self-limiting like the bleomycin model 
(96), making it more suitable for long-term studies. 
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Figure 4: Fibrosis develops in areas of FITC deposition.  
FITC was instilled intratracheally into C57Bl/6 mice on day 0. On day 21, lungs were harvested 
for histology. A: H&E stain at 4X magnification showing areas of consolidation, inflammation, 
and fibrosis. B: serial section of A at 4X magnification and viewed under UV light to show areas 
of FITC deposition. Note that areas of fibrosis in A correspond to areas of FITC fibrosis in B. 
The red arrows represent areas of the lung with normal architecture, which correspond to areas 
where FITC did not deposit. Patterns of both central and subpleural fibrosis are noted. (Adapted 
from (86)) 
 
Adoptive Transfer Models 
A prominent feature of pulmonary fibrosis is constant fibroblast proliferation, which is 
mediated by a number fibroblast subtypes. These subtypes include fibrocytes, epithelial-derived 
mesenchymal cells, tissue resident progenitor cells, pericytes and resident fibroblasts. Bone-
marrow derived collagen producing cells known as fibrocytes respond to chemotactic stimuli in 
response to injury and contribute to the wound healing process (97). It was shown that i.v. 
injection of human fibrocytes results in migration into the mouse lung following bleomycin 
challenge and these recruited cells appeared to contribute to the injury (98). In addition, adoptive 
transfer of murine lung fibrocytes to FITC-challenged mice exacerbated the fibrotic response 
(94). The transfer of human fibroblasts into immunodeficient mice also showed pathology by day 
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21(99). Overall these data suggest that bone marrow-derived mesenchymal cells or tissue 
resident mesenchymal cells can contribute to the pathogenesis of lung fibrosis.  
Pericytes are specialized mesenchymal cells that share basement membrane with 
endothelial cells (100) (101). Pericytes frequently express the markers PDGFR aSMA, 
angiopoietin 1, CD146 and glial fibrillary acidic protein (GFAP) (102). Pericytes have been 
studied extensively in the eye, brain, kidneys and have been shown to regulate angiogenesis and 
vascular permeability (102). This cell type has been implicated as a source of myofibroblasts 
differentiation but the data available in the literature is controversial. Rock et al showed that 
pericytes are not a source of origin for myofibroblasts (103). However, recent studies by Hung 
and colleagues showed an expansion of Foxd1 progenitor-derived pericytes post-bleomycin lung 
injury and illustrated that these cells express collagen I and SMA, a marker for myofibroblast 
differentiation (102), suggesting that pericytes are precursor cells in lung myofibroblast 
differentiation.  
 
Infections and Pathogenesis of Fibrosis 
Some patients with pulmonary fibrosis experience a slow progressive disease course over 
months to years while others experience rapid worsening of symptoms over a month or less. The 
rapid deteriorations are idiopathic in nature and are termed acute exacerbation [reviewed in 
(104)]. There is no animal model for the development of idiopathic acute exacerbations, but 
several studies have suggested that viral infections; mainly infections with herpesviruses, may 
augment fibrotic responses when given before the fibrotic challenge. In a bleomycin-induced 
model of lung fibrosis, gammaherpesvirus was shown to augments the fibrotic response (105, 
106). 
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Infections can also cause rapid deterioration of symptoms with enhanced morbidity and 
mortality in fibrosis patients (18). Viruses have long been suspected of playing a role in the 
pathogenesis of IPF and it is well recognized that many patients report viral-type symptoms 
following initial diagnosis (107). However, the evidence supporting a role for viruses in IPF is 
limited/inadequate and often conflicting.  
Hepatitis C virus (HCV) is a positive sense RNA virus that frequently causes fibrosis in 
the liver resulting in cirrhosis. In a Japanese study with 66 IPF patients and 9646 controls, Ueda 
and colleagues found that 28.8% of IPF subjects and 3.66% of controls had evidence of prior 
HCV infection (108). Multivariate analysis suggested that age, smoking and liver cirrhosis were 
all independent risk factors for the development of IPF. A number of studies have failed to 
replicate this association (109) and others have only shown an association of HCV with a range 
of non-fibrotic respiratory conditions (110). The lack of coherent signal across studies suggests 
that HCV is unlikely to be an important trigger for the development of IPF at least globally. 
The human herpes viruses (HHVs) are a large family of DNA viruses, including the 
common pathogens, herpes simplex virus type 1 (HSV-1), Epstein-Barr virus (EBV), 
cytomegalovirus (CMV), and HHV-7 and-8. In the first study to suggest an association between 
HHV and IPF, it was reported that 12 out 13 IPF patients were seropositive for EBV compared to 
none of the 12 patients with other forms of interstitial lung disease (111). Several other studies 
have since reported similar findings of increased incidence of EBV in lung biopsy and BALF 
specimens from IPF patients when compared to controls (112-115). The most frequently studied 
of the HHVs is EBV; however Tang and colleagues (116) looked broadly at HHV family 
members and found evidence of past infection with at least one HHV in 97% of patients with IPF 
compared to 36% of healthy controls (116). It has been suggested that reactivation of this virus 
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acts as a second hit to the epithelium following exposure to a first injurious insult (117). These 
studies, however, only demonstrate an association of HHV and IPF, not a causal relationship. 
Given the limitations of in vivo human studies most researchers have focused on animal models 
of fibrosis for what has been learned. 
Murine gamma herpesvirus type 68 (-HV-68) is closely related to HHV and like its 
human counterpart, infects respiratory epithelium (118). Infection of young healthy mice does 
not result in pulmonary fibrosis.  However, when -HV-68 is given in conjunction with known 
fibrotic stimuli; bleomyicn or FITC, it dramatically enhances lung fibrosis (119, 120). In further 
support of the human data, Stoolman and colleagues demonstrated that mice latently infected 
with -HV68 produce abundant TGFβ, which may promote the fibrotic response.  (121). Other 
observations in mice that may be relevant to IPF include the finding that interferon gamma 
(IFN) knockout mice develop fibrosis when infected with -HV-68 alone (120). These mice 
mimic the Th2-dependent cytokine environment found in the lungs of patients with IPF. 
Similarly, aged mice (15-18months), but not young mice also develop pulmonary fibrosis when 
infected with -HV-68 (122)(123).  
The mechanisms by which viruses might predispose patients to the development of IPF 
are beginning to be elucidated. HHV induces endoplasmic reticulum (ER) stress and apoptosis in 
vitro in epithelial cells (124). In human IPF biopsy samples, data showed co-localization of latent 
HHV and markers for ER stress and apoptosis (125). In the murine bleomycin model, chronic 
HV-68 infection results in deposition of collagen, increased TGFβ expression and the altered 
synthesis of surfactant proteins (121). Likewise, HV-68-induced pulmonary fibrosis in aged 
mice is associated with upregulation of TGFβ (122). Interestingly, stabilization of IPF, through 
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the administration of antiviral therapy, has been described in case reports, though generally in 
individuals with evidence of infection on either BAL or biopsy (116).  
Another study in patients with severe IPF and positive EBV-serology showed that 
following a 2 week course of ganciclovir, 9 out of 14 patients, at week 8 showed improvements 
in 3 out of 4 of the composites measured (126).  The small study size and short duration of the 
study makes it difficult to draw conclusions about antiviral therapy in IPF. However, it provides 
a rationale to have larger future studies involving antiviral therapy in treating IPF. 
Acute exacerbations are devastating episodes of rapidly progressive respiratory 
compromise that occur in individuals with IPF (104). Histologically, acute exacerbations are 
characterized by the finding of diffuse alveolar damage; which has been shown in clinical trials 
to affect between 4-15% of individuals with IPF per year and are the main cause of IPF related 
mortality with a 3-month survival of less than 50% (127). In patients with IPF, respiratory tract 
infections that result in hospitalization confer a mortality risk indistinguishable from that seen 
with acute exacerbations (128). In animal models there is now good evidence to show that viral 
infection can exacerbate established fibrosis and give rise to a lesion resembling diffuse alveolar 
damage (129). However, Wootton et al failed to clearly identify a viral or other infectious trigger 
as the cause for acute exacerbation in the majority of IPF patients included in their study (130). It 
is possible that by the time of presentation, the triggering viruses may no longer be detectable. 
 
Role of Bacteria in the Pathogenesis of IPF 
 
While there is some evidence to suggest a role for viruses in the pathogenesis of IPF, the 
role of bacteria is much less well established. The only observational evidence demonstrated 
positive BAL cultures for Haemphilus, Streptococcus and Psuedomonas in 8 of 22 stable IPF 
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patients (131). A large multicenter, randomized, placebo-controlled study evaluated the 
prophylactic use of 12 months of septrin in treatment of IPF (132), and the authors reported that 
there was no difference in the primary end-point of change in vital capacity when comparing 
septrin and placebo. However, post-hoc analysis suggested that in subjects that adhered to the 
treatment, septrin led to a reduction in infections and mortality. Together with high mortality 
associated with bacterial respiratory tract infections in IPF, this suggests that bacteria may play a 
role in driving IPF disease progression.  
 In a small study looking at the potential role of Pneumocystis jiroveci infection in IPF, it 
was demonstrated that a number of uncultured bacteria were in the BAL of IPF patients using 
basic, culture-independent techniques (133). A recent study investigating the role of bacteria in 
the pathogenesis and progression of IPF showed increased bacterial burden in BAL, which 
predicted decline in lung function and death (134). Patients with increased bacterial load at the 
time of diagnosis were identified as patients with more rapidly progressive IPF and higher risk 
mortality (134). 
Environmental triggers are integral to the pathogenesis and progression of IPF. Both 
bacteria and viruses have the potential to cause airway epithelial cell injury and apoptosis and 
both have the capacity to modulate the host response to injury. Han and colleagues showed in a 
patient cohort consisting of IPF patients within 4 years of diagnosis that the presence of 
Staphylococcus and Streptococcus genera was associated with the progression of IPF (135). 
Active infection in IPF is known to carry a high morbidity and mortality; the effect of latent viral 
infection or changes in lung microbiome remains unknown, but additional studies are necessary 
to determine if this is causal as well as to identify specific bacterial species.  Interestingly, one of 
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the next multi-center clinical trials to be conducted in IPF will involve an investigation of 
antibiotic therapy. 
 
Mechanisms involved in Pulmonary Fibrosis 
The work discussed in this dissertation will explore different areas in the pathobiology of 
pulmonary fibrosis with a major focus on using the bleomycin-induced model of fibrosis to 
demonstrate how viruses, bacteria, recruited inflammatory cells (fibrocytes) and matricellular 
proteins such as periostin cause damage to the epithelial cells. The effects of apoptosis in the 
epithelial cells as well as how secreted profibrotic mediators contributed to myofibroblast 
differentiation leading to an exacerbated fibrotic response was also explored.  As outlined in the 
model below; a number of steps are involved in fibrogenesis but this process can be 
differentiated into 4 distinct phases (Figure 5).  
 
Figure 5: Changes in normal wound healing contribute to the development of pulmonary 
fibrosis. 
Lung injury causes damage to the endothelial and epithelial cells eliciting an immune cascade 
that involves (1) coagulation, (2) inflammatory cell recruitment, (3) fibroblast proliferation and 
activation. (4) In the final remodeling and resolution phase, myofibroblasts can promote wound 
repair, leading to wound contraction and restoration of blood vessels. However, fibrosis often 
develops if the tissue repair program is dysregulated leading to fibrosis. (Adapted from (136)) 
 
 
 23 
 The work discussed in this dissertation will focus on areas outlined on figure 5.  (A) 
Understanding how different insults to lung epithelial cells contributed to the exacerbation of the 
other three phases; (B) Following lung injury and epithelial cell damage how the recruitment of 
hematopoietic bone-marrow derived fibrocytes contributed to myofibroblast differentiation; and 
(C) How the production of profibrotic mediators from structural or hematopoietic cells affected 
resident fibroblasts leading to lung fibrosis. The remainder of this chapter will outline 
background and preliminary data that led to the hypothesis for this project. 
 
Inflammatory Cells 
 
IPF is a progressive and irreversible disease that destroys the lung architecture in a series 
of steps that are poorly understood. Chronic inflammation can lead to an imbalance in the 
production of chemokines, cytokines and growth factors, and can disrupt cellular recruitment. 
Alveolar macrophages can both promote and limit pulmonary fibrosis through secretion of 
TNF-α, TGF-β1, interleukin-13 (IL-13)(94, 137, 138) and the production of the pro-
inflammatory chemokines, CCL2 and CCL12 (94, 139).  
In the earliest stages of tissue damage, epithelial cells and endothelial cells release 
inflammatory mediators initiating a coagulation cascade that triggers clotting and the 
development of ECM. Platelet aggregation and degranulation in turn promotes blood vessel 
dilation and increased permeability, allowing efficient recruitment of inflammatory cells such 
as neutrophils, macrophages, lymphocytes and eosinophils to the site of injury (136). 
Neutrophils are the most abundant inflammatory cells at the early stages of wound repair but 
are quickly replaced by macrophages that produce a variety of cytokines and chemokines that 
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amplify the inflammatory response and trigger fibroblast proliferation and recruitment 
[reviewed in, (136)] (Figure 5). 
Fibrotic lung diseases including IPF are associated with a distinct type of macrophage 
activation called M2 or alternative activation (140, 141). Classical/M1 macrophage activation 
by microbial agents and or Th1 cytokines, in particular by interferon gamma (IFN-γ), induces 
the production of IL-12. On the other hand, macrophages stimulated by Th2 cytokines display 
a different activation pathway called alternative activation or M2, which plays a critical role in 
wound healing (142). A profibrotic role of alternatively activated alveolar macrophages (AMs) 
was demonstrated in IPF (143), as well as in mouse models (143-146).   
Several animal models of pulmonary fibrosis have demonstrated that AMs display a 
phenotype with alternative activation. In the silica-induced model, mRNA expression of Ym1 
increased significantly in the lungs of wild type mice but did not increase in the silica-treated 
IL-4R null mice, indicating the importance of a Th2 environment for M2 polarization (147). In 
the herpes virus-induced and transgenic TGFβ models of fibrosis, AMs accumulated in the 
lungs and expressed alternative activation markers Ym1/2, Fizz1 and arginase-1 (140, 146, 
148). AMs collected from IPF patients showed increased expression of CD206 and generated 
higher levels of CCL17, CCL18 and CCL22 compared to healthy controls (143, 149). Levels 
of arginase-1 were also higher in AMs and lung tissue of IPF patients (148). Clearly, 
alternative activation can alter the profile of mediators secreted by macrophages.  The 
following section will describe profibrotic mediators and how they affect pulmonary fibrosis. 
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Profibrotic Mediators 
TGFβ1 
 Nearly two decades of research have suggested that TGFβ1 plays a central role in the 
pathogenesis of pulmonary fibrosis by regulating the proliferation, activation and differentiation 
of epithelial cells and collagen-producing myofibroblasts (150). TGFβ1 signals through 
activation of its downstream effectors, the SMAD proteins. TGFβ/Smad signaling induces EMT 
and fibrosis in a variety of organs (151-153). It was shown that TGFβ1 was able to induce 
alveolar epithelial cells to undergo EMT in vivo and in vitro via Smad2 activation (154).  
TGFβ1 is synthesized and secreted into small and large latent complexes. TGFβ1 genes 
encode a N-terminal latency-associated peptide (LAP) and a C-terminal mature cytokine that 
forms dimeric structures. In the LAP of TGFβ1 and TGFβ 3, but not TGFβ2, there is an arginine-
glycine-aspartic acid (RGD) site that facilitates the binding of integrins.  In some cells, the small 
latent complex can associate with latent TGFβ binding protein (LTBP) via interactions with LAP, 
forming the large latent complex (155).  
Two integrins, alphaVbeta6 and alphaVbeta8, appear to jointly regulate much of the 
TGFβ1 activation relevant to adaptive immunity, given that combined inhibition of these 
integrins largely mimics the immune dysregulation seen in mice with complete loss of TGFβ1 
signaling in T cells (155). Which integrins mediate TGFβ1 activation in other cells is an area of 
active study. 
In the lungs, TGFβ is produced by a wide variety of cell types, including AMs 
neutrophils, activated alveolar epithelial cells, endothelial cells, fibroblasts, and myofibroblasts 
(156). When activated, TGFβ is a pleiotropic growth factor with chemotactic and proliferative 
properties. TGFβ induces macrophage and fibroblast recruitment as well as fibroblast 
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proliferation via PDGF expression. In these cells, TGFβ also stimulates expression of a number 
of proinflammatory and fibrogenic cytokines, such as TNFα, PDGF, IL-1β, or IL-13, thereby 
further enhancing and perpetuating the fibrotic response (156). 
TNF-α 
TNF-α is the most widely studied cytokine member of the TNF super family. In 
pathophysiological conditions, generation of TNF-α at high levels leads to the development of 
inflammatory responses that are hallmarks of many diseases. Of the various pulmonary diseases, 
TNFα is implicated in asthma (157-161), chronic bronchitis, chronic obstructive pulmonary 
disease (162-165), acute lung injury, acute respiratory distress syndrome (166-169), and 
pulmonary fibrosis (170, 171).  Its role in fibrosis is controversial, but in vivo studies indicate 
that TNFα is predominantly a pro-fibrotic effector (172).  
Induction of TNFα overexpression causes fibrosis in rat lungs resulting in severe 
infiltration of the lungs by neutrophils, macrophages and lymphocytes (173). These data were 
supported by the analysis of peripheral CD4+ T cells from patients with IPF where CD4+ T cells 
from IPF patients synthesized higher levels of TNFα compared to normal subjects (174). Studies 
in bleomycin-induced TNF-α receptor knockout and wild type mice treated with anti-TNFα 
antibodies initially suggested that TNFα receptor signaling was required for the development of 
pulmonary fibrosis (175, 176).  However, a more recent study demonstrated that TNFα is 
involved in the resolution of established fibrosis by reducing numbers of profibrotic 
macrophages, suggesting an anti-fibrotic role for TNFα (171). 
CCL2 and CCL12 
Monocyte chemoattractant protein-1(CCL2) and monocyte chemoattractant protein-
5(CCL12) are potent chemotactic ligands for chemokine (C-C motif) receptor 2 (CCR2) 
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mediating recruitment of inflammatory cells and fibrocytes during pulmonary fibrosis (25, 177). 
Both bleomycin and FITC-induced murine models of lung fibrosis showed elevated levels of 
CCL2 in response to fibrotic injury (25, 93, 94). Patients with interstitial lung disease also have 
elevated CCL2 in their bronchoalveolar lavage fluid (BALF) (178-180) and high levels of CCL2 
correlated with poor survival (181). Fibrotic fibroblasts overexpress CCL2 (44, 182, 183), and 
respond to CCR2 stimulation by increasing TGFβ and limiting apoptosis (184).  
Fibrocytes are recruited by CCL12 in mice via CCR2 (94) and CCR2 stimulation of 
fibrocytes increased expression of collagen I (25); these findings were also confirmed in human 
studies (185).  Mice deficient in CCR2 are protected from pulmonary fibrosis suggesting that 
CCL2 and CCL12 are crucial for the development of pulmonary fibrosis in mice (93). Recent 
work from Deng and colleagues demonstrated that CCL2 expression is transcriptionally 
regulated by thrombin via the nuclear factor kappa B (NF-κB) and activation protein-1 (AP-1) 
pathways resulting in an overexpression of CCL2 in pulmonary fibrosis (182).  
 
Fibrocytes 
Originating in the BM, fibrocytes comprise a small subset (0.1%) of mononuclear cells 
and were first described as common leukocyte antigen (CD45) and type-I-collagen (Col I) 
expressing leukocytes that mediate tissue repair and are capable of antigen presentation to naïve 
T cells (97).  Human fibrocytes isolated from peripheral blood have a spindle-like shape but 
obtain a myofibroblastic phenotype upon differentiation on plastic in response to TGFβ1 (186-
189). Fibrocytes express leukocyte-associated antigens including CD45, a myeloid antigen CD13, 
hematopoietic stem cell antigen CD34, and major histocompatibility complex antigens class II 
(MHCII), CD80, CD54 and other antigens (186, 190).  
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Cultured fibrocytes have been shown to express collagen I, collagen III, and fibronectin 
(97, 189, 191-193). Under normal conditions, few fibrocytes can be detected in the peripheral 
blood or tissues. It is believed that fibrocytes contribute to wound healing and maintenance of 
tissue integrity thus playing a vital role in matrix remodeling and cellular homeostasis (194). 
Egress of fibrocytes from the BM and homing to peripheral organs is regulated by profibrotic 
mediators such as TGFβ1 and chemokines (CCL2, CCL3, and CCL12) (195). Importantly, 
fibrocytes express a number of chemokine receptors including CXCR4, CCR7 and CCR2, 
which likely mediate recruitment, and activation of fibrocytes to areas of tissue damage (25, 94, 
98). In a bleomycin-induced model of pulmonary fibrosis in mice, the number of bone marrow 
(BM)-derived fibrocytes recruited to the injured lung constituted up to 25% of the collagen 
producing cells (196), suggesting that fibrocytes play an important role in the development of 
pulmonary fibrosis (188).  
In patients with IPF, elevated numbers of circulating fibrocytes in the blood correlated 
with the severity of the disease and may serve as a prognostic marker (197). In addition, 
fibrocytes and monocytes have been shown to be the major producers of the matricellular 
protein, periostin, in the blood of IPF patients (198). In a murine model of lung injury, adoptive 
transfer of Tregs was shown to decrease CXCL12 expression and fibrocyte recruitment 
resulting in improvement in fibroproliferation (199). Conversely, adoptive transfer of 
fibrocytes has been shown to worsen fibrotic outcomes (94). Even though fibrocytes have been 
shown to contribute to the pathogenesis of pulmonary fibrosis and have been shown to express 
Col I, these cells are not an essential source of collagen during pulmonary fibrosis (200).  
Another study suggested that increased levels of the protein lumican; secreted by fibroblasts in 
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the presence of TNF-α, causes monocytes to differentiate into fibrocytes, providing another 
mechanism to account for accumulation of fibrocytes in fibrotic lesions (201).  
Fibrocytes are different from bone marrow-derived mesenchymal stem cells. Both 
fibrocytes and mesenchymal stem cells (MSCs) are derived from the bone marrow, but the 
cellular markers and functions are different. While fibrocytes, contribute to the ECM 
deposition and secrete pro-inflammatory cytokines like IL-1β, IL-6, TNF-α and TGF-β1, 
MSCs are derived from the stroma of the bone marrow and are believed to attenuate scar tissue 
formation and suppress inflammation in fibrotic lesions (202).   
 
Myofibroblasts and Fibroblasts 
 Fibroblasts are present in virtually all tissues and organs, albeit in limited numbers under 
normal conditions (203). Quiescent resident fibroblasts can be activated in response to 
extracellular triggers such as transforming growth factor beta (TGFβ1) (152, 204, 205), WNT 
(206), Jagged/NOTCH (207, 208),  Fizz1 (208, 209), and hedgehog. In response to specific 
stimuli, epithelial cells can give rise to fibroblasts or myofibroblasts in the lung through a 
process of epithelial to mesenchymal transition EMT. In addition, myofibroblasts can also be 
derived from resident fibroblasts.  
Myofibroblasts are characterized in part, by the presence of alpha smooth muscle actin 
(αSMA) and their ability to produce ECM proteins including type-I-collagen. Lung tissue from 
patients with pulmonary fibrosis contains myofibroblasts (210-212), which are responsible for 
the deposition of collagen and other ECM components during development and progression of 
pulmonary fibrosis (213). Data suggest that myofibroblasts are derived from at least three 
sources; resident lung fibroblasts may expand, alveolar epithelial cells may undergo EMT or 
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circulating bone marrow-derived stromal cells/fibrocytes may enter the lungs and differentiate 
into fibroblasts (214-216). During EMT, the expression of the epithelial marker E-cadherin is 
lost while the expression of mesenchymal markers including αSMA and MMPs are increased; 
resulting in the loss of cell-cell and cell-matrix interactions, increased cell-migratory behavior 
and excess ECM production (217).  
TGFβ1 is a potent inducer of myofibroblast differentiation (218). TGFβ1 not only 
induces synthesis of ECM proteins, particularly collagens and fibronectin but it also reduces 
MMP activity by promoting tissue inhibitor metalloproteinase proteins (Timp) expression (219, 
220). IPF is characterized by the accumulation of fibroblasts and myofibroblasts, which 
aggregate in clusters termed “fibroblastic foci”, the number of which correlates with patient 
mortality (221, 222). The myofibroblasts has been identified as a key mediator of IPF and 
other profibrotic conditions (223-225). The distinct myofibroblast phenotype is TGFβ-
dependent and arises secondary to chronic epithelial injury or inflammation. 
Additionally, myofibroblasts accumulate because they are resistant to apoptosis. TGF-β1 
and endothelin-1(ET-1) have been found to promote resistance to apoptotic stimuli in 
fibroblasts while prostaglandin E2 (PGE2) has been shown to  inhibit apoptotic resistance 
induced by TGF-β1 (226-229). Fibrotic disease can reduce the ability of lung fibroblasts to 
produce PGE2 due to a decrease in the upregulation of cyclooxygenase 2, an important enzyme 
for PGE2 synthesis (229). Additionally, fibroblasts in fibrotic lungs often lose the ability to 
respond to PGE2 (230, 231). While resident fibroblasts can differentiate into myofibroblasts 
and epithelial cells can undergo EMT, circulating cells can also contribute to progression of the 
disease. 
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Matricellular Proteins 
 The concept of a matricellular protein was first proposed by Paul Bornstein in the mid-
1990’s to account for the non-lethal phenotypes of mice with inactivated genes encoding 
thrompbospondin-1(TSP-1), tenascin-C or secreted protein acidic and rich in cysteine 
(SPARC)(232). Matricellular proteins are a family of structurally unrelated extracellular 
molecules that do not play a primary role in tissue architecture but are induced following injury 
and modulate cell-cell and cell-matrix interactions (232, 233). With the rapid expansion in our 
understanding of cell-matrix interactions several additional proteins were later included such as 
TSP-2 and -4, tenascin X, osteopontin (OPN), periostin, and the members of the CCN family of 
matricellular proteins which will be discussed. 
Matricellular proteins bind to various ECM proteins and to cell surface receptors, while 
associating with cytokines, growth factors, and proteases. These interactions allow them to serve 
as key integrators. TSP-1 is a major constituent of platelet alpha granules but can also be 
synthesized by many other cell types including endothelial cells, vascular smooth muscle cells, 
fibroblasts, keratinocytes, and macrophages (234). TSP-1 plays a key role in TGFβ activation 
through a cell and protease mechanism thus contributing to the exacerbation of fibrotic diseases 
(235, 236); in contrast, the other TSPs do not activate TGFβ. Studies in TSP-1 null mice 
demonstrated that TSP-1 was important for the activation of TGFβ, as these mice exhibited 
inflammatory changes in the lung and pancreas. Treatment of TSP null mice with a TSP-1 
derived peptide that activates TGFβ showed partial reversion of the lung and pancreatic 
abnormalities towards the wild type phenotype (237). The significance of TSP-1 mediated TGFβ 
activation has been further supported by findings in a wide range of biological processes 
including tissue repair, fibrosis and neoplasia (238).  
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Tenascins 
 The expression of tenascin C and –X is regulated by micro-environmental factors (239).  
Tenascin C is induced by a number of growth factors such as PDGF, fibroblast growth factor and 
TGFβ. Tenascin-C expression is associated with the development of fibrosis both in 
experimental models (240) and in patients with fibrotic conditions (241, 242). Loss of tenascin-C 
attenuated bleomycin-induced lung fibrosis (243). Decreased extracellular matrix deposition in 
the absence of tenascin C was associated with decreased TGFβ signaling. 
  
SPARC 
 SPARC regulates cell function and tissue remodeling by modulating growth factor 
signaling and affecting cell cycle arrest (244). In bleomycin-induced lung fibrosis, SPARC null 
mice showed decreased collagen deposition in the lungs (245). A more recent article showed that 
SPARC exerts different functions in pulmonary fibrosis depending on the cell of origin (246). 
Bone marrow chimera experiments demonstrated that SPARC produced by BM-derived 
leukocytes limits fibrosis by decreasing inflammation whereas, SPARC from fibroblasts or 
fibrocytes sustain fibrosis promoting collagen deposition. The anti-inflammatory activity of 
SPARC was dependent on its regulation of TGFβ signaling in macrophages (246). SPARC has 
also been shown to suppress apoptosis in fibroblasts from patients with IPF (247). 
 
Osteopontin 
Osteopontin (OPN) is expressed as a 33kDa protein, but can also be seen as a 44kDa 
protein due to posttranslational modification. OPN interacts with a number of integrins 
alphaVbeta1, alphaVbeta3, alphaVbeta5, alphaVbeta6, and alpha5beta1 integrins through its 
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RGD motif (248, 249). OPN is expressed by numerous immune cells and is upregulated in 
response to tissue injury and inflammation in a number of different organs (250). In dystrophic 
skeletal fibrosis, these findings were associated with alterations in the profile of immune cell 
infiltration and decreased TGFβ expression (251). 
 
Periostin 
Periostin was originally named osteoblast specific factor-2 (OSF-2) (252) and was 
suggested to play a role in bone metabolism. The name was later changed to “periostin” because 
of its intense expression in the periosteum and periodontal ligament (253). Increased periostin 
expression in tissue repair, remodeling and fibrosis may be due to activation of TGFβ and bone 
morphogenic protein (BMP) signaling. In vitro, TGFβ and BMP-2 are potent inducers of 
periostin in a variety of cell types including fibroblasts (254). In subepithelial fibrosis associated 
with asthma, periostin appears to play an important role by enhancing profibrotic TGFβ signaling 
(255). In asthma, the periostin gene is upregulated in epithelial cells by IL-4 and IL-13.  Persiotin 
is also recognized as a biomarker of type 2 inflammation and has been examined in the serum of 
asthma patients as a surrogate for clinical efficacy regarding anti-IL-13 therapy (256).  
Evidence supporting a role of periostin in lung fibrosis comes from studies using mouse 
models of experimental lung fibrosis, as well as data showing that periostin expression was 
upregulated in the lung tissue of IPF patients (198, 257). In patients with IPF, periostin is highly 
expressed in the lung tissue in areas of active fibrosis (198). Periostin was also detected in the 
circulation of IPF patients with significantly higher levels of serum periostin in IPF patients 
compared to healthy individuals or patients with other interstitial lung pneumonias (258). 
Periostin-deficient mice are protected from bleomycin-induced fibrosis, which is suggested to be 
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a result of impaired recruitment of inflammatory cells due to decreases in chemokine production 
by fibroblasts in mice on the Balb/c background (257). In periostin-deficient mice on the 
C57BL/6 background, periostin seemed to be playing a role in the fibroproliferation because no 
difference was found in inflammation in these knockout mice when compared to WT controls 
(198); however, there was still less collagen content in the lungs of these mice post-bleomycin 
treatment. 
Cross-linking of collagen is catalyzed by lysyl oxidases (LOX). Periostin has been shown 
to activate BMP-1 to cleave LOX, promoting its activation on the ECM and increasing cross-
linking between collagen fibrils (259). The subsequent stiffening of the matrix is thought to 
promote fibroblast activation, which may further promote a fibrotic environment in IPF.  
Periostin has also been shown to interact with a number of integrins. OC-20, an antibody that 
blocks periostin interaction with integrins, limited lung fibrosis and improved survival in a 
murine bleomycin-induced model of fibrosis (198). 
 
CCN Family of Matricellular Proteins  
The CCN gene family (Cyr61/CTGF/NOV) consists of six members; CCN1(cyr61), 
CCN2(CTGF), CCN3(NOV), CCN4, (WISP1), CCN5(WISP2) and CCN6(WISP3)(260, 261). 
The mechanisms of regulation have been characterized in detail for CCN2, because of its 
mitogenic activity in connective tissue; CCN2 was named connective tissue growth factor 
(CTGF) (262). CCN3 was cloned as a gene that is overexpressed in nephroblastoma, CCN4 and 
5 were identified as genes that were upregulated in response to Wnt-1 and were named wnt-1 
inducible signal pathway protein 1 (WISP1) and WISP2 (263). Finally CCN6 was identified as a 
WISP1 homolog and named WISP3. The CCNs interact with a number of ECM proteins and 
 35 
growth factors, and in some cases specific domains have been identified to be responsible for this 
interaction (264). CCNs bind and signal through a number of receptors several of which are 
integrins, transmembrane receptors that bridge cell-cell and cell-ECM interactions (265). The 
binding of CCNs to co-receptors such as heparin sulfate proteoglycans, the TrkA receptor, or 
low-density receptor proteins (LRP) are thought to help provide for unique signaling (266, 267). 
CCN2/CTGF has been shown to be a downstream profibrotic mediator of TGFβ (268). 
However, this paradigm is complicated by observations that CCN2 activates or co-activates 
TGFβ-mediated profibrotic responses and appears in itself to play a primary role in fibrosis (268). 
CCN2 induces the expression of a variety of cytokines such as VEGF and TGFβ (269) which 
induces even more expression of CCN2/CTGF. There are multiple positive feedback loops 
involving CCN2/CTGF expression that can contribute to the progressive nature of fibrosis. 
Breaking this loop should enable organs to restore normal wound healing response and normal 
function. In terms of mechanism, CCN2/CTGF acts to initiate and extend fibrosis by directly 
increasing the production and accumulation of ECM proteins (270). Its presence induces the 
formation of myofibroblasts through transdifferentiation of other cells including epithelial cells 
via epithelial to mesenchymal transition ( EMT) (271) or resident fibroblasts (272) or fibrocytes 
that have been recruited to organs through chemokines (273).  It was shown that AECs 
undergoing TGFβ-mediated EMT in vitro were able to activate lung fibroblasts in a 
CCN2/CTGF-dependent manner (274). In a radiation-induced model of pulmonary fibrosis, 
inhibition of CCN2/CTGF with small molecule inhibitor (FG-3019) attenuated lung fibrosis and 
showed an increase in tissue remodeling (275). 
CCN3 is a negative regulator of CCN2 and an inhibitor of renal fibrosis (276). CCN3 has 
been shown to counter the profibrotic effects of CCN2/CTGF by inhibiting the upregulation and 
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accumulation of ECM proteins such as collagen, ultimately limiting or reversing the progression 
of fibrosis (277). CCN4 has also been implicated in fibrotic diseases (278). It has important roles 
in inflammation and tissue injury. There is significant upregulation of CCN4 expression as well 
as other proinflammatory and profibrotic mediators such as nuclear factor- kB (NFkB) in carbon 
tetrachloride (CCL4)-induced liver fibrosis (279). Blocking CCN4 in vivo, with a monoclonal 
antibody significantly attenuated CCL4-induced liver injury and progression of liver fibrosis 
(279). Similar results were observed in pulmonary fibrosis where treatment with a neutralizing 
antibody specific for CCN4 reduced pulmonary fibrosis in mouse models (280). CCN4 is also 
upregulated in patients with IPF (280). 
CCN5 has been suggested to play an inhibitory role in some fibrotic diseases such as 
cardiac fibrosis (281). CCN5 is expressed at low levels in fibroblasts and was shown to exert 
inhibitory effects on the fibrotic phenotypes of pulmonary fibroblasts both in vitro and in vivo 
(282). CCN6 was shown to cause proliferation of lung fibroblasts by binding to integrin beta 1, 
leading to the phosphorylation of focal adhesion kinase (Y397). CCN6 was highly expressed in 
the lung tissues of bleomycin-treated mice suggesting that CCN6 may play a role in fibrogenesis 
(283). Based on the evidence available for the CCN family of proteins and their role in fibrosis, 
these proteins could be potential targets for the treatment of pulmonary fibrosis. 
Integrins 
Integrins are a large family of heterodimeric transmembrane glycoprotein receptors, 
shown to mediate cell adhesion to ECM proteins and mediate cell surface counter-receptors 
including members of the immunoglobulin and cadherin families (284). Integrins also regulate 
other families of proteins including growth factors (285) and proteases (286). They can serve as 
scaffolds for the assembly of signaling complexes and are composed of a single alpha and a 
 37 
single beta subunit. In mammals, there are 18 human alpha subunit and 8 beta subunits forming a 
total of 24 integrin heterodimers (287)(Figure 1). A number of specific integrins have been 
shown to play a role in pulmonary fibrosis in various animal models or have been shown to have 
an important role in mechanisms that might contribute to pulmonary fibrosis. Integrins have been 
shown to associate with TGFβ (288). Most tissues including the lung contain significant amounts 
of latent TGFβ. Early evidence for the mechanism behind latent TGFβ activation suggested that 
TGFβ1 and -3 might interact with integrins because they contain a RGD peptide sequence (289). 
It is now known that this RGD sequence in TGFβ 1 and 3 is recognized by 6 different integrins, 
two of which perform the function of activating the latent TGFβ complex based on in vivo data 
(288).  
 AlphaVbeta6 is expressed at low levels in the alveolar epithelium; associates with latent 
TGFβ thru interaction with the RGD sequence of LTBP and is also a receptor for the ECM 
proteins, fibronectin (290) and tenascin C (291). Data suggest that alphaVbeta6 is not important 
in development because mice lacking this integrin develop normally (292). The expression of 
alphaVbeta6 was dramatically upregulated in patients with scleroderma who had UIP, the 
pathologic correlate of IPF or in patients with IPF (293). 
A second integrin, alphaVbeta8 also binds the same RGD sequence in latent TGF but 
appears to activate TGF in a different manner.  The cytoplasmic domain of the beta 8 subunit is 
not required for the activation of TGF. AlphaVbeta8 appears to activate TGF by presenting 
the latent TGF complex to metalloproteases that cleave the LAP and release free TGF (294). 
AlphaVbeta8 has not been shown to be important for development of alveolar fibrosis, 
suggesting that it is likely alphaVbeta6, which plays a role in the activation of TGF-associated 
pathogenesis of pulmonary fibrosis.  However, alphaVbeta8 has been shown to play a role in 
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airway fibrosis; conditional deletion of alphavbeta8 in lung fibroblasts attenuated airway fibrosis 
(295). The integrins alphavbeta3 and alphavbeta5 have also been shown to bind the RGD 
sequence in LAP of TGF but only alphaVbeta3 has the potential to activate latent TGF (285, 
294, 296-298).  
Alpha3beta1, an epithelial integrin has been shown to colocalize with E-cadherin and 
beta-catenin at adherens junctions (299). In a mouse model of pulmonary fibrosis, conditional 
epithelial cell-specific deletion of alpha3 integrin expression showed normal response to acute 
bleomycin-induced lung injury, but these mice had reductions in lung myofibroblasts and type I 
collagen and did not progress to fibrosis (300).  Alphavbeta1, which is highly expressed on 
fibroblasts, directly binds to the LAP of TGFβ and mediates TGFβ activation. A novel 
alphaVbeta1 inhibitor (C8) was recently shown to attenuate bleomycin-induced pulmonary 
fibrosis and CCL4-induced liver fibrosis (301). In mouse models of pathological hepatic or 
pulmonary fibrosis, subcutaneous administration of C8 after the establishment of fibrosis led to 
significant reduction in fibrosis by downregulating TGFβ signaling (301). Based on the data to 
date, integrins are suggested to be involved in activating one of the key profibrotic mediators, 
TGFβ. Since, TGFβ deletion results in autoimmunity targeting signaling pathways that activate 
TGFβ maybe the path to identifying novel therapeutics for IPF, but they will have to be carefully 
balanced to avoid autoimmunity. 
Therapeutic targeting of Integrins 
Blocking antibodies to alphavbeta6 have shown therapeutic promise in a wide range of 
preclinical models of fibrosis including lung fibrosis (293, 302) and renal fibrosis (303, 304). 
Furthermore in the lung, low doses of alphavbeta6 blocking antibodies can prevent bleomycin-
induced or radiation-induced pulmonary fibrosis in mice without causing inflammation (293, 
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302). A monoclonal antibody targeting alphavbeta6 (clone6.3G9) has been humanized as STX-
100 and is currently being evaluated in phase 2 clinical trials for the treatment of patients with 
IPF. In addition, recent preclinical data suggests that targeting alphavbeta1 integrin on fibroblasts 
shows potential therapeutic application in fibrotic diseases (301). 
 
Figure 6: The members of the human integrin superfamily and how they combine to form 
heterodimeric integrins.  
There are 18 alpha subunits and 8 beta subunits that have been identified in humans, which are 
able to form 24 different integrins. Solid lines as indicated above connect Integrin subunits that 
bind to each other to form a heterodimer. Each integrin has distinct ligand-binding specificity, 
tissue and cell distribution (305).  
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Background Information for Chapter 5: 
 
Apoptosis, Wound Healing and Aging 
The late phase of normal wound repair coincides with a decrease in fibroblast numbers by 
apoptosis, a mechanism that is still not clearly understood (306, 307). However, research has 
shown that a member of the IAP family of proteins, X-linked inhibitor of apoptosis (XIAP) 
localizes to fibroblastic foci in IPF tissue and that PGE2 suppresses XIAP expression while 
increasing fibroblast susceptibility to apoptosis (308). Ajayi et al further demonstrated that 
inhibition or silencing of XIAP enhanced the sensitivity of lung fibroblasts to Fas-mediated 
apoptosis (308). Overall these data suggest that XIAP and/or other IAPs were regulating or 
contributing to the apoptosis-resistant phenotype in IPF fibroblasts. In this study we further 
assess how targeting IAPs would affect bleomycin-induced fibrosis.  
Regardless of the activation pathway, apoptosis plays a role during injury and wound 
healing. Rapid apoptotic responses increase the magnitude of injury and the possibility of 
forming scar tissue. Apoptosis is necessary for the removal of inflammatory cells during wound 
healing. In IPF, with enhanced apoptosis of AECs in combination with resistance to apoptosis in 
fibroblasts and myofibroblast, these differing cell-specific sensitivities to apoptosis are believed 
to be critical to the pathogenesis of lung fibrosis (307). 
Aging in human lungs show loss of epithelial cells and homogeneous enlargement of the 
alveolar spaces. During injury, enhanced apoptosis of AECs may result in a defect in the 
regeneration of the damaged alveolar wall, thus promoting fibrotic tissue repair response (309). 
Studies have shown that type II lung epithelial cells from aging lungs of mice are highly 
susceptible to apoptosis during injury and that increased apoptosis was associated with 
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expression of ER stress proteins; BiP and Xbp1 that are not expressed in the lungs of young mice 
(123).  
Defective wound healing in the aging lung can also be associated with increased 
apoptosis of epithelial cells by a pro-apoptotic pathway. Data from animal models showed 
activation of Fas-mediated apoptosis as well as TGFβ overexpression causing apoptosis of lung 
epithelial cells (310, 311). Mitochondrial dysfunction has been shown to promote apoptosis and 
may be the central mechanism during mammalian aging (312). The maintenance of 
mitochondrial function during stress conditions is established by the balance between pro-
apoptotic and anti-apoptotic members of the B-cell lymphoma 2 (BCL2) family of proteins, as 
well as levels of heat shock proteins (HSP) which are up-regulated following exposure to 
environmental stress and help to stabilize or facilitate the degradation of mediators BAX, Bak, 
cytochrome C and caspase-3 (313). Mice over-expressing heat shock protein (HSP)-70 showed 
attenuated bleomycin-induced fibrosis (314), possibly associated with protection against 
apoptosis of lung epithelial cells. In IPF, low levels of BCL2 were observed in lung epithelial 
cells, but fibroblasts had high levels of HSP and BCL2.  
In conclusion, the association of apoptosis with age-related susceptibility to lung injury 
and the cell/tissue specificity of this process demands further investigation. However, it is clear 
that changes in the lung environment or the immune response during aging could cause older 
adults to be more susceptible to fibrotic lung diseases or other diseases that causes damage to the 
lung epithelium. 
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Background Information for Chapter 6: 
 
Biomarkers in IPF 
Currently there are no molecular biomarkers available for clinical use in IPF and the 
search for potential markers remains in its infancy. Despite improvements in the clinical 
classification of patients with IPF, there is still no cure for the disease. The FDA recently 
approved two new drugs; Nintedanib and Pirfinedone but these drugs only offer mean 
progression free survival of 13 months (33). Identifying biomarkers in IPF would be beneficial in 
many ways. It would improve the ability to identify patients at risk for developing IPF leading to 
earlier diagnosis, could determine patient’s baseline prognosis, could stage disease severity or 
allow for monitoring for progression (Prognostic biomarkers).  Biomarkers could also be useful 
for identifying target engagement with a specific mechanistic response or predicting response or 
toxicity to therapy, either by identifying subgroups that are most likely to respond to therapy or 
serving as a measurable substitute for a clinically meaningful outcome (315, 316).  
There are two fundamentally different approaches for biomarker discovery: a hypothesis-
based approach where a candidate biomarker is selected based on preexisting evidence or an 
unbiased approach. The candidate biomarker has been the approach taken by the majority of the 
biomarker studies in IPF. The advantage of this approach is that it is supported by strong 
biological evidence and preliminary data but lacks efficiency in the discovery process. Next is 
the unbiased or hypothesis-free approach that explores systems biology methods whether 
genomic, transcriptomic, or proteomic to screen a large number of candidate markers for their 
association with the disease, greatly increasing efficiency and scope of the discovery process but 
also increasing the risk of false discovery. For biomarker studies, measurements from easily 
accessible body fluids or tissues are preferred (e.g. blood/serum and urine). Molecular markers 
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require a wide range of validation across gender, ages, ethnicities and disease severity to create 
generalization across the study (317, 318). Over the past decade, the pathogenic paradigm of IPF 
has shifted to alveolar epithelial stress and dysfunction resulting in activation of profibrotic 
signaling pathways, fibroblast proliferation and continuous ECM deposition (1, 319). The 
resulting epithelium destruction leads to organ dysfunction, shortness of breath and exercise 
limitation and ultimately death from respiratory failure. 
Genetic changes that contribute to AEC dysfunction involve mutations in genes encoding 
surfactant proteins (SP) A and D and mucin1/krebs von den Lugen-6 (KL-6). These 
polymorphisms or the respective proteins have been evaluated as both diagnostic and prognostic 
biomarkers for IPF (320-322). Short telomeres have been associated with the risk of developing 
IPF, (323); with further validation telomere length holds promise as a mechanistic biomarker to 
help predict disease prognosis. Further studies will also be necessary to determine whether the 
cytoskeletal protein, cytokeratin 18 that’s upregulated in the serum of IPF patients could serve as 
an efficient marker for drugs intended to target ER-stress or AEC apoptotic pathways.  
Additionally, proteins involved in innate immunity such as toll-like receptor 3 (TLR3) 
(324), ELMOD2 (325, 326), toll-interacting protein (TOLLIP) (327), alpha defensin (328), 
CCL18 expression (143), and YKL40 which is elevated in serum and BALF (329, 330) have all 
been studied as potential biomarkers of IPF. Changes in the adaptive immune response that 
affect T cells, chemokines and autoantibodies have also been evaluated. Anti-HSP70 antibodies 
were identified in IPF patients (331), as were high levels of CXCL13 in the blood and lung tissue 
of IPF patients (332). IPF patients also had lower percentages of CD28+CD4+ T cells in the 
peripheral blood (53) suggesting a defect in T cell activation. Quantification of the genes CD28, 
ICOS, LCK and ITK that are involved in T cell activation correlated with the percentage of 
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peripheral blood CD4+CD28+ T cells (333). Finally, proteins that play a role in  
fibroproliferation and ECM remodeling have also been examined as potential biomarkers of IPF. 
These proteins include metalloproteinases (MMPs), matricellular proteins and circulating 
fibrocytes. Several MMPs are of interest in the pathobiology of IPF because of their role in the 
ECM as well as tissue remodeling. In a recent multi-center observational study, it was reported 
that concentrations of protein fragments generated by MMP activity were increased in the serum 
of IPF patients compared to controls (334). Matricellular proteins, OPN and periostin are highly 
expressed in the lung tissue of IPF patients who had progressive disease (198, 258, 320). Serum 
levels of periostin were also elevated in IPF patients and correlated to disease progression. 
Finally, fibrocytes were assessed as potential biomarkers for activity and progression of IPF 
(197). It was reported that fibrocytes were present in IPF but not control lung tissues, along with 
higher numbers of fibrocytes in circulation of IPF patients compared to controls (197). These 
data suggest that fibrocytes in circulation may allow for early prediction of mortality in IPF 
patients since the presence of fibrocytes was associated with worse survival.  
Integrins have been studied extensively for their role in TGFβ activation. In a study 
phenotyping tissue biopsies from ILD patients, Saini and colleagues used immunostaining to 
show that there were high levels of αSMA, alphaVbeta6, Pro-surfactant protein-C (SPC), human 
growth factor, tenascin-C and fibroblastic foci present in the tissue of ILD patients (335). The 
relationship of all the proteins to survival was also analyzed but only alphaVbeta6 showed an 
association with mortality (335).  
There is still a need to identify pivotal mediators that may contribute to fibrosis and serve 
as clinically relevant biomarkers; in this study we used an unbiased hypothesis-free approach to 
explore potential biomarkers in plasma from IPF patients compared to controls. We utilized 
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novel reagents (Slow Off-rate Modified Aptamers, or SOMAmer reagents)  (336, 337), in an 
assay that uses modified nucleotide bases to offer expanded diversity for interactions, in 
particular hydrophobic groups similar to amino acid residues. Modifications on nucleotides also 
significantly improve the ability to select SOMAmers for various protein targets with excellent 
affinity. Plasma from IPF patients was assayed using this technology and samples were analyzed 
for proteins that predicted progression free survival in IPF. Serum biomarkers in IPF may 
provide deeper insights into the disease pathogenesis suggesting new therapeutic approaches; in 
addition, they could be useful surrogate outcome measures to predict later clinical benefits.  
 
Summary 
Despite improvements in the clinical classification of patients with UIP, the pathological 
lesion of IPF, there is still no cure for this fatal disease.  Recent advances have led to more 
persistent models of experimental fibrosis and have created systems to allow for studies to target 
specific cell types as well as proteins that may play a role in lung fibrosis. Although these models 
still don’t recapitulate all the features of IPF pathogenesis they allow for specific analyses of 
signaling pathways and interactions among various cell types. Thus, we have taken advantage of 
animal models in our investigations. 
In the work that is discussed in this dissertation, we expanded our knowledge of how viruses 
and bacteria may or may not contribute to the exacerbation of established fibrosis and analyzed 
the cytokine signaling pathways that may regulate pathogen-augmented fibrosis.  Our results 
suggest that the ability of a pathogen to augment fibrosis may be restricted to certain pathogen 
types.  In addition, we utilized novel transgenic and chimeric mouse approaches to address the 
relevance of fibrocytes and their ability to secrete periostin in the development of fibrosis. We 
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demonstrated that periostin derived from fibrocytes increased XIAP, leading to apoptosis-
resistant myofibroblasts.  We also proved that fibrocytes function via these paracrine interactions 
as opposed to differentiation into myofibroblasts.  We showed periostin, CTGF and TGFβ co-
regulation pathways lead to the progression of fibrosis. Finally, this work also identified different 
proteins in the plasma of IPF patients that relate to immune response, protease and angiogenesis 
as predictors of IPF progression. 
 
 
The dissertation is outlined in the following manner: 
Chapter 1: The background related to all projects relevant to the dissertation. 
Chapter 2: The methods utilized in these projects and the reagents, animals and human 
subject data collected to address the biological questions of relevance to future chapters. 
Chapter 3: How do infections whether viral or bacterial exacerbates lung fibrosis? Results 
of this chapter were published in Am. J Physiol. Lung Cell Mol. Physiol. 
Chapter 4: How does periostin production by fibrocytes contribute to the pathogenesis of 
pulmonary fibrosis? Results of this chapter are in revision for Mucosal Immunology. 
Chapter 5: What is the effect of periostin on the accumulation of apoptosis-resistant 
myofibroblasts during lung fibrosis? Results of this chapter were published in Am. J Resp Cell 
and Mol. Biol 
Chapter 6: Can we use a proteomic approach to identify biomarkers that could play a role 
in disease progression and provide prognostic information for IPF patients? Results in this 
chapter have been submitted for publication. 
 Chapter 7: Conclusions and Future Directions.
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Chapter 2: 
Materials and Methods 
Animals 
 
Male wild type C57BL/6(B6, Ly5.1, and CD45.2) mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME). A number of different knockout mice were used for these studies.  
XIAP
-/y
 and wild type littermate control mice were bred at the University of Michigan. Because 
XIAP is an X-linked gene, male mice carrying a non-functional XIAP allele were designated as 
XIAP
-/y
 and are devoid of XIAP expression (338). Periostin
-/-
 mice were bred at the University of 
Michigan. These mice were originally purchased from Jackson laboratory on a 
129SvEvbackground but were backcrossed for eight generations onto the C57BL/6 background. 
For these studies wild-type C57BL/6 (B6) age and sex-matched mice were obtained from The 
Jackson Laboratory. Collagen-1A2-CRE mice were a generous gift from Paul Noble and were 
bred in the Unit for Laboratory Animal Medicine (ULAM). ROSA-Floxed-DTR mice were 
obtained from the Jackson laboratory. Crossing Collagen1a2-Cre mice with ROSA-floxed stop 
DTR mice generated collagen-1A2-CRE-DTR transgenic mice. These mice were used as bone 
marrow transplant donors to irradiated C57BL/6 (CD45.2) recipients so that donor vs recipient 
host cells could be distinguished by staining with CD45.1 and CD45.2 alleles using antibodies 
that are commercially available from BD PharMingen (San Diego, CA).  
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Both male and female mice were used in various studies between 6- 10 weeks of age. 
Mice were housed under pathogen-free conditions and provided food and water ad libitum. All 
animal experiments complied with the university and federal guidelines for humane use and care. 
Animals were anesthetized by i.p administration of 200 μl of a sterile solution of ketamine, 
xyaline and saline when required. All mice were euthanized by CO2 asphyxiation. 
Human Subjects 
 
Plasma samples from 60 IPF patients were used in the SOMAmer high throughput screen 
studies.  Patients were enrolled in the COMET multi-center, observational cohort study of well-
defined IPF patients that were followed at 16 week intervals out to approximately 80 weeks 
(NCT01071707); our subcohort consisted of 60 patients diagnosed by characteristic CT or 
pathology on lung biopsy with available baseline plasma and known 80-week progression status.  
Subjects underwent baseline assessment, including demographics, patient-reported descriptors, 
spirometry, diffusion capacity for carbon monoxide (DLCO), 6-minute walk testing and high 
resolution CT. Patients remained on their current therapy.  The combined endpoint was 
progression-free survival determined by the time until any of the following: death, acute 
exacerbation of IPF, lung transplant, or relative decrease in forced vital capacity (FVC, liters) of 
≥10% or DLCO (ml·min
−1
·mmHg
−1
) of 15%.   Each site received local Institutional Review 
Board approval. Studies and consent procedures were performed in accordance with the 
Declaration of Helsinki at the University of Michigan. All human subjects gave written informed 
consent. Peripheral blood was collected in EDTA-containing vacutainers at study centers and 
was shipped cold overnight to University of Michigan.  Whole blood was centrifuged at 2500 
rpm for 10 minutes and plasma was collected, aliquoted and frozen (-80
o
C).  Samples shipped to 
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SomaLogics were diluted to 3 different concentrations for analysis at optimal concentrations for 
each SOMAmer. 
Bone Marrow Transplant 
 
Recipient mice were treated with 13 Gy total body irradiation using a cesium 137 
irradiator, delivered in two doses separated by 3 hours. Whole bone marrow was harvested from 
the femur and tibia of collagen1a2-CRE-DTR donor mice and resuspended in serum-free 
medium (SFM; DMEM, 0.1% BSA, 1% penicillin-streptomycin, 1% L-glutamine and 0.1% 
Amphotericin B). Donor bone marrow cells (5x 10
6
) were injected via the tail vein into irradiated 
C57BL/6(CD45.2) recipient mice. Mice were given acid water (ph3.3) for the first 3 weeks after 
BMT. All experiments with BMT mice were performed 5-6 weeks post-BMT. Total numbers of 
hematopoietic cells were fully reconstituted in the lungs and spleen at this timepoint, with the 
percentage of donor-derived cells being 93% (339). 
Harvesting Alveolar Macrophages (AMs) 
 
Resident AMs were harvested from mice by ex vivo broncheoalveolar lavage using a 
previously described protocol(340). Briefly, AMs were collected in complete medium (DMEM, 
10% fetal-calf serum (FCS), 1% penicillin-streptomycin, 1% L-glutamine, 0.1% Fungizone) and 
5mM EDTA.  Red blood cells were lysed with 3 mL of RBC lysis buffer for 2 mins on ice, and 
then diluted in 10 mls of Dulbecco’s phosphate buffered saline (PBS). Cells were enumerated on 
a hemocytometer by trypan blue exclusion before plating. 
P.aeruginosa PA01 and FITC Labeling  
 
A culture of P.aeruginosa was grown in tryptic soy broth (Difco, Franklin, NJ). The 
culture concentration was determined using absorbance measurements as previously described 
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(341).  For FITC labeling, P.aeruginosa culture was centrifuged and washed two times by 
resuspending the pellet in 1mL of sterile PBS and transferred to a new tube. The bacteria was 
heat killed by autoclaving for 20 mins then resuspended at 10
9
-10
10
 colony forming units per mL 
(CFU/mL) in 0.1 mL in 0.1M NAHCO3 (pH 9.2). A total of 0.2mg/mL FITC (Sigma Aldrich, St 
Louis, MO) in DMSO was added to the heat killed P.aeruginosa and allowed to incubate in the 
dark for 1 hour at room temperature with constant shaking. Following FITC-labeling, heat killed 
P aeruginosa was washed three times and resuspended in sterile PBS at 6 x10
9
 CFU/mL. 
Infection with P. aeruginosa 
 
As previously described, P. aeruginosa PA01 inoculum was prepared for injection into 
mice. Mice were anesthetized and i.t injected with 50 uL of inoculum equivalent to a sublethal 
dose of 5 x 10
5
 CFU as previously described (340, 342).  
Quantification of Bacterial Burden in the Blood and Lung 
 
Mice were euthanized 24h following i.t infection with P. aeruginosa. Blood and whole 
lung samples were collected from each mouse and bacterial burden in whole lung and blood 
samples were analyzed by CFU assay as previously described (342). Data are expressed as total 
CFU per lung. 
In Vitro Phagocytosis Assay 
 
AMs phagocytosis of FITC-labeled P. aeruginosa was measured in vitro as previously 
described (343). Briefly, AMs were harvested and the ability of AMs from saline (control) and 
bleomycin-treated mice to phagocytize bacteria was assessed. Cells were plated out at 2 x10
5
 
cells per well in 100uL of complete media on a 96-well, flat-bottomed, half-area tissue culture 
plate (Costar) and cultured overnight. The following day the media was aspirated and replaced 
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with 100 uL of SFM. AMs were incubated at 37° C with FITC-labeled P. aeruginosa at 300:1 
multiplicity of infection. Two hours post-incubation, 50 L of trypan blue (250 g/mL in 0.09 M 
Citrate buffer solutions, Sigma) was added to each well to quench fluorescence of non-
phagocytized FITC labeled P. aeruginosa. AMs phagocytosis of FITC-labeled bacteria was 
measured using a microplate fluorimeter and expressed in arbitrary fluorescence intensity units. 
For differences in AM cell numbers that adhered to the plate, data were normalized for cell 
number using a LDH Cytoxicity Detection Kit (Roche Diagnostics) as previously described 
(342). 
 Bacterial Killing and Tetrazolium Dye Reduction Assay 
 
AMs were isolated from BALs of saline control and bleomycin-treated mice. The ability 
of AMs from control and bleomycin-treated mice to kill P. aeruginosa was quantified using 
tetrazolium dye reduction assay as described elsewhere(344). Briefly, AMs from saline or 
bleomycin-treated mice were plated at 2X10
5
 cells per well on to two 96-well tissue culture 
plate; one control (4C) and one experimental (37C). Cells on both plates were infected with 
IgG-opsonized P. aeruginosa at 50:1 multiplicity of infection for 30 mins at 37°C. Cells on 
experimental plate were washed and incubated for 2h at 37°C, whereas cells on control plate 
were washed and lysed in 0.5% saponin in tryptic soy broth (Sigma) and placed at 4°C. After 2h, 
the experimental plate was washed and lysed in 0.5% saponin in tryptic soy broth. Both plates 
were then incubated at 37C for 3 hours. Five mg/mL of MTT (sigma) was added to each plate 
and incubated for 30 mins or until a purple precipitate was visible. Solubilization solution was 
added to dissolve the formazan salts and the absorbance was measured at 595nm. Results were 
expressed as a percentage of survival of ingested bacteria normalized to percentage of control, 
where A595 experiment values were divided by the average of the A595 control values. Survival of 
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ingested bacteria =(A595 experimental/ A595 control) x 100%. The results were expressed as 
“percent of control’ to indicate the percentage survival of ingested bacteria normalized to the 
percentage of control. 
Viral Infection 
 
Mice were anesthetized and infected intranasally with 50 plaque-forming units (PFU) of 
Influenza A virus (A/PR/8/34(H1N1), 5 x10
4
 PFU of γHV-68 clone WUMS (American Type 
Culture Collection, Manassas, VA) or 5 x10
4
 PFU ∆ORF72 (a v-cyclin mutant virus described 
previously) in 20µL saline. Other mice were mock infected with 20 μL saline.  
Viral Plaque Assay 
 
3T12 cells (American Type Culture Collection) were cultured in DMEM with 4% FBS, 
harvested using trypsin digestion and added to 12-well plates at 8.33 x 10
4
 cells per well. The 
cells were incubated overnight to confirm greater than 70% confluence. Whole lungs from 
infected mice were homogenized in 2 mLs DMEM with complete® protease inhibitor cocktail 
(Roche diagnostics) and Triton X-100 (7μL/7mL media; Sigma. St Louis, MO) then centrifuged 
at 1500 rpm for 5 minutes at 4°C. Dilutions were made in DMEM from the supernatant. 250 μL 
of each dilution was placed on the 3T12 cells; the plates were then incubated at 37°C and rocked 
every 15mins for 1 hour. The inoculum was not removed and overlaid with 0.75% 
carboxymethylcellulose and 2X MEM with 10% FBS was layered onto the cell monolayers. The 
plates were incubated at 37°C. On day 6, the overlay was removed and the cells were fixed and 
stained with 70% methanol and 0.35% methylene blue to assess plaque formation. 
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Total Lung Leukocyte Preparation 
 
Whole lung samples were harvested from mice and collagenase-digested as previously 
described (343). Briefly, lungs were collected, minced and enzymatically digested for 30 mins 
using 15 mL/lung of digestion buffer (complete media, 1mg/mL collagenase and 30μg/mL 
DNase).  The undigested tissue fragments were further dispersed by repeated passage through a 
10mL syringe. The total cell suspension was pelleted and red blood cells lysed with RBC lysis 
buffer as described above. Cells were centrifuged and resuspended in 5 mLs SFM, where the 
cells were again dispersed by passing through a 10 mL syringe 20 times. The dispersed cells 
were filtered through a Nytex filter (Sefar, Depew, NY) to remove clumps. The final volume was 
brought up to 10mL with complete media. An equal volume of 40% Percoll (Sigma) in complete 
media was added, and the cells were centrifuged at 3000 rpm for 20 mins with no brake.  The 
cell pellets were resuspended in complete media and total leukocytes were counted on a 
hemacytometer by trypan blue exclusion. Differential analysis was done using the BAL cells and 
total lung cells isolated from the collagenase-digested whole lung samples to determine the 
percentage of neutrophils, eosinophils, monocytes/macrophages and lymphocytes as previously 
described (343). 
Flow Cytometry 
 
Whole lungs were enzymatically digested using collagenase and DNase(93) and 
leukocytes were isolated. Leukocytes were incubated with Fc block (1:100) clone 24G2 (BD 
Pharmingen, San Diego, CA) for 15mins, then stained with CD45-PerCPCy5.5, CD4-PE, CD8-
FITC (1:500 dilution, BD Pharmingen) to label cell surface markers. To assess fibrocyte markers, 
surface-stained cells were then followed by fixation/permeabilization using the BD Pharmingen 
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Cytofix/cytoperm kit according to manufacturer’s instructions. Cells were washed twice and then 
incubated with rabbit anti-mouse collagen I ( 1:400, Rockland, Immunochemicals, Gelbertville, 
PA) or rabbit IgG 1:2000, Jackson ImmunoResearch, West Grove, PA) as an isotype control and 
secondary antibody Donkey anti-rabbit PE (1:200, Jackson ImmunoResearch).  Cells were 
analyzed on the flow cytometer (FACScan, BD Biosciences,  Mountain View, CA). The cells 
were further analyzed using the Flow Jo software (FlowJo LLC, Ashland, OR).  
 Bleomycin Injections 
 
For bleomycin experiments, mice were given bleomycin (0.025 U (Sigma) dissolved in 
sterile saline in a 50-μl volume) intratracheally as described previously(93) or via oropharyngeal 
aspiration. In some experiments, AT-406, an orally bioactive Smac/Diablo mimetic, which was 
provided by Dr. Wang’s laboratory (345), was administered at a dose of 100 mg/kg by oral 
gavage daily starting either on day 0 or day 10 post-bleomycin. 
Mesenchymal Cell Isolation 
 
Lung mesenchymal cells were grown for two weeks from lung minces.  At this time, all 
cells expressed collagen I and were designated lung mesenchymal cells.  In some experiments, 
mesenchymal cells were magnetically sorted for expression of CD45 to obtain CD45
+
 collagen I
+
 
fibrocytes or CD45
- 
collagen I
+
 fibroblasts as previously described (94). Briefly, labeled cells 
were then sorted using LS-positive selection columns using a SuperMacs apparatus (Miltenyi 
Biotech) according to manufacturer's instructions. For extra purity, CD45+ cells were sometimes 
reapplied to a second LS-positive selection column.  
Adoptive Transfer 
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Fibrocytes were purified by magnetic separation from lung mince cultures from untreated 
wild-type or periostin
-/-
 mice as described above. 5 × 10
5
 fibrocytes were injected via tail vein in 
a 200-μl volume into mice that had received bleomycin inoculation intratracheally 4 d 
previously. Mice were harvested and lungs collected on day 21 after bleomycin, and lung 
collagen content was determined by hydroxyproline assay. 
Type II Alveolar Epithelial Cells (AEC) Purification  
 
 Type II AECs were isolated using dispase and DNase digestion of the lower lungs as 
previously described (346). Bone marrow-derived cells were removed via anti-CD45 and anti-
CD32 magnetic bead depletion. Mesenchymal cells were removed by overnight adherence to 
tissue culture plates. After the initial plating, AECS were isolated from the remainder of non-
adherent cells by putting the non-adherent cells on fibronectin-coated tissue culture plates. Cells 
were harvested or treated 3 days after adhering to the fibronectin-coated plates. 
Lung Histology 
 
 Hematoxylin and eosin (H&E) and Picrosirius Red staining were done as previously 
reported (93, 347). 
Lung Collagen Measurements 
 
Collagen deposition in the lungs of all mice from each treatment group was measured 
using a hydroxyproline assay as described previously (93). Hydroxyproline is a useful surrogate 
for measuring collagen content because elastin is the only mammalian protein besides collagen 
that contains hydroxyproline. Mice were euthanized and perfused via the heart with 5 mLs of 
PBS. Individual lobes were removed and homogenized in 1mL PBS with protease inhibitor, then 
500 μL of the homogenate was hydrolyzed by the addition of 500 μL of 12N hydrochloric acid 
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(HCL). Samples were then incubated in the oven overnight at 120°C. Aliquots (5 μL) were then 
assayed by adding Chloramine T solution for 20 mins followed by development with Erlich’s 
reagent at 65°C for 15 mins. Absorbance was measured 540 nm, and the amount of 
hydroxyproline was determined against a standard curve generated using known concentrations 
of hydroxyproline standard (Sigma). 
In vivo Apoptosis Assessments 
 
To assess total apoptosis in the whole lung lysate, active caspase 3/7 levels were 
measured using Promega Caspase-Glo 3/7 Assay, according to manufacturer’s protocol. Samples 
were analyzed using a Veritas Microplate Luminometer and results normalized to the PBS 
treated lungs. Immunostaining for TUNEL and α-smooth muscle actin was done as previously 
described (347).  
In vitro Apoptosis Assay 
 
Mesenchymal cell apoptosis was induced by treatment with activating anti-Fas antibody 
CH11 (Millipore, Billercia, MA) and assessed through identification of caspase 3/7 activity as 
previously described (347).  
Enzyme-linked Immunoassay/ELISA 
 
Whole lung homogenates were prepared for analysis of cytokines and chemokines as 
described previously (343). Each ELISA assay was done using a Duoset ELISA kit (R&D 
systems, Minneapolis, MN) according to manufacturer’s instructions. Some of the ELISA 
measurements for TGFβ and periostin were performed on lung mesenchymal cells supernatants 
according to manufacturers’ instructions. The CTGF ELISA was purchased from NeoBiolab 
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(Cambridge, Massachusetts) and the levels of CTGF were assessed in fibrocyte supernatants 
post-bleomycin treatment according to manufacturers’ instructions. 
Western Blot 
 
4 x 10
5 
AECs, primary fibrocytes or fibroblasts were plated per well on a 6- well tissue 
culture plates.  After treatment cells were washed with cold PBS and lysed in 
radioimmunoprecipitation assay (RIPA) buffer with protease inhibitor cocktail [Sigma]) for 15 
min at 4°C and centrifuged.  Total protein concentrations in each sample were determined using 
the Bicinchoninic acid assay (Thermo Scientific, Rockford, IL). 5 to 10 μg of protein from each 
lysate was separated on a 4-20% gradient SDS-polyacrylamide gel (Invitrogen, Carlsbad, CA) 
and transferred to a PVDF membrane (Amersham/GE Healthcare, Pittsburgh, PA). For some 
experiments PVDF membranes were probed with rabbit polyclonal poly ADP ribose polymerase 
(PARP), GAPDH, SMAD3 (Cell signaling, Beverly, MA), monoclonal αSMA and β-Actin 
(Sigma) as a loading control. 
Semiquantitative real-time RT-PCR 
 
Semiquantitative real time RT-PCR was performed on an Applied Biosytems StepOne 
Plus thermocycler (Applied Biosystems, Foster City, CA). Gene specific primers and probes 
were designed using GeneScript online software (Piscataway, NJ). Sequences for primers and 
probes used can be found in Table 1.  LOX expression was measured using Taqman® Probes 
based assay (Applied Biosystems, Foster City, CA). RNA was extracted from the BAL cells or 
left lung or mesenchymal cells using TRIzol reagent (Invitrogen, Carlsbad, CA) then  used in the 
real-time PCR.  Gene specific primers and probes were purchased from Sigma-Aldrich (St Louis, 
MO). Relative expression was calculated using the comparative CT method with beta actin (β-
actin) as an internal standard gene control. Fold change in mRNA was quantified using the ΔΔCT 
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method.  Additionally, RNA isolated from bleomycin-treated WT and periostin 
-/- 
fibrocytes was 
analyzed using the Mouse Fibrosis RT
2
 Profiler 
TM 
PCR Array (PAM120ZE-4) and then 
confirmed using gene specific primers and probes as previously described. 
Table 1: List of primers and probes used for the real-RT-PCR experiments 
Gene Name Oligo Sequences (5'- 3')     
Beta Actin Forward CCGTGAAAGATGACCCAGATC     
  Reverse CACAGCCTGGATGGCTACGT     
  Probe TTTGAGACCTTCAACACCCCCAGCCA     
          
Integrin 
Alpha1  
Forward ATTTATCATGGCAGTGGCAA     
  Reverse AATTTCAGCGTCTTCCCATC     
  Probe ATGCGCAACGCATTCCCTCA     
          
Integrin 
AlphaV 
Forward TGAGAATCAAGACACCCGAA     
  Reverse TGATTCCTTTCTCCCTGTCC     
  Probe CGCCGCCGCTGTGTCATT     
          
Integrin Beta 
1 
Forward CTCCAGAAGGTGGCTTTGAT     
  Reverse TGTTACATTCCTCCAGCCAA     
  Probe TCAGCGATCCACAAACCGCA     
          
Integrin Beta 
3 
Forward AAGTGGGACACAGCAAACAA     
  Reverse CCGGTAGGTGATATTGGTGA     
  Probe CCGCTGTATAAAGAGGCCACCTCCA     
          
Integrin Beta 
5 
Forward TACAGTAGCATCCGGGCTAA     
  Reverse CAGGTGGCAGTGAAGAAGAG     
  Probe TGGCTGATCCCACACTGACAGC     
          
CTGF Forward GAGTGTGCACTGCCAAAGAT     
  Reverse GGCAAGTGCATTGGTATTTG     
  Probe CGCAGCGGTGAGTCCTTCCA     
          
PDGFα Forward CGAAGTCAGATCCACAGCAT     
  Reverse GGGCTCTCAGACTTGTCTCC     
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  Probe CCGGGACCTCCAGCGACTCT     
          
ET-1 Forward CGTATGGACTGGGAGGTTCT     
  Reverse TCTAACTGCCTGGTCTGTGG     
  Probe TCCAGGTCCAAGCGTTCCTTGA     
          
DNApol Forward ACAGCAGCTGGCCATAAAGG     
  Reverse TCCTGCCCTGGAAAGTGATG     
  Probe CCTCTGGAATGTTGCCTTGCCTCCA     
          
gB Forward CGCTCATTACGGCCCAAA     
  Reverse ACCACGCCCTGGACAACTC     
  Probe TTGCCTATGACAAGCTGACCACCA     
          
cIAP1  Forward AGCACGCCTGTGGTTAAA     
  Reverse CATTGACGGTCCTGTAGTTCTC     
  Probe TCCTACTGAAGCCCATTTCCAAGGC     
          
cIAP2  Forward CGCAGCAATCGTGCATTT     
  Reverse  GCTCCTACTGAAGCCCATTT     
  Probe ATCTTCCGAACTTTCTCCAGGGCC     
          
mPOSTN  Forward GGGGTTGTCACTGTGAACTG     
  Reverse CGGCTGCTCTAAATGATGAA     
  Probe CGTGTCCTGACACAAATTGG     
          
COL I  Forward TGACTGGAAGAGCGGAGAGTACT     
  Reverse GGTCTGACCTGTCTCCATGTTG     
  Probe CTGCAACCTGGACGCCATCAAGG     
 
Reagents Used 
 
Complete media is DMEM (Lonza, Walkersville, MD) with 10% FBS, 1 % penicillin-
streptomycin, 1% L-glutamine, and 0.1% Amphotericin B (Lonza). SFM is DMEM with 0.1% 
bovine serum albumin (Sigma), 1% penicillin-streptomycin, 1% L-glutamine and 0.1% 
Amphotericin B.  
Statistical Analysis 
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Statistical analysis was measured by analysis of variance or Student t test using GraphPad 
Prism 6 software (San Diego, CA). Comparisons between three or more experimental groups 
were performed with ANOVA. Data shown represents SEM+/-, P< 0.05 was considered 
significant. 
For the proteomic studies assessing biomarkers in the plasma from IPF patients; each 
SOMAmer analyte is reported in relative fluorescent units (RFU) and is directly proportional to 
the amount of native protein in the sample.  Steps in constructing the disease progression index: 
1. Ability of each continuous biomarker to predict IPF progression status at 80 weeks was 
evaluated via ROC curves and a biomarker threshold was chosen to maximize combined 
sensitivity plus specificity. Estimated AUC > 0.7 from ROC analysis of the biomarker as 
a binary variable (above versus below its threshold) was required for further 
consideration.   
2. Both unadjusted and adjusted odds ratios for 80-week progression were estimated 
separately via logistic regression.  Adjustment factors included age, gender, smoking 
status, baseline percent predicted FVC and baseline percent predicted DLCO.  Biomarker 
threshold variables had to maintain statistical significance at the 0.05 level in both 
unadjusted and adjusted analyses, and odds ratios from these models had to maintain the 
same direction of association 
3. To ensure independent prognostic ability of biomarker threshold variables when used in 
combination, both multivariable logistic and Cox regression models were investigated.  
Based on available sample size, a limit of four biomarker threshold variables in each 
multivariable model was enforced to prevent model instability. Automated model 
selection via the score method identified the top four binary biomarkers based on (a) 
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multivariable logistic regression predicting 80-week progression status and (b) 
multivariable Cox proportional hazard regression predicting time to progression over the 
80 week follow-up period.  Between the two models, 6 unique biomarker threshold 
variables were identified with p < 0.05 for predicting either 80-week progression status or 
time-to-progression; these were used to create the IPF progression index.   
4. For the 6-biomarker threshold variables used in the index, we estimated the difference in 
progression-free days during the first 80 weeks of follow-up using area between Kaplan-
Meier estimates of progression-free survival for those above and below each biomarker 
threshold.  These differences were used to generate a weighted numeric score.  
5.  To calculate this score, for each patient, if baseline levels of LGMN were below 5173.33 
RFU, then the score got +3; if FCN2 was below 2015.33 RFU, then the score got +2; if 
VEGFsR2 was below 9559.30 RFU, then the score got +1; if Cath-S was below 1451.44 
RFU, then the score got +1; if TRY3 went above 928.22 RFU, then the score got +2; if 
ICOS went above 8032.61 RFU, then the score got +2.  This generates a score for each 
patient accounting for all 6 biomarkers on a scale of 0 to 11. 
Analyses evaluating the IPF progression index were then conducted.  Three severity 
groups based on the index were created and evaluated via Cox regression and ROC analysis.  
Progression-free Kaplan-Meier survival curves for the 3 severity groups were displayed.  We 
performed boot-strap analysis to determine how this index would perform theoretically in 
additional patient cohorts.  Analyses were performed using SAS 9.4 (SAS Institute, Inc.), 
with plots created using R 3.2.0 (The R Foundation for Statistical Computing Platform). 
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Chapter 3: 
γ-Herpesvirus-68, but not Pseudomonas aeruginosa or Influenza A (H1N1) Exacerbate 
Established Murine Lung Fibrosis 
 
Background 
 
Fibrosis is a condition characterized by the deposition of extracellular matrix (ECM) 
proteins such as collagen and fibronectin causing stiffening of interstitial tissue or airways when 
it occurs in the lung.  Fibrosis can be triggered by known agents such as allergens, toxic 
chemicals and radiation or can occur for unknown reasons such as in the case of idiopathic 
pulmonary fibrosis (IPF) (348). IPF is a progressive disease eventually causing death from 
respiratory insufficiency usually within 2-5 years of diagnosis.  Lung transplantation is the only 
proven therapy in the United States and this procedure has a median patient survival rate of 3 
years (349). The pathogenesis of IPF remains unknown but key events likely involve continuous 
cycles of injury and abnormal repair with evidence suggesting that the variation in fibrotic 
lesions is due to repeated lung injury over the course of the disease (350). Chronic viral infection, 
mainly herpesviruses have been implicated as one cause of ongoing epithelial injury and 
therefore have been implicated as a cofactor in either the initiation or exacerbation of the disease 
[reviewed in (351)].  
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Previous studies have shown the presence of Epstein-Barr virus (EBV), cytomegalovirus, 
herpes simplex virus 1, as well as human herpesviruses (HHV)-7 and 8 in lung tissue of human 
IPF patients (113, 114, 116, 352). However, this is somewhat controversial as other studies 
found no association between herpesviral infection and IPF (353, 354). There is strong evidence 
in animal models linking γ herpesvirus infection with development of fibrosis in T helper type 2 
(Th2) biased mice (119, 120, 355, 356).   In these cases, fibrosis was associated with persistent 
reactivation of the virus and development of alternatively activated macrophages (120, 140, 356, 
357).  Additionally, infection of aged mice with murine γ herpesvirus-68 (γHV-68) results in 
development of lung fibrosis (122, 123) and the pathogenic mechanisms have been shown to 
include epithelial cell stress and apoptosis and enhanced susceptibility of fibroblasts to viral-
induced TGFβ secretion. 
We previously showed that γHV-68 infection given prior to stimulation with bleomycin 
or fluorescein isothiocyanate (FITC) augmented development of lung fibrosis (346).  Possible 
mechanisms involved alterations in alveolar epithelial cells such as increased synthesis of 
cysteinyl leukotrienes, induction of transforming growth factor beta (TGF)-β and recruitment of 
circulating fibrocytes (346).  Similarly, infection of mice with γHV-68 after the establishment of 
lung fibrosis worsened deposition of collagen within the lung, and this increased fibrosis 
correlated with enhanced production of IL-13, IFNγ and TNFα (129).  Exacerbation of fibrosis 
required virus capable of replication as UV-inactivated virus did not exacerbate disease (129). 
This study aimed to investigate whether the ability to exacerbate established pulmonary 
fibrosis in mice was unique to γHV-68 or whether other inflammatory/infectious insults could 
augment fibrosis. Thus, we sought to determine whether an acute bacterial infection with 
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Pseudomonas aeruginosa (P. aeruginosa) or an acute viral infection that does not establish 
latency, influenza A (H1N1) could augment fibrotic outcomes.   
  P. aeruginosa is a Gram-negative opportunistic human pathogen which rarely causes 
disease in healthy individuals. However, P. aeruginosa is responsible for life threatening 
infections in immunocompromised patients, the elderly and following prolonged hospitalization 
(358). Clearance of P. aeruginosa from the lungs requires a functional innate immune system 
with the involvement of macrophages and polymorphonuclear leukocytes (PMNs)(359). 
Influenza A is a RNA virus which replicates in the respiratory epithelium leading to the 
infiltration of inflammatory cells, mainly mononuclear leukocytes and small numbers of PMNs. 
Innate defense against influenza A infection involves the production of high levels of type I 
interferons by infected epithelial cells, AMs, recruited conventional dendritic cells (cDCs), 
PMNs and NK cells (360-362).  DCs lining the airways play key roles in activating effector CD8 
T cells mediating viral clearance and protection (363, 364). In contrast, γHV-68 can infect a 
variety of cells within the lung including epithelial cells, fibroblasts, macrophages and B cells 
(121, 365).  There is low level induction of type I interferon and plasmacytoid DCs are necessary 
to activate cDCs (366).  Production of both IFNγ and perforin are important for viral control 
(367, 368).   In this study,  bleomycin was used to establish fibrosis in mice, and then, the ability 
of P. aeruginosa, H1N1 and γHV-68 to exacerbate the fibrotic response was examined. 
Results 
P. aeruginosa infection had no effect on bleomycin-induced pulmonary fibrosis 
 
To determine the effects of P. aeruginosa infection on established pulmonary fibrosis, 
mice were given intratracheal saline or bleomycin on day 0. On day 14, mice were then given 5 x 
10
5
 CFU P. aeruginosa intratracheally or were mock infected.  All lungs were harvested on day 
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21 and lung collagen content was measured by hydroxyproline assay.  As expected, bleomycin-
treated mice showed significant increases in collagen content when compared to saline controls.  
However, subsequent infection of bleomycin-treated mice with P. aeruginosa showed no 
significant increase in collagen content when compared to bleomycin-treated mice that were 
mock infected (Figure 7).  Thus, P. aeruginosa infection in wild type mice did not exacerbate 
bleomycin-induced fibrotic response in the lungs.  Furthermore, at this dose of infection, there 
was no difference in the survival of bleomycin-treated mice that were mock infected or infected 
with P. aeruginosa. 
 
Figure 7: P. aeruginosa infection did not exacerbate bleomycin-induced fibrosis. 
Wild-type mice were given bleomycin or saline intratracheally on day 0. On day 14, half of the 
mice in each group were given P. aeruginosa intratracheally or saline as a vehicle control.   
Lungs were harvested on day 21 for hydroxyproline assay. Data shown represent n= 6-10 mice 
per group pooled from three independent experiments. 
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Fibrotic mice did not show increased susceptibility to P. aeruginosa 
 
To determine whether the bleomycin-treated mice were more susceptible to infection 
with P. aeruginosa, mice were treated with saline or bleomycin as previously described. On day 
14, both groups of mice were infected with 5 X 10
5
 CFU P. aeruginosa. Blood and lungs were 
collected on day 15 (24 h post-infection, a time point noted for maximal bacterial growth post-
infection) (342) and plated for CFU assay.   Mice treated with bleomycin prior to infection with 
P. aeruginosa showed no difference in bacterial load in the lung (Fig 8A) or in the blood (Fig 
8B) compared to mice first treated with saline.   
 
Figure 8: Bleomycin-treated mice showed no defect in the clearance of P. aeruginosa 
infection.   
Mice were first treated with saline or bleomycin on day 0 followed by infection with P. 
aeruginosa on day 14.  On day 15 lungs (A) and blood (B) were collected for CFU analysis.  
Data represent n=5-8 mice per group from two independent experiments. 
 
 
H1N1 Influenza A infection did not exacerbate bleomycin-induced fibrosis 
 
To determine whether the exacerbation of established pulmonary fibrosis could occur 
with an acute viral infection that does not establish latency. Wild type mice were treated with 
bleomycin or saline on day 0. On day 14, a time of established pulmonary fibrosis, bleomycin-
treated mice received 5 × 10
4 PFU γHV-68 or 50 PFU H1N1 intranasally or were mock infected.  
These doses were chosen to be non-lethal in control mice.  Lungs were harvested on day 21 to 
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measure lung collagen content by hydroxyproline assay.  Figure 9A demonstrates that 
subsequent γHV-68 infection resulted in significantly more collagen deposition in the lungs than 
did bleomycin treatment followed by mock infection or bleomycin followed by H1N1 infection 
(p< 0.05).  These data replicated early findings that γHV-68 can exacerbate established lung 
fibrosis (129).  However, H1N1 was not able to exacerbate fibrosis at day 21.   
To see if H1N1 might be able to exacerbate bleomycin-induced fibrosis at an earlier time 
point that corresponded to expected peak viral replication, mice injected with bleomycin on day 
0 were infected with H1N1 on day 18 and lungs were harvested for hydroxyproline content on 
day 21 (Figure 9B); however, no elevations in collagen deposition were noted at this time point 
either. To determine whether H1N1 or γHV-68 infection altered fibrosis at a later time point, 
another experiment was set up to harvest lungs at days 21 and 35 following the same initial 
treatments (Figure 9C and D).  Levels of fibrosis in γHV-68-infected mice were still the highest 
of all groups, and the only ones to show significant increases over bleomycin and mock infection.  
Figure 10 shows representative histology of lungs from all 3 groups of mice harvested at day 21. 
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Figure 9: H1N1 infection did not exacerbate bleomycin-induced pulmonary fibrosis.  
A) Mice were given bleomycin or saline intratracheally on day 0. On day 14, bleomycin or 
saline-treated mice received γHV-68, H1N1 or saline intranasally.  Lungs were harvested for 
collagen determination on day 21. B) On day 18, bleomycin-treated mice received H1N1 or 
saline intranasally. Lungs were harvested 3 days post infection to measure collagen content and 
were compared to mice treated with saline alone. Data represents n=5-8 mice per group collected 
in two independent experiments. C and D) In a separate experiment, mice were treated with 
saline or bleomycin on day 0, viral or mock infections occurred at day 14 and lungs were 
harvested at day 21 or 35; n=3-6 mice per group. 
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Figure 10: Histologic analyses.  
Immunohistochemistry showing representative lungs of mice treated with bleomycin + vehicle 
control (saline), bleomycin + γHV-68 infection or bleomycin + H1N1 infection.  Shown are 
hematoxylin and eosin or Masson’s trichrome staining.  Magnification is 200x.  Left panels) 
Mice treated with bleomycin were harvested on day 21 post-injection and show diffuse 
mononuclear infiltrates and collagen deposition noted as blue coloration in the bottom panel.  
Middle panels) Mice were infected with bleomycin on day 0 and infected with γHV-68 on day 
14.  Lungs were harvested on day 21 and show both focal areas of dense mononuclear 
inflammatory cells as well as diffuse inflammation. Collagen deposition was noted within the 
interstitium.  Right panels) Mice were injected with bleomycin on day 0 and H1N1 on day 14.  
Lungs were harvested on day 21 and showed diffuse mononuclear infiltration.  While collagen 
deposition was seen within the interstitium, it is similar to that noted in mice treated with 
bleomycin alone.  Overall, the mice treated with bleomycin + γHV-68 showed the greatest 
degree of lung involvement. Representative of n=4 lungs in each group 
 
γHV-68 replication was enhanced post-bleomycin and the ability to reactivate from latency was 
required for exacerbation of fibrotic response 
 
To determine the levels of viral replication which were present in the lungs on day 21, 
total lung RNA was subjected to RT-PCR analysis for expression of the influenza M1 gene 
(Figure 11A) or for the lytic γHV-68 DNA polymerase (DNA pol)( Figure 11B).  These levels 
were compared to animals that had been given saline prior to viral infection.  Regarding H1N1 
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infection, expression of M1 was significantly decreased 7 days post-infection (dpi) between mice 
that were pretreated with saline or pretreated with bleomycin.  This suggested that bleomycin 
administration did not make the mice more susceptible to H1N1 replication measured at 7 dpi. 
Because of the low level inoculum of H1N1 (50 PFU) or perhaps due to viral clearance, we 
could not detect virus by plaque assay in the lungs at either day 3 or day 7 post-infection in 
saline or bleomycin-pretreated mice (data not shown).   In contrast, the γHV-68 DNA pol gene 
was significantly elevated 7 dpi in bleomycin-treated mice when compared to saline-treated mice 
confirming earlier observations (129).  In addition, we were able to demonstrate virus by plaque 
assay following γHV-68 infection (Figure 11C).   
 
Figure 11: γHV-68 replicated to a greater extent than did H1N1 post-bleomycin.   
Mice were injected on day 0 with saline or bleomycin.  On day 14 mice were infected with γHV-
68 or H1N1.  On day 21, lungs were collected and levels of H1N1 viral M1 (A) or γHV-68 DNA 
polymerase (DNA pol) (B) gene expression were measured by real-time RT-PCR. C) Similarly 
lungs were collected from mice infected with γHV-68 on days 17 and 21 and virus titers in the 
lungs were measured by plaque assay. Data shown are from n=3-5 lungs/group representative of 
2 experiments. 
 
Exacerbation of lung fibrosis by γHV-68 required the ability to reactivate from latency and was 
not a property shared by cytomegalovirus (CMV) 
 
 A v-cyclin mutant γHV-68 (ΔORF72) is 100-fold decreased in its ability to reactivate 
from latency (369).  In our hands, mice infected with ΔORF72 display decreased replication 
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within the lung compared to wild-type marker rescue virus by day 3 post-infection (data not 
shown).  To see if on-going viral replication was required to promote fibrosis, we infected 
bleomycin-treated mice with mock control, marker-rescue virus or ΔORF72 mutant virus and 
analyzed collagen deposition at day 21 (Figure 12A).  Wild-type (marker rescue) virus 
significantly enhanced fibrosis whereas ΔORF72 did not.  Surprisingly, infection with a β 
herpesvirus, CMV did not exacerbate bleomycin-induced fibrosis either (Figure 12B). There 
was no plaque formation of infectious CMV from the lungs of these C57Bl/6 mice, but the 
expressions of viral E1 and envelope gB proteins were detectable by real-time RT-PCR (Figure 
13).  
 
Figure 12: Exacerbation of bleomycin-induced fibrosis was specific to γHV-68 and dependent on 
viral replication.  
Mice were first treated with saline or bleomycin on day 0. On day 14 mice were infected with A) 
5x10
4
 PFU of γHV-68 containing a mutation in the v-cyclin gene (ΔORF72) or marker rescue 
(essentially wild-type) virus or B) 5 x 10
4
 murine cytomegalovirus (CMV) or were mock 
infected. On day 21, lungs were harvested for collagen determination. Data shown represents n= 
5-8 mice per group collected in two independent experiments; *p<0.05. 
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Figure 13: Detection of CMV viral genes in mice post-bleomycin and CMV infection.  
Mice were injected on day 0 with saline or bleomycin.  On day 14 mice were infected with 5 x 
10
4
 murine cytomegalovirus (CMV) or were mock infected. On day 21, lungs were collected and 
levels of CMV viral (A) gB and (B) Early 1 (E1) gene expression were measured by real-time 
RT-PCR. Data shown are from n=3-5 lungs/group representative of 2 experiments. 
 
 
The profibrotic effects of γHV-68 compared to H1N1 and P. aeruginosa infection were not 
explained by inflammatory cell recruitment. 
 To determine whether the inflammatory cell composition was different following the 
various infections, mice were treated with bleomycin on day 0.  Next, bleomycin-treated mice 
were infected with P. aeruginosa, H1N1 or γHV-68 on day 14. Lungs were harvested on days 15 
or 21 which represent 1 and 7 dpi respectively. Single cell suspensions were isolated, counted 
and analyzed by flow cytometry to assess leukocyte populations.  As demonstrated in Figure 
14A, total cells were not different between groups at day 15, but there was a noticeable increase 
in the percentage of CD45+ leukocytes in the P. aeruginosa infected mice at this time point 
(Figure 14B).  This increased percentage of leukocytes in the P. aeruginosa group was not 
maintained at day 21, consistent with rapid clearance of the organism from the lungs (Figure 
14C).  In contrast, the viral infected mice showed increased percentages of CD45+ leukocytes on 
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day 21, consistent with the recruitment of leukocytes in response to viral infection.  Both H1N1 
and γHV-68 infected mice showed similar increases in leukocyte accumulation in the lung 
(Figure 14D), although histologic evidence in Figure 10 suggests that γHV-68-infected mice 
showed both diffuse and focal inflammatory infiltrates.   
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Figure 14: Leukocyte recruitment was enhanced following infection.  
Mice were injected with bleomycin on day 0.  On day 14, mice were infected with saline, P. 
aeruginosa, H1N1 or γHV-68.  Lungs were harvested from n=4 mice each on day 15 or day 21.  
Total lung leukocytes were enumerated (A and C) and percentage of CD45+ leukocytes were 
assessed (B and D) by flow cytometry.  Data are from one experiment representative of 2. 
 
Because H1N1 infected mice did not exacerbate fibrosis whereas γHV-68 infected mice 
did, we analyzed the various leukocyte subsets between these two groups.  There were no 
discernable differences in the percentages of CD4, CD8, NK, NK-T, B, monocyte, PMN, or 
eosinophils between these groups (Figure 15).  Thus, differential accumulation of leukocyte 
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subsets could not explain why γHV-68 infection augments fibrotic responses in the lung whereas 
H1N1 infection did not. 
 
Figure 15: Leukocyte recruitment was enhanced following infection.  
Mice were injected with bleomycin on day 0.  On day 14, mice were infected with saline, P. 
aeruginosa, H1N1 or γHV-68.  Lungs were harvested from n=4 mice each on day 15 or day 21.  
Total lung leukocytes were enumerated and absolute numbers of A) CD45+, B) CD4 TcRβ, C) 
CD8 TcRβ, D) Nk1.1 TcRβ E) CD19, and F) NK1 positive cells were determined based on flow 
cytometry. Differential analysis was done to determine the percentage of G) 
monocytes/macrophages H) neutrophils and I) eosinophils. Data shown are from one experiment 
representative of 2. 
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Differences in profibrotic mediators do not explain the ability of γHV-68, but not H1N1 to 
exacerbate fibrosis. 
 
 The production of several pro- and anti-fibrotic mediators were determined by ELISA.  
Expression of CCL12 (Figure 16A) was elevated in both viral infections, but only reached 
significance in the H1N1-infected mice.  Expression of CCL2 (Figure 16B) was decreased post-
γHV-68 infection, but was unchanged post-H1N1.  Expression of active and total TGFβ (Figure 
16C) was similar in all groups.   
 
Figure 16: Differences in CCL12, CCL2 and TGFβ could not explain the differential ability 
of γHV-68, but not H1N1 to exacerbate ECM deposition post-bleomycin.    
Mice were treated with bleomycin on day 0 and infected with saline, γHV-68 or H1N1 on day 14.  
On day 21, lungs were harvested and whole lung homogenates were analyzed by ELISA for 
CCL12 (A), CCL2 (B), levels of active (Panel C, left side) or acid-activated total TGFβ (panel C, 
right side).  n=3-5 mice/group representative of 2 experiments. 
 
When evaluating Th1, Th2 and Th17 cytokines, IFNγ was elevated in γHV-68-infected 
mice when compared to bleomycin plus mock infection (Figure 17A), confirming earlier results 
in FITC and γHV-68-infected mice (129).  Interestingly, levels of IFNγ were reduced in H1N1-
infected mice, perhaps consistent with the observation that H1N1 replication is resolving at this 
time point. Levels of IL-13 (Figure 17B) and IL-17 (Figure 17C) were reduced in both groups 
of virally infected mice compared to the bleomycin control group, but only reached significance 
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in γHV-68 infected animals.  This is also consistent with the earlier observation that γHV-68 can 
augment fibrosis in the absence of Th2 cytokines (129).  Previous studies have shown that aged 
mice, which are susceptible to γHV-68-induced fibrosis have elevated levels of TGFβ receptors 
on lung fibroblasts (122).  However, in the present studies, levels of TGFβR1 (Figure 17D) were 
not different, and levels of TGFβRII (Figure 17E) were elevated only in H1N1-infected mice 
when measured in the whole lung.   
 
Figure 17: Differences in Th1, Th2, and Th17 and TGFβ receptors in whole lung did not 
explain the differential ability of γHV-68, but not H1N1 to exacerbate ECM deposition 
post-bleomycin.   
Mice were treated with bleomycin on day 0 and infected with saline, γHV-68 or H1N1 on day 14.  
On day 21, lungs were harvested and whole lung homogenates were analyzed by ELISA for 
IFNγ (A), IL-13 (B), and IL-17 (C); n=5 for each group.  In panels D and E, whole lung RNA 
was prepared and analyzed for expression of TGFβRI and II by real-time RT-PCR, n=3-5 for 
each group; all representative of 2 experiments 
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Comparing the induction of IFNγ or TNFα in mice treated with either virus alone 
compared to the amount made in response to viral infection post-bleomycin, it was noted that 
pre-treatment with bleomycin did not alter levels of either cytokine in response to H1N1 
infection significantly.  However, the ability of bleomycin-treated mice to produce TNFα was 
significantly inhibited post-γHV68 infection, and production of IFNγ tended to be lower (Figure 
18).  These results may indicate a sub-optimal anti-viral response to γHV-68 in bleomycin pre-
treated mice. 
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Figure 18: Bleomycin-treated mice showed a defect in the production of TNFα to γHV-68 
infection but not H1N1.  
Mice were treated with saline or bleomycin on day 0. On day 14 mice from each treatment group 
were infected with 50PFU H1N1 or 5x 10
4
 PFU of γHV-68. On days 17 and 21 (days 3 and 7 
post-infection), lungs were harvested and whole lung homogenates were analyzed by ELISA for 
IFNγ (A and B), TNFα (C and D). Data shown is representative from one experiment n=3-4/mice 
per group. 
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Alveolar epithelial cells are more sensitive to TGFβ signaling and show evidence of apoptosis 
post-γHV-68 infection. 
 
 Human studies that have associated exacerbation of lung fibrosis with herpes virus have 
shown presence of virus in alveolar epithelial cells (AECs), and because latent infection of AECs 
with γHV-68 have demonstrated elevated production of cysteinyl leukotrienes (346),  AECs 
were isolated  from bleomycin + mock infection, bleomycin +H1N1 or bleomycin+γHV-68 
infected mice on day 21 and analyzed them for expression of leukotriene synthetic enzymes, 
expression of TGFβ receptors and analyzed their protein lysates for evidence of SMAD3 
phosphorylation and apoptosis via cleaved PARP (Figure 19).  Expression of leukotriene 
synthetic enzymes [5-lipoxygenase (5-LO) and 5-LO activating protein (FLAP)] were increased 
in response to both infections.  However, only infection with γHV-68 resulted in increased 
expression of TGFβR1, increased evidence of SMAD3 phosphorylation and increased evidence 
of apoptosis as noted by cleaved PARP. 
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Figure 19: AECs from bleomycin and γHV-68-treated mice showed increased sensitivity to 
TGFβ signaling, and increased evidence of leukotriene synthesis and apoptosis post- γHV-
68 infection.  
Mice were treated with bleomycin on day 0. On day 14, some mice were infected with saline, 
H1N1 or γHV-68. Primary AECs were isolated from the lungs of all groups of mice on day 21. 
Total RNA was isolated and by real time RT-PCR we measured the expression of TGFβ receptor 
I/II (A, B), 5-LO (C) and FLAP (D).  Phosphorylated SMAD3, total SMAD3, cleaved PARP, 
total PARP and beta actin were detected by western blotting (E). Data in all panels represent 
n=3/group 
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Discussion 
 
The cause of IPF is unknown, yet several lines of evidence have suggested that viral 
infections may play a role either as initiating or exacerbating agents.  Mounting clinical evidence 
suggests that patients with IPF have T cells with low expression of CD28 (370, 371).  This 
suggests chronic activation of T cells in IPF patients, potentially due to underlying and 
undiagnosed infections.  Thus, the goal of this study was to determine whether both bacterial and 
viral infections could exacerbate bleomycin-induced fibrosis. 
 Even though P. aeruginosa has the capability of infecting epithelial cells (372) and IPF 
patients tend to do poorly when they develop bacterial pneumonia (373), P. aeruginosa infection 
was effectively cleared from the lungs and did not exacerbate fibrosis.   While our results 
suggested that this bacteria would not worsen fibrosis due to enhanced ECM deposition, there is 
caution in extrapolating these results to humans.  The progressive nature of IPF is not modeled 
by bleomycin, thus, it is likely that in humans with chronic disease and more diminished lung 
capacity, a bacterial infection could be far more devastating, and certainly an influx of 
inflammatory cells might worsen dyspnea even if it does not alter ECM deposition. A recent 
study assessing the role of the lung microbiome in IPF demonstrated that the presence of high 
numbers of the staphylococcus and streptococcus genera of bacteria was associated with disease 
progression in IPF (374). So, it is possible that since we saw no exacerbation of disease with 
Psuedomonas aeruginosa, using a different genus of bacteria may show a different phenotype.    
Our results using bleomycin verified earlier results using FITC as a fibrotic stimulus 
(129) and demonstrated that γHV-68 could exacerbate ECM deposition post-bleomycin stimulus.  
The ability of γHV-68 to do this likely involves ability of the virus to reactivate from latency as 
the ΔORF72 mutant was not able to do this.  Our unpublished observations suggest that the first 
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three days of replication by ΔORF72 and γHV-68 are similar, but viral gene expression is 
significantly diminished by 7 days post-infection in ΔORF72-infected mice.  Thus, exacerbation 
of fibrosis likely requires on-going viral replication or spread within the AECs.  These data are 
consistent with earlier studies showing that ongoing viral replication is necessary for fibrosis in 
Th2-biased mice as well (357).   It may also be a unique feature of γHV-68 or perhaps of γ 
herpesviruses in general since CMV (a β herpesvirus) did not enhance fibrosis.  It should be 
noted that our experiments used the same dose of γHV-68 and CMV; however, C57Bl/6 mice are 
relatively resistant to CMV infection and we could not plaque infectious CMV from the lungs on 
day 7 post-infection whereas we could demonstrate infectious virus in γHV-68-infected mice 
(Figure 11).  We could demonstrate by RT-PCR that CMV viral RNA was expressed (data not 
shown), albeit at low levels.  However, our earlier finding that murine adenovirus type 1 
(MAV1) was also unable to exacerbate fibrosis following FITC challenge (129) and our current 
results with H1N1 suggest that this is not a feature of all viral infections which can infect AECs. 
Caution should be used when interpreting these data however since it is clear that the rates of 
infection are different for all these viruses. 
When examining a variety of pro-and anti-fibrotic mediators and the composition of the 
inflammatory cell influx which followed both infections, no notable differences could explain 
the discrepancy between the ability of γHV-68, but not H1N1 to exacerbate fibrosis.  This 
prompted us to look at changes that might be specific to AECs, the initial site of infection and 
viral replication within the lung.  We have observed that γHV-68 can replicate in AECs in 
culture without lytic destruction of all the cells.  In contrast, H1N1 may be more likely to 
ultimately destroy all infected epithelial cells.  Our results in vivo suggest that γHV-68-infected 
mice have AECs that are more responsive to TGFβ signaling and show signs of apoptosis.  This 
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is consistent with earlier work showing that γHV-68 infection in aged mice is associated with 
AEC apoptosis and ER stress (123).  One caveat was that our analyses of AECs were done at day 
7 post-infection, a time point when H1N1 replication was diminished, but γHV-68 replication 
was on-going.  It is possible that the prolonged replication of γHV-68 at 7 dpi may cause more 
epithelial stress.  We have previously demonstrated that AECs isolated from mice with latent 
γHV-68 infection overproduce profibrotic factors such as TGFβ and cysteinyl leukotrienes (121, 
346).   
Our current data confirm that infection with γHV-68 and H1N1 both significantly 
upregulate FLAP in AECs, enzymatic machinery necessary for cysteinyl leukotriene synthesis, 
however induction of FLAP was highest with γHV-68.  Because cysteinyl leukotrienes can 
promote fibrocyte proliferation (375) and activation of resident lung fibroblasts (376, 377), this 
could promote ECM deposition post-viral infection.   When we looked for evidence of TGFβ 
signaling in AECs, we observed elevated TGFβR1 in AECs from γHV-68-infected mice.  This 
resulted in increased evidence of TGFβ activation of these cells at this time point as 
demonstrated by increased phospho-SMAD3 expression.  Ultimately, we believe these AECs 
may be undergoing apoptosis in vivo as there was evidence of cleaved PARP, a marker of 
apoptosis.  Thus, we speculate that the ability of γHV-68 to undergo persistent rounds of 
reactivation and an enhanced sensitivity of the infected AECs to respond to TGFβ leads to 
ongoing apoptosis in AECs along with induction of profibrotic factors such as cysteinyl 
leukotrienes which ultimately promote ECM deposition in these mice.  Because H1N1 has also 
been shown to induce apoptotic machinery in AECs as a way to promote viral replication (378), 
it is not clear why our results differ with these two viral infections.  These results may merely 
reflect the doses of virus used the extent of ultimate damage to the AECs, alterations in the 
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ability to repair damaged epithelium following each infection or additional signaling cascades 
induced by the distinct viruses that we have not yet identified. 
While our results in AECs highlight cell-specific increases in susceptibility to TGFβ 
signaling post-γHV-68 infection, we did not observe differences in total or active TGFβ in the 
lungs of bleomycin-treated mice infected with γHV-68 or H1N1.  As this cytokine is often 
activated locally on the cell surface, it is likely that measurements in lung homogenates do not 
accurately reflect levels available during cell-cell communication.  However, we were surprised 
that levels of TGFβRII were actually elevated in H1N1-infected mice within the whole lung.  
One caveat of these interpretations however is that receptor expression levels were measured in 
whole lungs, not in isolated fibroblasts.  As TGFβ receptors can be expressed on numerous cell 
types, it is not clear what cells may be overexpressing TGFβRII in H1N1-infected mice.  
Because TGFβRII can interact with various other cellular proteins such as cyclin B2 (379) 
endoglin (CD105) (380) or TGFβRIII (381), this may result in differential cell activation of some 
cell types in the H1N1 infected mice that may further explain the discrepancies between 
outcomes with H1N1 vs. γHV-68.   
  Finally, the differences in cell types that are readily infected by each virus may play an 
additional role.  We have demonstrated that γHV-68 is readily found as both lytic and latent 
infection in lung AECs, fibroblasts, macrophages and B cells (121).  However, H1N1 tends to 
restrict replication predominantly to the epithelial cells within the lung (382) and in our hands 
does not replicate well in macrophages.  It is interesting that one study has suggested that H1N1 
can replicate more effectively in type II AECs from IPF patients (383).  Additionally, a recent 
case report noted acute exacerbation of IPF following H1N1 vaccination (384).  Thus, as 
mentioned before, bleomycin may not be effectively modeling all the epithelial changes noted in 
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patients with IPF.  It should also be noted that while H1N1 infection at the doses used in this 
study do not appear to worsen ECM deposition, that is not to say that H1N1 infection is not 
detrimental to fibrotic lungs.  At higher doses of H1N1 (500 PFU), bleomycin-treated mice were 
highly susceptible to rapid death, most likely from acute lung injury so we were unable to 
analyze data from these experiments. However, this dose was also lethal in some control mice.   
In summary, γHV-68 was able to exacerbate bleomycin-induced fibrosis or FITC-
induced fibrosis (129) and stimulated collagen deposition.   Infection with P. aeruginosa, H1N1 
and CMV did not exacerbate bleomycin-induced fibrosis at the doses tested in our studies.  The 
difference in the ability of γHV-68, but not the other pathogens tested to exacerbate collagen 
deposition required the ability of γHV-68 to undergo reactivation from latency as demonstrated 
by our experiments with the ΔORF72 mutant virus.  Additionally, we have demonstrated 
evidence of enhanced sensitivity to TGFβ signaling in AECs from γHV-68-infected mice likely 
leading to enhanced profibrotic release of cysteinyl leukotrienes, AEC stress and apoptosis.
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Chapter 4: 
 
Periostin regulates fibrocyte function to promote myofibroblast differentiation and lung 
fibrosis 
 
Background 
 
Fibrosis can be triggered by various known insults (e.g., infection, allergens, toxins, or 
radiation), or can occur for unknown reasons as in the case of idiopathic pulmonary fibrosis 
(IPF) (348).  IPF is a chronic progressive parenchymal lung disease of unknown origin, with 
mean survival rate of 3-5 years after diagnosis.  Prevalence and mortality rates are increasing 
globally (1, 17, 385). The cellular mechanisms leading to IPF remain unclear but a commonly 
held paradigm describes continuous cycles of injury to the alveolar epithelium leading to 
dysregulated repair. Prominent features of this dysregulated repair include fibroblast 
differentiation, myofibroblast accumulation and excessive collagen deposition in the alveolar 
space (137, 386, 387).  Mediators such as growth factors and cytokines from different cell types 
contribute to the persistence of activated fibroblasts and myofibroblasts(388).  Based on our 
current knowledge, bone marrow-derived collagen producing cells (e.g. fibrocytes and other 
collagen producing cells) play a significant role in the development of lung fibrosis ((102, 217, 
389-395). Fibrocytes respond to a number of cytokines and chemokines that are typically 
associated with migration and activation of inflammatory cells(189). Fibrocytes are 
hematopoietic bone marrow-derived cells that express both mesenchymal and leukocyte markers. 
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They circulate in the peripheral blood and can be isolated from tissues.  Cultured fibrocytes have 
been shown to express a number of ECM proteins including collagen 1, collagen 3 and 
fibronectin (97, 189, 191, 192, 396). In addition, fibrocytes also express a number of chemokine 
receptors, including CXCR4, CCR7 and CCR2 which may contribute to the recruitment and 
activation of fibrocytes resulting in migration to damaged tissues (25, 94, 98). Although several 
reports indicate that fibrocytes express type I collagen, others have suggested that uptake of 
secreted type I collagen by hematopoietic cells characterizes the fibrocyte population (397, 398).  
A more recent study demonstrated that cells of hematopoietic origin produce type I 
collagen but are not a necessary source of type I collagen during experimental lung fibrosis (200). 
Kleaveland et al. illustrated that fibrocytes can efficiently uptake type I collagen even though the 
underlying mechanism is not clearly understood (200). Adoptive transfer of fibrocytes leads to 
augmented fibrosis in a FITC-induced mouse model and several studies have found a correlation 
between increased numbers of fibrocytes and worse disease progression(94, 187, 396, 399, 400). 
Recently, fibrocytes were shown to contribute to the progression of pulmonary fibrosis without 
differentiating to myofibroblasts themselves using a transforming growth factor alpha model of 
fibrosis (401). Additionally, Garcia de Alba et al. also showed that fibrocytes contributed to 
increased mRNA levels of ECM proteins in both fibrosis and chronic pneumonitis (400).  Work 
from our laboratory demonstrated that fibrocytes in circulation of IPF patients are major 
producers of the matricellular protein, periostin, and that periostin accumulates in the lung tissue 
of IPF patients (402). 
Periostin, also known as osteoblast-specific factor 2, is a recently characterized 
matricellular protein that binds to components of the ECM including type I collagen and 
fibronectin and has been shown to be involved in collagen fibrillogenesis (403). Periostin protein 
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transmits signals from the ECM to the cell by binding to cellular receptors such as integrins that 
affect cell adhesion, proliferation, migration and tissue angiogenesis (253). It has been reported 
that periostin promotes cancer cell invasion and metastasis through the 
integrin/phosphatidylinositol 3-kinase/AKT pathway, leading to the development of various 
tumors (404). Work from our laboratory and others have shown that there is an increased 
circulating periostin level in IPF patients compared to controls (258, 402). Our work further 
showed that the increased periostin expression in IPF tissues was localized to active areas of 
fibrosis and that IPF patients also showed increased percentages of periostin-expressing 
fibrocytes and monocytes in the blood (402).  
Chimeric mouse studies showed that both structural and hematopoietic sources of 
periostin were important in protecting periostin-deficient mice from bleomycin-induced fibrosis 
(402). Although periostin has diverse functions, it is becoming increasingly clear that periostin is 
upregulated in lung tissue in the context of several respiratory diseases (256). At present, the 
precise function of periostin in the lung has not been fully elucidated. In this study we used 
bleomycin to establish fibrosis in mice, and then analyzed how hematopoietic-derived fibrocytes 
might signal structural myofibroblast differentiation through their ability to secrete periostin or 
other soluble mediators in the presence of periostin. We explored the use of periostin-deficient 
fibrocytes in adoptive transfer experiments as well as the use of integrin blocking antibodies to 
demonstrate that periostin interacts with different receptors on fibrocytes and fibroblasts and that 
periostin secretion by fibrocytes is important for the exacerbation of bleomycin-induced lung 
fibrosis. 
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Results 
 
Mesenchymal cells increased periostin mRNA expression after bleomycin treatment 
 
To specifically assess the upregulation of periostin expression in lung mesenchymal cells 
after bleomycin treatment, WT mice were given intratracheal saline or bleomycin on day 0. All 
lungs were harvested on day 14 and mesenchymal cells were cultured for 14 days then sorted 
into fibrocytes (CD45 positive) and fibroblasts (CD45 negative).  RNA was isolated for real-time 
RT-PCR analysis. We observed that both fibroblasts and fibrocytes had significant increases in 
periostin mRNA expression post bleomycin treatment (Figure 20). 
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Figure 20: Increased mRNA expression of periostin in lung mesenchymal cells post-
bleomycin treatment.  
Wild type mice were given 0.25U of bleomycin or saline intratracheally on day 0. On day 14, 
lung mesenchymal cells were cultured and sorted by Magnetic bead separation for fibroblasts 
and fibrocytes.  Total RNA was isolated and by real time RT-PCR we measured the expression of 
periostin and β-actin in fibrocytes and fibroblasts. Data represent n=3 per group pooled from 
multiple mice. **p < 0.01, *p< 0.05, ns=not significant.  
 
TGFβ and periostin co-regulated each other in lung mesenchymal cells 
 
Previous data from our laboratory demonstrated that treatment of WT mesenchymal cells 
with TGFβ showed a significant increase in periostin production (402). To assess whether 
periostin also up-regulated TGFβ1 production in murine mesenchymal cells sorted to separate 
the fibroblasts and fibrocytes, we isolated these cell types from lung mince cultures from naïve 
mouse lungs and treated with recombinant periostin (500 ng/mL) in serum-free media. Treatment 
of WT fibrocytes and fibroblasts with periostin lead to increased TGFβ1 production as measured 
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by ELISA (Figure 21A). In addition, treatment of fibroblasts and fibrocytes with recombinant 
TGF-β (2ng/mL) increased protein production of periostin as measured by ELISA (Figure 21B), 
as well as increased mRNA expression of periostin (Figure 21C-D).  
Figure 21: Periostin and TGFβ treatment regulated each other in fibroblasts and fibrocytes. 
Fibroblasts and fibrocytes from wild-type mice were treated with periostin (500ng/mL) or TGFβ 
(2ng/mL) for 48 hours.  Cell-free supernatants were collected and analyzed by ELISA for TGFβ 
(A) and periostin (B). Total RNA was isolated and by real time RT-PCR we measured the 
expression of periostin and β-actin in fibrocytes (C) and fibroblasts (D). Data are representative 
of mean ±SEM, n=3 wells/treatment per group. *p< 0.05, **p < 0.01 ,****p<0.0001, ns=not 
significant 
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Since, periostin and TGFβ1 seemed to be co-regulating each other, we wanted to assess 
whether the production of collagen I from fibroblasts and fibrocytes was different in the presence 
of periostin and if this effect was dependent on TGF-β1 signaling. Figure 22 illustrates that 
treatment of murine lung mesenchymal cells with periostin for 48hrs led to a significant increase 
in mRNA expression for collagen I. However, the increase in collagen I expression was 
independent of TGFβ1 signaling in the fibrocytes compared to the fibroblasts as indicated by 
treatment with the A8301 TGF-β1 receptor inhibitor.  Overall these data suggested that TGFβ1 
and periostin are co-regulating each other but periostin can signal to fibrocytes independently of 
TGFβ1 and that the receptor needed for periostin signaling may be different on fibrocytes 
compared to fibroblasts.  
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Figure 22: Periostin induced collagen 1 expression in fibrocytes independently of TGFβ 
signaling. 
Mesenchymal cells were cultured in complete media, sorted into fibrocytes and fibroblasts, then 
switched to serum-free media where they were treated with TGFB (2ng/mL), A8301 (ALK5 
inhibitor) or periostin (500ng/mL) for 48hours.  Total RNA was isolated and by real time RT-
PCR we measured the expression of collagen I and β-actin in fibrocytes (A) and fibroblasts (B). 
Data are representative of mean ±SEM, n=3 wells/treatment per group from 2 independent 
experiments ****p<0.0001, ***p<0.001,**p<0.01, *p<0.05 and ns + not significant 
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Decreased integrin expression in fibrocytes from periostin
-/-
 mice post-bleomycin treatment  
 
In many cancers, periostin binds to integrins activating the AKT/PKB and FAK-mediated 
signaling pathways. This leads to increased cell survival, invasion, angiogenesis, metastasis and 
epithelial-mesenchymal transition (405). Periostin also functions as a ligand for integrin 
alphaVbeta3 and alphaVbeta 5 to support adhesion and migration of epithelial cells (406). 
Because our data suggested that periostin might be signaling differently in fibrocytes vs 
fibroblasts, we wanted to examine the expression levels of integrins in WT and periostin
-/-
 naïve 
lung mesenchymal cells. As illustrated in figure 23A-D, there was no significant difference in 
the baseline mRNA expression levels of alpha 1, alpha V, beta 1 and beta 5 integrin levels on 
fibrocytes and fibroblasts from WT or periostin
-/-
 mice, although in most cases, the expression 
levels of integrins were lower in fibrocytes than fibroblasts. We next treated WT and periostin
-/-
 
mice intratracheally with saline or bleomycin for 14 days then cultured lung mesenchymal cells, 
sorted for fibrocytes and assessed mRNA expression for different integrins post-bleomycin 
treatment. Alpha 1, alpha V and beta 1 were found to be significantly upregulated in WT 
fibrocytes post bleomycin treatment but beta 5 expression was not altered. None of the integrins 
were upregulated post-bleomycin in the periostin
-/-
 cells (Figure 23E-J).   
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Figure 23: Loss of periostin decreased the expression of integrins post-bleomycin treatment.    
(A-D) Wild type or periostin-/- mice were given bleomycin or saline intratracheally on day 0. On 
day 14 lungs were harvested and mesenchymal cells were cultured and sorted as previously 
described. Total RNA was isolated and by real time RT-PCR we measured the expression of 
alpha1, alphaV, beta 1 and beta 5 expressions in saline treated (A-D) and bleomycin treated (E-
H) fibrocytes. Values are expressed as mean ± SEM, and represent n=3 animals/group from two 
independent experiments ns=not significant, ***p<0.001,**p<0.01 and *p<0.05. 
 
To determine if the increase in mRNAs for the different integrins correlated with TGFβ1 
production, we treated fibrocytes with exogenous TGFβ1 and found increased mRNA expression 
for alpha V, alpha 1 and beta 5 in wild-type cells (Figure 24).  Expression of these integrins was 
similarly increased in the periostin
-/- cells treated with TGFβ1.  In contrast, TGFβ1 treatment 
caused modest, but not significant increase in beta 1 expression in WT cells, but did not in 
periostin
-/-
 cells suggesting that beta 1 integrin expression may be necessary for periostin 
signaling to fibrocytes in murine lungs (Figure 24). Next, WT fibrocytes and fibroblasts were 
treated with periostin in the presence of a beta 1 integrin-blocking antibody (102209-Biolegend) 
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and after 48h, collagen1 mRNA expression was assessed as an indication of mesenchymal cell 
activation. Fibrocytes treated with periostin in the presence of beta 1 blocking antibody had 
markedly less collagen I mRNA expression compared to samples treated with periostin and 
isotype control. In contrast, addition of beta 1 integrin blocking antibody to fibroblasts showed 
no change in collagen I expression (Figure 25).  Taken together our data suggested periostin 
signals collagen expression through beta 1 integrin to activate fibrocytes and this is independent 
of TGFβ signaling.  
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Figure 24:TGFβ treatment did not induce β1 integrin mRNA expression in fibrocytes in the 
absence of periostin.   
Fibrocytes from wild-type and periostin-/- mice were treated with recombinant TGFβ (2ng/mL) 
for 48 hours.  Total RNA was isolated and by real time RT-PCR we measured the expression of 
different integrins and β-actin in fibrocytes (A) Alpha 1, (B) AlphaV, (C) Beta 1(β1) and (D) 
Beta 5. Data are representative of mean ±SEM, n=3 wells/treatment per group ,**p<0.01, 
*p<0.05 and ns=not significant. 
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Figure 25: β1 integrin blockade in WT fibrocytes caused decreased Collagen 1 expression 
with periostin treatment but showed no effect in fibroblasts. 
Mesenchymal cells were cultured in complete media, sorted into fibrocytes and fibroblasts, then 
switched to serum-free media where they were treated with purified rat anti-mouse β1(HMβ1-1, 
rat CD29) blocking antibody  or purified armenian Hamster IgG (400916) isotype control for 
30mins, then incubated with or without periostin (500ng/mL) for 48hours.  Total RNA was 
isolated and by real time RT-PCR we measured the expression of collagen 1 and β-actin in 
fibrocytes (A) and fibroblasts (B). Data are representative of mean ±SEM, n=3 wells/treatment 
per group *p<0.05 and ns=not significant. 
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Fibrocytes exacerbated bleomycin-induced fibrosis through paracrine effects and in a periostin-
dependent manner  
 
We previously showed that fibrocytes augmented FITC-induced lung fibrosis (94). In 
addition, fibrocytes and monocytes were the major producers of periostin in circulation and a 
hematopoietic source of periostin was important for fibrogenesis in the bleomycin model of lung 
fibrosis (402). To specifically assess the role of periostin produced by fibrocytes in lung 
fibrogenesis, WT or periostin
-/-
 mice were given intratracheal saline or bleomycin on day 0. On 
day 4 post-bleomycin, mice were give 5x10
5
 additional cultured WT or periostin
-/-
 lung 
fibrocytes.  Lungs from all mice were harvested on day 21 post-bleomycin and lung collagen 
content was measured by hydroxyproline assay. As expected, bleomycin-treated WT mice 
showed a significant increase in collagen content when compared to saline controls but WT mice 
that received the additional WT fibrocytes had significantly higher amounts of collagen in the 
lungs compared to bleomycin alone.  Interestingly, bleomycin-treated WT
 
mice given the 
periostin
-/-
 fibrocytes showed similar levels of lung collagen as the bleomycin-treated wild-type 
mice with no added cells (Figure 26A).  Figure 26B demonstrates that periostin
-/-
 mice treated 
with bleomycin then given additional WT lung fibrocytes had significantly more collagen 
content in the lungs compared to periostin
-/- 
mice treated with bleomycin alone. Additionally, we 
analyzed the ability of fibrocytes to maintain their CD45 expression post-transfer over time. 
Using flow cytometry analysis we found that all the labeled PKH26 positive fibrocytes were 
detected as CD45 positive cells 4-8 days after transfer. These data demonstrate that fibrocytes 
were not differentiating into CD45-negative fibroblasts after transfer (Figure 26C) 
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Figure 26: Adoptive transfer of WT but not periostin
-/-  
fibrocytes augmented bleomycin-
induced fibrosis but fibrocytes of both genotypes maintained CD45 expression in vivo. 
(A) Wild type mice were given 0.25U of bleomycin or PBS intratracheally on day 0. On day 5, 
post-bleomycin treatment half of each group received 5x105 WT of periostin-/- fibrocytes by 
intravenous tail vein injection. Lungs were harvested on day 21 post-bleomycin for 
hydroxyproline quantification. Data shown are pooled from two independent experiments, with n 
= 4-6 mice per group in each experiment. **p<0.01, *p<0.05 and ns=not significant (B) 
Periostin-/- mice were given 0.25U of bleomycin intratracheally on day 0. On day 5 post-
bleomycin treatment, half of each group received 5x105 WT fibrocytes, lungs were harvested and 
assessed collagen content on day 21 by hydroxyproline assay *p<0.05. 
(C) Wild type mice were given 0.25U of bleomycin or PBS intratracheally on day 0. On day 5, 
post-bleomycin treatment half of each group received 5X105 PKH-26 labeled WT of periostin-/- 
fibrocytes by intravenous tail vein injection. On day 3 and 7 post-transfer, lungs were then 
harvested and total lung leukocytes were enumerated and then labeled with CD45 APC to 
determine the percentages of PKH-26CD45+APC fibrocytes. Data shown represents mean ± 
SEM, n=3 animals/group, ns, not significant. 
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Periostin production by fibrocytes promoted their profibrotic effects on myofibroblasts via other 
mediators  
Myofibroblast differentiation is characterized, in part, by induction of αSMA gene 
expression as well as by increased production of ECM components and fibrogenic cytokines 
such as TGFβ1 (213, 405, 406). To assess how fibrocyte-derived periostin affected 
myofibroblast differentiation, we analyzed protein expression of αSMA in WT untreated 
fibroblasts that were incubated with cell-free supernatants from CD45 positive fibrocytes from 
bleomycin-treated WT and periostin
-/-
 mice. Cells were incubated in this media for 24h. After 
24h we analyzed expression of αSMA by western blot and saw less αSMA expression in WT 
fibroblasts that were incubated with bleomycin-treated supernatants from periostin
-/-
 cells 
(Figure 27A). To address whether this effect was solely due to periostin or possibly involved 
other downstream signaling proteins a microarray analysis using a targeted mouse fibrosis array 
was performed with the goal of identifying differences between the WT and periostin
-/-
 
fibrocytes. A significant decrease in connective tissue growth factor (CTGF) and Lysyl oxidase 
(LOX) but not platelet-derived growth factor (PDGF) α was seen in periostin-/- fibrocytes. 
Findings were confirmed by RT-qPCR (Figure 27B). In addition, there was a significant 
increase in CTGF mRNA expression in fibrocytes treated with exogenous periostin but this 
increase was diminshed in the presence of a beta1 integrin blocking antibody (Figure 27C). 
There was no change in CTGF mRNA expression in fibroblasts (Figure 27D). Given the 
importance of CTGF in fibrogenesis, we measured the amount of CTGF protein in the 
supernatants used in the experiments described in Figure 27A by ELISA and saw less CTGF in 
the periostin
-/-
 fibrocyte supernatants (Figure 27E). Taken together these data suggested that 
fibrocytes in the presence of periostin secrete additional pro-fibrotic mediators such as CTGF 
that contributed to myofibroblast differentiation. 
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Figure 27: WT fibrocytes secreted CTGF in the presence of periostin and increased αSMA 
protein expression in fibroblasts in the presence of periostin. 
(A) Wild type mice were given 0.25U of bleomycin or PBS intratracheally on day 0. On day 14, 
post-bleomycin treatment lung mesenchymal cells were cultured for 14 days. After 14 days in 
culture cells were sorted and CD45 positive fibrocytes were incubated in serum-free media 
overnight. Cell-free supernatants were collected from both bleomycin-WT and periostin-/- cells 
and added 1:1 onto WT untreated fibroblasts (CD45 negative) cells for 24h. Cells were lysed in 
RIPA buffer with protease inhibitor and we assessed the expression of αSMA and GAPDH by 
western blot. (B) Total RNA was isolated from the WT and periostin-/- fibrocytes after overnight 
incubation in serum-free media and by real time RT-PCR we measured the mRNA expression of 
CTGF, PDGFα and LOX. Data shown represents mean ± SEM, n=3 wells/group, ns=not 
significant, ****p<0.0001, **p<0.01 and *p<0.05. (C-D) Total RNA was isolated from WT 
mesenchymal cells treated with periostin (500ng/mL) and by real time RT-PCR we measured the 
mRNA expression of CTGF. Data shown represents mean ± SEM, n=3 wells/group, ns=not 
significant and *p<0.05. (E)) Cell free supernatants were analyzed by ELISA for CTGF 
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Discussion 
 
Previous studies have shown that periostin
 -/-
 mice treated with bleomycin intratracheally 
had decreased collagen content compared with WT littermates (257, 402). Both monocytes and 
fibrocytes likely contribute to the pool of circulating periostin in IPF patients and chimeric 
mouse studies demonstrated that both the hematopoietic-derived and structural sources of 
periostin contributed similarly to fibrogenesis (402).  However, lung fibroblasts secrete more 
periostin than circulating cells (Figure 21). Together these studies suggested that a circulating 
source of periostin could be playing a significant role in the exacerbation of lung fibrosis, but it 
was unclear how the lower levels of periostin produced by these cells vs. structural cells (e.g. 
fibroblasts, Figure 21B) were influencing disease. Our current findings in vivo, and in vitro, 
suggest that fibrocyte profibrotic function is likely via multiple paracrine mechanisms. 
We examined the effects of fibrocytes in the exacerbation of bleomycin-induced fibrosis 
in WT and periostin
-/-
 mice. Adoptive transfer of WT fibrocytes during established lung fibrosis 
augmented bleomycin-induced fibrosis in recipient mice, corroborating the earlier studies in a 
fluorescein isothiocyanate (FITC)-induced model of pulmonary fibrosis (94). Furthermore, in 
periostin
-/-
 mice receiving WT fibrocytes there was a significant increase in lung hydroxyproline 
which is evidence of enhanced lung fibrosis relative to the periostin
-/-
 mice that did not receive 
additional fibrocytes.  We first wondered whether there was a defect in migration of periostin
-/-
 
fibrocytes to the injured lung.  However, Figure 19C shows that periostin
-/- 
fibrocytes could be 
identified in the lungs as easily as WT fibrocytes.  Furthermore, we found no defect in the 
expression of chemokine receptors on the WT vs the periostin
-/- 
fibrocytes after bleomycin 
treatment (Figure 28). Therefore, the decrease in fibrosis in mice treated with the periostin
-/-
 
fibrocytes could not be attributed to a migration defect.  Furthermore, we considered the 
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possibility that WT fibrocytes might better be able to differentiate into fibroblasts or 
myofibroblasts once arriving in the injured lung.   
 
 
Figure 28: Chemokine receptor expression in WT and periostin knockout fibrocytes post-
bleomycin treatment. 
Wild type mice were given 0.25U of bleomycin or PBS intratracheally on day 0. On day 14, 
post-bleomycin treatment lung mesenchymal cells were cultured for 14 days. Total RNA was 
isolated from the WT and periostin-/- fibrocytes after overnight incubation in serum-free media 
and by real time RT-PCR we measured the mRNA expression of CCR2 and CXCR4. 
 
 
While in vitro work has clearly shown that fibrocytes can differentiate into 
myofibroblasts (98, 186, 407), our in vivo work corroborates recent findings in another model 
system to suggest fibrocytes are not differentiating into myofibroblasts during fibrosis (Figure 
26C)  (401).  We also previously showed that fibrocytes migrate to areas in the lungs adjacent to 
fibroblasts (25). Given that collagen production by circulating cells is also dispensable for 
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development of lung fibrosis (200), these data, when taken together, suggest that fibrocytes work 
mostly by paracrine mechanisms to induce fibrogenesis.   
It is likely that some of the paracrine effects of periostin-producing fibrocytes are due to 
periostin itself.  We have previously shown that periostin can directly influence ECM deposition 
and migration of lung fibroblasts (402).   Another feature of myofibroblasts is their ability to 
resist apoptosis, likely due to upregulation of anti-apoptotic proteins such as X-linked inhibitor 
of apoptosis (XIAP) expression (308).  Periostin may directly contribute to myofibroblast 
resistance to apoptosis via stimulating XIAP protein expression (Figure 29).  We recently 
demonstrated that blocking inhibitor of apoptosis family proteins using pharmacologic 
interventions attenuated bleomycin-induced fibrosis (308, 408). Thus, periostin likely contributes 
to the exacerbation of bleomycin-induced fibrosis at least in part via direct effects on fibroblasts. 
 
 
Figure 29: Exogenous periostin treatment increased protein expression of XIAP in lung 
mesenchymal cells. 
WT mesenchymal cells were cultured in complete media for 14 days. Cells were then plated in 
serum-free media where they were treated with different concentrations of mouse recombinant 
periostin. Cells were then lysed in RIPA buffer with protease inhibitor and immunoblotted for X-
linked inhibitor of apoptosis (XIAP) and β-actin 
 
Another possibility is that periostin signals back to the fibrocytes themselves to influence 
production of other profibrotic mediators.  We demonstrated that treatment with exogenous 
periostin increased CTGF mRNA expression in fibrocytes (Figure 27C) and fibrocytes secreted 
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less CTGF in the absence of periostin post-bleomycin treatment (Figure 27D).  CTGF has 
previously been described as an activator of mesenchymal cells (274, 275, 409), while LOX is 
known to promote collagen crosslinking, likely leading to stiffer ECM and more robust matrix-
dependent fibroblast activation (259, 403).  CTGF can induce a variety of cytokines such as 
TGFβ and vascular endothelial growth factor [reviewed in (409)], which in turn induce more 
expression of CTGF, indicating a positive feedback loop involving CTGF expression that can 
contribute to the progression of fibrosis.  It is also likely that a similar feedback loop is occurring 
with periostin. Inhibiting this positive feedback loop would be ideal for understanding the 
mechanism by which CTGF from fibrocytes enables persistent lung fibrosis and promotes 
myofibroblast differentiation in the presence of periostin. However, there is not a specific 
receptor antagonist for CTGF due to the complex mechanism of CTGF signaling.  Treatment of 
WT untreated fibroblasts with 10µM of an MRTF inhibitor (CCG 203971, shown to inhibit 
CTGF expression), in the presence of WT bleomycin fibrocyte supernatant resulted in a decrease 
in αSMA protein expression similar to what was seen with the periostin-/- supernatants 
demonstrating the importance of autocrine CTGF expression in the fibroblasts (Figure 30). 
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Figure 30: Inhibition of CTGF expression within fibroblasts limited the upregulation of 
αSMA in these cells when cultured with WT fibrocyte supernatants. 
WT mesenchymal cells were cultured in complete media for 14 days. Cells were then sorted in 
fibroblasts (CD45-) and fibrocytes (CD45+).  Fibroblasts were plated in serum-free media 
overnight.  Cell-free supernatants were from both bleomycin-WT fibrocytes was added 1:1 onto 
WT untreated fibroblasts (CD45 negative) with or without 10μM MRTF inhibitor for 24h. Cells 
were lysed in RIPA buffer with protease inhibitor and we assessed the expression of αSMA and 
GAPDH by western blot. 
 
To further examine the effects of periostin on fibrocytes we designed experiments using 
integrin-blocking antibodies.  Our results suggest that periostin signals uniquely to fibrocytes via 
beta 1 integrin.  A recent study by Reed and colleagues (301) suggested that inhibition of the 
alphaVbeta1 integrin using a small molecule inhibitor significantly attenuated bleomycin-
induced pulmonary fibrosis. In that study the authors only looked at lung mesenchymal cells 
which are a combination of fibroblasts and fibrocytes. Given our findings that beta1 integrins are 
critical for periostin signaling to fibrocytes, it will be important to determine if the alphav-beta1 
heterodimers are responsible for periostin signaling to fibrocytes.  
One very interesting experiment would have been to deplete fibrocytes during fibrosis; 
however this strategy proved technically unsuccessful.  We generated a collagenIα2-Cre-DTR 
transgenic mouse and used these animals to generate bone-marrow chimeras in a CD45.2 mouse 
so that the bone-marrow derived cells (but not lung resident cells) would only be expressing 
CD45.1 and the collagenIα2-Cre-DTR transgene. These mice were then given bleomycin and 
treated with diphtheria toxin on different days over a 3-week period to deplete the recruited 
collagen I-CRE-DTR expressing cells. Despite excellent chimerism in peripheral organs, 
surprisingly, there was a high percentage of recipient fibrocytes present in the lung at day 21 
post- bleomycin treatment suggesting that either through recruitment from the bone marrow and 
/or expansion of progenitors upon recruitment to the lung, there remains a population of recipient 
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cells that expanded as a consequence of the bleomycin-induced lung injury that could not be 
eliminated by diphtheria toxin treatment (Figure 31). We feel it is important for the lung 
community to know that this strategy to create a fibrocyte-knock-out mouse was not effective.  
Definitive proof of the role of fibrocytes in lung fibrosis awaits the characterization of a 
fibrocyte-specific promoter that can be used in future cellular depletion studies.   
In conclusion, the current study showed that fibrocyte-derived periostin caused an 
increase in myofibroblast differentiation. Once recruited to the lungs, fibrocytes did not 
differentiate into fibroblasts directly, but provided paracrine factors such as CTGF in a periostin-
dependent manner to promote myofibroblast differentiation.  
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Figure 31- Generation of a Col1a2-Cre DTR mouse to deplete fibrocytes. 
(A)Rosa- DTR mice (Jackson labs) were crossed with Col1a2-Cre mice (a gift from Paul Noble’s 
laboratory) to generate Col1a2-Cre-DTR expressing mice.Spleens were analyzed by flow 
cytometry to demonstrate that the donor mice were CD45.1 (B) Bone-marrow chimeras were 
generated using these mice as donors into WT-C57BL/6 (CD45.2) mice. After 5 weeks, the 
bone-marrow transplanted mice were given intratracheal bleomycin 0.25U. 10 days post-
bleomycin treatment, half of the mice were given 10μg/kg diphtheria toxin in PBS intratracheally 
to deplete the bone-marrow derived DTR expressing cells that were recruited to the lungs. This 
dose was repeated twice. Lungs were harvested from these mice on day 21 post-bleomycin 
treatment. Three lungs from each group was collagenase digested to generate single cell 
suspension of leukocytes. Cells were stained with a pan-CD45APCCD45.2PERCPCy5.5, 
collagen-I- PE to assess the percentages of donor derived vs host fibrocytes. (C) Remaining 
lungs were homogenized and collagen content was assessed by hydroxyproline assay. 
For the flow cytometry analyses, from left to right. Cells were gated on pan CD45APC+, 
then from the CD45 + we looked for CD45.2PERCPCy5.5, then 2
nd
  row is CD45.2 negative 
cells (Donor) that are pan CD45APC+ and Col I PE +(Fibrocytes). 3rd row is CD45.2+ 
cells(Host) that are pan CD45APC+ and Col I PE (Fibrocytes)  
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Chapter 5: 
Targeting inhibitor of apoptosis proteins protects from bleomycin-induced lung fibrosis 
 
Background 
 
Pulmonary fibrosis is characterized by the accumulation of extracellular matrix resulting 
in decreased lung compliance and impairment of gas exchange (6).  Fibrosis can be triggered by 
various known insults (e.g., infection, allergens, toxins, or radiation), or can occur for unknown 
reasons as in the case of idiopathic pulmonary fibrosis (IPF) (348).  IPF is a progressive disease 
with a high mortality rate and a prevalence that is increasing globally (1, 17). The pathogenesis 
of IPF remains unclear but a commonly held paradigm attributes this pathology to continuous 
cycles of injury to the alveolar epithelium coupled with a dysregulated repair response. 
Prominent features of this dysregulated repair include fibroblast differentiation, myofibroblast 
accumulation and excessive collagen deposition in the alveolar space (137, 386, 387).  
Regardless of the initial insult, the persistence of myofibroblasts is aided by their acquisition of 
an apoptosis-resistant phenotype (229, 308, 410-413). 
Cell susceptibility to apoptotic stimuli is regulated, in part, by the presence of proteins 
that can block the propagation and execution of pro-apoptotic signals (414).  One example is the 
inhibitor of apoptosis protein (IAP) family which is composed of eight proteins: XIAP (X-linked 
IAP), cIAP-1 (cellular IAP1), cIAP-2, LM-IAP (melanoma IAP)/Livin, ILP2 (ILAPlike protein-
2), NAIP (neuronal apoptosis-inhibitory protein), Bruce/Apollon and survivin (415). Each IAP 
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family member contains at least one baculovirus IAP repeat (BIR) domain which allows these 
proteins to bind caspases and, in some cases, prevent apoptosis by directly blocking caspase 
activation (415-417). The most studied IAP, XIAP, is well known to inhibit the intrinsic and 
extrinsic apoptotic pathways through both direct mechanisms (blocking activation of caspases 3, 
7 and 9) and indirect mechanisms involving its RING domain (418-424).  cIAP-1 and cIAP-2 
contain a similar domain structure to XIAP. While these cIAPs do not directly inhibit caspase 
activation, they can impair apoptosis through alternative mechanisms (e.g. by promoting NFkB-
induced activation of anti-apoptotic proteins) and they have been shown to function 
cooperatively with XIAP (419, 425-427).   The anti-apoptotic function of XIAP and the two 
cIAPs can be blocked by second mitochondria-derived activator of caspases (Smac) / direct IAP-
binding protein with low PI ( DIABLO), an IAP-binding protein released from mitochondria 
during apoptosis (428). 
Recent reports indicate that XIAP is important in the pathogenesis of IPF.  For example, 
XIAP is highly expressed within fibroblastic foci in IPF lungs (229).  Also, fibroblasts from IPF 
lung tissue are apoptosis-resistant and show increased XIAP expression (308).  Both TGF-β1 and 
another profibrotic mediator, endothelin (ET)-1, induce XIAP protein expression in normal 
human fibroblasts while knockdown of XIAP sensitizes lung fibroblasts to Fas-mediated 
apoptosis (308).   XIAP also plays a role in TGFβ-mediated signaling that is distinct from its 
direct anti-apoptotic functions (429).   Consistent with a pro-fibrotic role for XIAP, treatment of 
lung mesenchymal cells with the anti-fibrotic lipid mediator prostaglandin E2 suppresses XIAP 
expression and enhances Fas-mediated apoptosis (229).  Although much less is known about the 
role of cIAPs in lung fibrosis, based on their structural overlap with XIAP we speculate that 
these proteins may also influence fibroblast apoptosis resistance. We hypothesized that XIAP, 
 113 
and potentially the cIAPs, are critical to the pathogenesis of lung fibrosis.  To address this 
hypothesis, we employed a murine model of lung fibrosis and antagonized the IAPs with AT-406 
(an orally active mimetic of Smac/DIABLO with activity against XIAP, cIAP1 and cIAP2) and 
specifically disrupted XIAP via gene deletion (345).  
Results 
 
Murine mesenchymal cells had a significant increase in XIAP, cIAP-1 and cIAP-2 mRNA after 
treatment with TGFβ1 
 
TGFβ1, the central profibrotic mediator in pulmonary fibrosis, induces an apoptosis 
resistant phenotype in mesenchymal cells and significantly increases XIAP expression in normal 
human lung fibroblasts (308). To assess whether TGFβ1 also up-regulateed IAP expression in 
murine mesenchymal cells, fibroblasts and fibrocytes were isolated from naïve mouse lungs and 
treated with TGFβ1 (2 ng/mL) in serum-free media.  RNA was then isolated for real-time RT-
PCR analysis. We observed that both fibroblasts and fibrocytes had significantly increased levels 
of XIAP, cIAP-1 and cIAP-2 mRNA in response to TGFβ1 stimulation (Figure 32). 
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Figure 32: TGFβ treatment increased the expression of XIAP and cIAPs in fibroblasts and 
fibrocytes.  
Fibroblasts and fibrocytes from wild-type mice were treated with TGFβ (2ng/mL) for 48 hours.  
Total RNA was isolated and by real time RT-PCR we measured the expression of XIAP, cIAP-1 
and cIAP-2 and β-actin in fibroblasts (A-C) and fibrocytes (B-D). Data represent cells collected 
from n=3 mice total from 2 different experiments. ***p<0.001,**p<0.01 and *p<0.05. 
 
Functional inhibition of IAPs with AT-406 protected wild type mice from bleomycin-induced 
lung fibrosis  
 
To examine the role of IAPs on lung fibrosis in vivo, an orally bioavailable IAP 
antagonist AT-406 (100 mg/kg by oral gavage) or vehicle control was administered from days 0-
6 (for assessment of inflammation) or 0-20 (for assessment of fibrosis) to wild-type mice treated 
with intratracheal PBS or bleomycin on day 0. AT-406 significantly decreased remodeling of 
lung architecture and fibrosis as determined on day 21 by hydroxyproline quantification (Figure 
33A) and histology, including analysis of Picrosirius Red stained sections to elucidate collagen 
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deposition in the lungs (Figure 33B).   To determine whether AT-406 treatment impacted the 
recruitment of inflammatory cells, we determined the number and composition of the 
inflammatory cell infiltrate at day 7 post-bleomycin.  Figure 26C demonstrates that the total 
inflammatory cell number was not different with AT-406 treatment.  The differential analysis 
showed modest reductions in the percentage of monocyte/macrophages and small increases in 
lymphocytes and neutrophils (Figure 33D).  Taken together, these data demonstrated that 
inhibition of XIAP together with cIAP1 and cIAP2 limited the development of fibrosis following 
bleomycin-induced injury without major effects on inflammation. 
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Figure 33: Blockade of IAPs with AT-406 inhibited lung collagen accumulation on day 21 
post-bleomycin treatment and decreases lung levels of CCL12.  
(A) Wild type mice were given 1.15 U/Kg of bleomycin or PBS intratracheally on day 0. AT-406 
(100 mg/kg by oral gavage) was administered daily through day 20 to half of the mice and 
vehicle control (PBS) was administered to the other half. Lungs were harvested on day 21 for 
hydroxyproline quantification. (B) Histochemical staining showing representative lungs of mice 
treated with vehicle control (PBS), bleomycin or bleomycin with AT-406. Shown are 
hematoxylin and eosin (H&E) and Picrosirius Red (PS). Magnification is via the 4x, 10x and 20x 
objectives from left to right. (C) On day 7, lungs were harvested, digested and total lung 
leukocytes were enumerated. (D) Differential analysis of leukocytes was done to determine the 
percentage of monocytes/macrophages, lymphocytes, neutrophils, and eosinophils. Data shown 
represents mean ± SEM, n=3 animals/group, ns=not significant. (E) Leukocytes were plated at 
3x106 cells/mL in serum free media overnight. Cell-free supernatants were analyzed by ELISA 
for IL1β, (F) CCL12, (G) TNF-α and (H) IFNγ. Data shown are pooled from two independent 
experiments, with n = 4-6 mice per group in each experiment.  ****p<0.0001, **p < 0.01, *p< 
0.05, ns=not significant.  
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AT-406 treatment diminishes CCL12 and IFNγ 
 
 To determine the impact of AT-406 treatment on lung cytokine levels, lung homogenates 
collected on day 7 were analyzed for the expression of IL-1β, TNFα, CCL12 and IFNγ.  Figures 
26E-H demonstrates that AT-406-treated mice showed significant inhibition of both CCL12 and 
IFNγ, but no alteration in IL-1β.  There was a trend towards reduction of TNFα. 
Delayed administration of AT-406 has therapeutic benefit 
 
 To determine whether inhibition of IAP proteins could have an anti-fibrotic effect during 
the post-inflammatory phase of bleomycin-induced fibrosis, we next administered AT-406 using 
a treatment protocol. Wild type mice were given bleomycin or PBS on day 0, daily treatments 
with AT-406 (or vehicle) were given from days 10-20 and lungs were harvested for analysis on 
day 21.  Supporting an anti-fibrotic effect that is independent of the early inflammatory phase, 
the therapeutic dosing regimen of AT-406 maintained efficacy with reductions in lung collagen 
to similar levels as observed with the preventive strategy as indicated by hydroxyproline 
quantification (Figure 34A), histology and Picrosirius Red staining (Figure 34B). 
 118 
 
Figure 34: Therapeutic administration of AT-406 limits lung fibrosis. 
(A) Wild type mice were given 1.15 U/Kg of bleomycin or PBS intratracheally on day 0. Half of 
each group received 100 mg of AT-406 (100 mg/kg) by oral gavage daily starting on Day 10 
through day 20 and lungs were harvested on day 21 for hydroxyproline quantification. (B) 
Histochemical staining showing representative lungs of mice treated with intratracheal PBS and 
vehicle control (PBS), intratracheal bleomycin and AT-406, intratracheal bleomycin and vehicle 
control or intratracheal bleomycin and AT-406. Shown are hematoxylin and eosin (H&E) and 
Picrosirius Red staining. Magnification is via the 20x objective. Data shown represents mean ± 
SEM, represent n=4-6 mice/group, ns,=not significant. ****p<0.0001 and *p<0.05. 
 
Therapeutic administration of AT-406 enhanced mesenchymal cell apoptosis in vivo 
 
To determine whether therapeutic AT-406 treatment enhanced apoptosis in vivo, AT-406 
was administered beginning on day 11 post-bleomycin and apoptosis was assessed on day 13. 
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First, the total level of caspase 3/7 activity was measured in lung homogenates.  AT-406 
treatment showed a trend towards increasing caspase activity in the lung compared to the activity 
measured in lungs from mice treated with bleomycin and vehicle control (Figure 35A). To 
assess apoptosis within the myofibroblast population (α-SMA expressing mesenchymal cells), 
lung sections were co-stained with α-SMA and TUNEL (Figures 35B-H).   Enumeration of 
apoptotic myofibroblasts in stained sections revealed significantly increased myofibroblast 
apoptosis in the bleomycin-injured AT-406-treated mice (Figure 35B). 
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Figure 35: AT-406 augmented myofibroblast apoptosis in vivo after bleomycin injury. 
Wild type mice were given 1.15 U/Kg of bleomycin or PBS intratracheally on day 0. On days 11, 
12 and 13 half of each group was administered AT-406 (100 mg/kg via oral gavage) and the 
lungs were harvested on day 13. (A) Whole lung homogenates were assessed for activation of 
caspase 3/7. p < 0.01for Bleo/AT-406 compared to controls. (B-H). Lung sections were co-
stained for TUNEL (C and F) and α-smooth muscle actin (SMA; D and G). Cells that were 
positive for both TUNEL and α-SMA were quantified using merged images (E and H) in four 
random 20x objective fields by an investigator who was blinded to the treatment groups. This 
quantification (B) demonstrated significantly more co-positive cells in bleomycin/AT-406 lung 
sections compared to bleomycin/PBS lung sections. p=0.01. Co-stained cells in representative 
merged images (E and H) are indicated by arrows 
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Genetic deficiency of XIAP did not protect against bleomycin-induced lung fibrosis 
 
To specifically assess the role of XIAP in lung fibrogenesis, wild-type (XIAP
+/+
) and 
XIAP
-/y
 mice were given intratracheal PBS or bleomycin on day 0. On day 7, lungs were 
collected and XIAP expression was assessed from cultured lung mesenchymal cells. These 
results demonstrated the upregulation of XIAP in mesenchymal cells from the lungs of wild-type 
mice following intratracheal bleomycin (Figure 36A). As expected, mesenchymal cells from the 
lungs of XIAP
-/y
 mice had undetectable levels of XIAP (data not shown).  The remaining lungs 
were harvested on day 21 and lung collagen content was measured by hydroxyproline assay in 
XIAP
+/+
 and XIAP
-/y
 mice treated with PBS or bleomycin.  As expected, bleomycin-treated wild 
type mice showed a significant increase in collagen content when compared to PBS controls.  
However, in contrast to the results with AT-406 treatment, bleomycin-treated XIAP
-/y 
mice 
showed similar levels of lung collagen as the bleomycin-treated wild-type mice (Figure 36B). 
Representative histology also showed similar levels of remodeling and cellular infiltration 
between the two strains (Figure 36C).  XIAP deficiency had no significant effect on total 
inflammatory cell recruitment (Figure 36D) or inflammatory cell composition (Figure 36E) at 
day 7 following bleomycin. 
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Figure 36: XIAP deficient mice were not protected from bleomycin-induced pulmonary 
fibrosis and show elevated levels of IL-1β.  
Wild-type littermate (XIAP+/+) or XIAP-/y mice were given bleomycin or PBS intratracheally on 
day 0. Lungs were harvested on day 7. Lung minces were then digested in collagenase and total 
lung leukocytes were enumerated and lung mesenchymal cells were cultured. (A) XIAP mRNA 
expression was assessed in cultured lung mesenchymal cells by RT-PCR. (B) On day 21 lungs 
were harvested for hydroxyproline quantification. (C). Representative hematoxylin and eosin 
staining from day 21.  Magnification is through the 10x (top) and 20X (bottom) objectives. 
Representative of n=4 mice examined. (D) Total lung leukocytes from day 7 lung minces were 
enumerated. (E) Differential analysis was done to determine the percentage of 
monocytes/macrophages, lymphocytes, neutrophils, and eosinophils. Data shown represent n = 
6–10 mice per group pooled from 3 independent experiments. Cells were plated at 3X10
6
 
cells/ml in serum free media overnight and cell free supernatants were analyzed by ELISA for 
IL1β (F), TNFα (G), CCL12 (H), and IFNγ (I). Data shown represents mean ± SEM, represent 
n=4-6 mice/group, ns, not significant. ****p<0.0001, ***p<0.001   
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XIAP
-/y 
mice expressed more IL-1β post-bleomycin treatment 
 
 In contrast to the changes observed in wild-type mice treated with AT-406, the XIAP
-/y
 
mice had no significant changes in TNFα, CCL12 or IFNγ. The XIAP-/y mice did show enhanced 
production of IL-1β (Figure 36F-I).  However, this increase in IL-1β did not seem to impact the 
levels of fibrosis when compared to wild-type mice. 
XIAP
-/y
 mesenchymal cells are resistant to Fas-mediated apoptosis 
 
Because mesenchymal cell accumulation is a critical feature of lung fibrosis, we next 
sought to determine how the loss of XIAP impacted mesenchymal cell apoptosis.  Lung 
mesenchymal cells (a mixture of both fibroblasts and fibrocytes) from wild-type and XIAP
-/y 
mice were treated with a Fas-activating antibody and apoptosis was assessed over time as 
indicated by caspase 3/7-mediated cleavage of a fluorogenic substrate.  In contrast to our 
findings in normal human lung fibroblasts in which XIAP was silenced with siRNA (308), we 
observed that murine lung mesenchymal cells congenitally lacking XIAP had increased 
resistance to Fas-mediated apoptosis when compared to wild-type cells (Figure 37A).  This 
finding suggested that alternative anti-apoptotic mechanisms might provide functional 
compensation for the genetic deficiency in XIAP
-/y
 mice, and offered a potential explanation for 
why these mice remained susceptible to bleomycin-induced fibrosis. 
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cIAPs expression was increased in XIAP gene-targeted mice 
 
Initial characterization of the XIAP
-/y 
mice demonstrated that the expression of cIAP-1 
and 2 proteins was increased, suggesting that in the congenital absence of XIAP, there exists a 
mechanism by which the increased production of other IAP family members may contribute to 
functional compensation (338).  The expression of cIAP-1 and 2 in lung homogenates and in 
lung mesenchymal cells cultured from XIAP
+/+
 and XIAP
-/y
 mice treated with bleomycin were 
analyzed by qRT-PCR. In the lung homogenates, levels of cIAP-1 were significantly elevated 
following intratracheal bleomycin in wild type and XIAP deficient mice and cIAP-2 showed a 
non-statistically significant increase in XIAP
-/y
 mice (Figure 37B and C).  In isolated 
mesenchymal cells from untreated mice however, the opposite result was seen with basal levels 
of cIAP-1 being unchanged (Figure 37D) while cIAP-2 mRNA expression was significantly 
increased in XIAP
-/y 
cells when compared to wild type (Figure 37E). These data support the 
possibility of a functional compensation at baseline by cIAPs in the XIAP
-/y
 mice.    
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Figure 37: XIAP
-/y
 mesenchymal cells have increased cIAP expression associated with 
decreased susceptibility to Fas-mediated apoptosis and inhibition of cIAPs enhanced their 
apoptosis.  
(A) Lung fibroblasts from wild type and XIAP-/y mice were treated with/without Fas-activating 
antibody (250 ng/mL) along with CellplayerTM kinetic caspase 3/7 reagent. Plates were loaded 
into the IncuCyte incubator and photographed every 2 hours for 24 hours. Apoptosis was 
quantified by automated counting “objects per well” (object = green fluorescence indicating 
cleavage of a fluorogenic substrate by caspase 3/7). (B-C) Total RNA was isolated from 
fibroblasts cultured form the lungs of XIAP+/+ and XIAP-/y mice treated with/without bleomycin 
and expression of cIAP-1, cIAP-2 and β-actin was measured by real time RT-PCR. Data 
represent n=3 per group pooled from multiple mice. *P<0.01. (D-E) RNA isolated from lung 
homogenates of untreated XIAP+/+ and XIAP-/y mice were assessed for cIAP-1 and cIAP-2. Data 
represent n=3 per group pooled from multiple mice. *P<0.01. (F) Lung fibroblasts from XIAP-
/y
 were treated with/without Fas-activating antibody (250 ng/mL) and/or AT-406 (1.0 µM). 
Apoptosis was evaluated as described above with n=3 wells/group.  * p < 0.05 vs. control and 
AT-406, p < 0.01 vs. Fas treatment.  Data are representative of mean ±SEM, n=3 wells/treatment 
per group, with 9 images per well at each time point. 
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AT-406 sensitized XIAP
-/y
 mesenchymal cells to Fas-mediated apoptosis 
 
 To determine if increased cIAP expression  provided functional compensation for the 
deficiency of XIAP in lung mesenchymal cells, we determined whether inhibition of cIAP-1 and 
cIAP-2 would restore sensitivity to Fas-induced apoptosis in XIAP
-/y
 mesenchymal cells.  XIAP
-
/y 
cells were treated with the IAP antagonist, AT-406, and susceptibility to Fas-mediated 
apoptosis was assessed over 24 hours.  Supporting the hypothesis of functional compensation by 
cIAPs, inhibition of cIAP-1 and cIAP-2 with AT-406 enhanced the apoptotic sensitivity of the 
XIAP-deficient mesenchymal cells (Figure 37F).  Of note, treatment of XIAP deficient 
mesenchymal cells with AT-406 alone did not increase apoptosis in the absence of Fas-activation, 
suggesting that the increased apoptosis was not a non-specific effect of the compound. 
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AT-406 treatment limited fibrosis in XIAP
-/y
 mice 
 
 To verify that AT-406 treatment could reduce bleomycin-induced fibrosis in vivo, XIAP
-
/y
 mice or XIAP
+/+
 mice were treated with intratracheal PBS or bleomycin and AT-406 or vehicle 
control beginning on day 0.  There was an unexpected early toxicity of AT-406 treatment that 
was observed during the acute inflammatory phase of the model (between days 4-7) in the cohort 
of XIAP
-/y
 mice that had received intratracheal bleomycin. This effect was observed in multiple 
experiments and reduced the n value for these experiments.  However, in the mice that did 
survive the inflammatory phase of the model, there was a trend towards reduced levels of 
collagen accumulation in the lungs as measured by hydroxyproline assay (Figure 38A). Analysis 
of accumulated inflammatory cells and cytokines at day 7 showed no changes other than 
increased neutrophils in the XIAP
-/y
 mice that received bleomycin which was accentuated in the 
XIAP
-/y
 mice that received the bleomycin and AT-406, suggesting that toxicity in this group 
might be related to alterations in the acute response to injury (Figures 38B-E).  In addition, AT-
406 treatment was associated with a trend for decreased elaboration of IL-1β and CCL12 from 
leukocytes isolated from the XIAP deficient mice on day 7 after bleomycin (Figures 38F and G). 
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Figure 38: AT-406 decreased bleomycin-induced lung fibrosis in XIAP
-/y
 mice.  
(A-I) XIAP+/+ or XIAP-/y mice were given bleomycin or PBS intratracheally on day 0. Lungs 
were harvested and assessed for inflammation on day 7 and fibrosis on day 21 as described in 
Figure 5. (A) Hydroxyproline quantification at day 21. Data shown represents mean ± SEM.  n = 
7-11 mice/group. ns, not significant. ****p<0.0001, ***p<0.001, * p<0.05. (B-E) Leukocyte 
differentials in lung collagenase digest on day 7. n = 3 lungs per group. * p<0.05. (F-G) 
Cytokines in cell-free supernatants from day 7 leukocytes.  
 
Discussion 
 
Previous studies have shown that fibroblastic foci, but not the epithelial cells in IPF 
tissues, express high levels of XIAP (229, 430), that PGE2 suppresses XIAP expression while 
increasing fibroblast susceptibility to apoptosis, that the pro-fibrotic mediators TGFβ1 and ET-1 
increase XIAP expression in normal fibroblasts and that XIAP (but not cIAP-1 or cIAP-2) 
expression is increased in lung fibroblasts from patients with IPF (229, 308). Together, these 
studies suggested XIAP might contribute to the accumulation of myofibroblasts and extracellular 
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matrix in IPF and that targeting XIAP could represent a therapeutic approach for lung fibrosis.  
Testing this hypothesis in a murine model of experimental lung fibrosis using pharmacologic and 
genetic approaches led to discordant findings in vivo, and our subsequent studies suggested other 
IAP family members (i.e. the cIAPs) may contribute to mesenchymal cell apoptosis resistance 
and fibrogenesis. 
Consistent with our findings in human lung fibroblasts, we found that the profibrotic 
mediator, TGFβ1, enhanced expression of XIAP in murine mesenchymal cells. Importantly, 
TGFβ1 also increased the expression of cIAPs (cIAP-1 and cIAP-2) in these cells.  Similarly, 
bleomycin treatment upregulated both XIAP and cIAP-l.  Treatment of mice with the IAP 
antagonist, AT-406 substantially decreased lung fibrosis in vivo, establishing a causal role for 
the IAPs in lung fibrogenesis.  In contrast to the broad inhibition of the IAPs with AT-406, the 
specific targeting of XIAP by transgenic deletion did not protect against bleomycin-induced 
fibrosis.  Assessment of early inflammatory responses to bleomycin-treated mice showed no 
differences in total inflammatory cell recruitment in the mice treated with AT-406 or in XIAP
-/y
 
mice compared to wild-type mice treated with bleomycin. Differential cell counts showed no 
difference between inflammatory cell populations in wild-type and XIAP-deficient mice which 
were not protected from fibrosis; in contrast, mice receiving AT-406 did have a small, but 
statistically significant decrease in the monocyte/macrophage population coupled with increases 
in the lymphocyte and neutrophil populations.  Thus, it seems unlikely that the protection from 
fibrosis seen by AT-406 administration is due to decreased lung injury and inflammation. In fact, 
we were surprised to find that AT-406 treatment in the XIAP
-/y
 mice actually showed some 
toxicity and enhanced neutrophil recruitment. 
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When analyzing the cytokine profiles of XIAP
-/y 
or AT-406-treated mice, the XIAP
-/y
 
mice showed increases in IL-1β, but this did not alter levels of lung fibrosis.  In contrast, the AT-
406 treated mice had equivalent levels of IL-1β, but did show reduced expression of CCL12, 
IFNγ and, a trend for decreased TNFα.  Certainly CCL12 has been shown to promote fibrotic 
responses in the lung by mediating fibrocyte recruitment (94), so reduced levels of CCL12 may 
limit fibrocyte accumulation. Similarly, the CCL12 receptor CCR2 has been shown to be critical 
for the recruitment of exudate macrophages to the lung, and decreased recruitment of exudate 
macrophages was associated with decreased fibrosis in a model of targeted type II alveolar 
epithelial injury (395). The impact of IFNγ on lung fibrogenesis is controversial, and clinical 
trials have failed to demonstrate a significant therapeutic benefit for IFNγ as a treatment for IPF 
(431, 432).  However, as these clinical trials were predicated on the multitude of anti-fibrotic 
actions of IFNγ in pre-clinical models, it seems unlikely that the decline in IFNγ observed with 
AT-406 treatment accounted for the decreased fibrosis observed in our experiments. Thus, while 
acknowledging that differences in the accumulation of monocyte/macrophages and fibrocytes, or 
decreased levels of CCL12 or IFNγ might contribute to the discordant fibrotic outcomes in these 
two approaches, we went on to investigate the apoptotic susceptibility of murine lung 
mesenchymal cells.  
Studies increasingly support the hypothesis that impaired apoptosis contributes to 
myofibroblast accumulation in lung fibrosis (55, 229, 308, 412, 413, 433, 434).  Consistent with 
the initial characterization of XIAP deficient mice (338), our investigation revealed that 
mesenchymal cells from the XIAP-deficient mice did not demonstrate increased susceptibility to 
Fas-mediated apoptosis. Indeed, the cells lacking XIAP actually had a significant decrease in 
apoptotic susceptibility.  Because XIAP
-/y 
mesenchymal cells maintained expression of cIAP-1 
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and displayed enhanced expression of cIAP-2, we interpreted these results to suggest that 
alternative anti-apoptotic mechanisms, including the increase in cIAP protein expression, might 
provide a functional compensation for the genetic loss of XIAP.  Consistent with this hypothesis, 
treatment of XIAP
-/y
 mesenchymal cells with AT-406 restored the anticipated apoptotic 
susceptibility to XIAP
-/y
 cells in vitro, and treatment of the bleomycin-treated mice with AT-406 
increased myofibroblast apoptosis in vivo.  Because resistance to apoptosis contributes to the 
persistence of myofibroblasts, we speculate that the different outcomes to bleomycin-induced 
lung injury are related to the differential apoptotic susceptibility of mesenchymal cells in these 
different genetic and pharmacologic models.  If true, it is encouraging that AT-406 was able to 
limit fibrosis following bleomcyin challenge.  IAP antagonist compounds are already being 
tested in clinical trials as cancer therapeutics (418, 435-439), such therapies could potentially be 
adopted quickly in IPF. 
The fact that AT-406 exerted beneficial effects that were not mirrored by XIAP 
deficiency, and the fact that cIAP proteins do not antagonize caspase activation (420, 440, 441), 
raises the question of how the cIAP proteins may be functioning to promote bleomycin-induced 
fibrosis.  Certainly, this family of proteins functions through a variety of mechanisms involving 
TGFβ signaling, NFκB activation, and E3 ligase activity (427, 429, 442).  cIAP1 and -2 have 
been shown to be important in TNF-α mediated NFkB activation (443); however, we did not 
observe a significant difference in TNFα in vivo. Thus, it is likely that cIAP-1 and cIAP-2 
contribute to the anti-apoptotic phenotype via induction of other anti-apoptotic proteins or via 
modulation of cell signaling pathways yet to be determined.  Importantly, AT-406 acts to 
promote degradation of cIAP-1 and cIAP-2, raising additional mechanistic possibilities for the 
anti-fibrotic actions of this approach (444-446).   
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XIAP is expressed in the fibroblastic foci of IPF tissues and is increased in IPF 
fibroblasts, but cIAP-1 and cIAP-2 are not increased in IPF fibroblasts (229, 308).  This suggests 
that in human IPF fibroblasts, there may be less compensation than is occurring in XIAP
-/y 
mice 
or that cIAP protein function is sufficient at levels present in IPF cells.  The potential for cIAPs 
to compensate for the post-natal loss or inhibition of XIAP in adults has yet to be explored. 
Regardless, it is encouraging that AT-406 has previously been shown to restore apoptotic 
sensitivity of IPF fibroblasts to Fas-mediated apoptosis (308) and that our murine studies show 
benefit of AT-406 when given therapeutically during the fibroproliferative phase of the disease. 
 
. 
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Chapter 6: 
Six-SOMAmer index relating to immune, protease and angiogenic functions predicts 
progression in IPF 
 
Background 
 
Clinical, radiographic and pathologic features differentiate idiopathic interstitial 
pneumonias.  However, the most common and deadly diagnosis is idiopathic pulmonary fibrosis 
(IPF).  IPF is diagnosed using clinical and laboratory features corroborated by characteristic 
high-resolution computed tomography (CT) or by presence of usual interstitial pneumonia 
histopathology on lung biopsy (447).  Natural course of IPF can vary significantly with some 
patients experiencing relative stability, while others experience more rapid disease progression 
(448).  Well-validated biomarkers from peripheral blood could have tremendous impact if they 
differentiate diagnosis of IPF from other more-treatable forms of interstitial lung disease or if 
they provide accurate prognostic information.   
 IPF biomarkers have been identified using approaches like transcriptomic profiling, 
microbiome analyses and candidate biomarker analyses in blood and lung (134, 374, 449, 450).  
These data along with findings that IPF patients treated with the immunosuppressive prednisone, 
azathioprine and N-acetylcysteine (451) do worse; have led to speculation that occult immune 
insults may drive some IPF progression.  This is underscored by studies showing progressive 
disease in IPF associated with overall bacterial burden and certain classes of organisms (134, 
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374).  Such biomarker analyses have provided potential insight into pathogenic mechanisms for 
IPF progression. 
Studies have explored angiogenesis in fibrosis with mixed results.  Some IPF studies 
showed elevations in angiogenesis inhibitors (452) or reduced angiogenic factors (453, 454).  
Another study reports mixed phenotypes measuring higher levels of both angiogenic and 
angiostatic factors (455).  These variations suggest angiogenesis is important for both 
pathogenesis and repair.  Regarding protease imbalances, alterations in metalloproteases are 
common (456), but proteasomal processing is also implicated in fibrotic lungs (457). 
The slow-off rate-modified aptamer (SOMAmer) SOMAscan panel (337)-based proteomics 
platform measures 1129 analytes with increased sensitivity for low-abundance biomarkers. 
Using this assay proteins are measured using a modified aptamer reagent and measured 
quantitatively in relative fluorescence units (RFU’S) on a custom Agilent hybridization chip. 
Using this unbiased approach, we analyzed plasma from 60 IPF patients enrolled in the 
observational study, COMET (Correlating Outcome Measures to Estimate Time to progression in 
IPF.   Biomarkers were correlated with measures of disease progression and identified a six-
SOMAmer index that predicted IPF progression.  
Results 
 
Patient demographics were similar in progressor and non-progressor groups 
 
Sixty IPF patients enrolled in COMET with longitudinal plasma samples collected at 
weeks 0, 48 and 80 were selected for analysis.  Within this cohort, 35 (58%) met criteria for 
disease progression at some time over 80 weeks follow-up while 25 (42%) did not.  There were 
no statistical differences in age, gender, and smoking history or baseline lung physiology 
between patients when categorized by progressor status (Table 2). 
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Table 2: IPF Patient Characteristics for N=60 COMET patients by 80-week Progression 
Status; Continuous Variables Reported as Mean (Standard Deviation), Categorical Variables 
Reported as N (%) 
 All (N=60) Progressor (N=35) Non-progressor (N=25) P-value 
Age in Years  64.6 (7.7) 65.2 (8.3) 63.7 (6.9) 0.48 
Male 41 (68.3) 22 (62.9) 19(76.0) 0.28 
Smoker 
  Never 
  Past 
  Current 
 
19 (31.7) 
40 (66.7) 
1 (1.7) 
 
12 (34.3) 
23 (65.7) 
0 
 
7 (28.00) 
17 (68.00) 
1 (4.00) 
0.58* 
0.61** 
0.85** 
0.42** 
FVC, % pred  70.0 (16.2) 71.2 (16.3) 68.2 (16.3) 0.50 
DLCO, %pred  46.1 (13.1) 46.9 (12.9) 44.8 (13.8) 0.56 
 
*Overall Chi-square comparison; **Comparisons of corresponding category vs others. 
 
Nine analytes predicted progression in IPF 
 
Out of 1129 biomarkers analyzed, only 9 biomarkers satisfied criteria for estimated AUC 
> 0.7 from ROC analysis of the biomarker as a binary variable (above versus below its 
threshold); these were carbonic anhydrase 13, Cath-S, FCN2, GRN, ICOS, LGMN, nascent 
polypeptide-associated complex subunit alpha (NACA), TRY3 and VEGFsR2.  Univariate ROC 
analysis for these 9 biomarkers is shown in Table 3, along with odds ratios (ORs) for 
progression for those above versus below their biomarker thresholds.   Above threshold values of 
VEGFsR2, LGMN, FCN2, Cath-S and GRN were associated with lack of progression during 
follow-up (OR < 1.0, p < 0.05), and above threshold values for ICOS, TRY3, carbonic anhydrase 
13 and NACA were associated with progression during follow-up (OR > 1.0, p< 0.05) in both 
adjusted and unadjusted analyses.  
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Table 3: Biomarker Threshold Values in RFU, Corresponding Sensitivity and Specificity 
for Predicting 80-week Progression Status and Univariate Odds Ratios (Unadjusted and 
Adjusted) for Progression When Above Versus Below the Threshold.   
 
Thresholds were chosen to maximize sensitivity plus specificity in separate ROC curve analyses.  
Odds ratios greater than 1.0 indicate higher risk of progression when above threshold; Odds 
ratios less than 1.0 indicate lower risk of progression when above threshold.  Nine biomarkers 
met screening criteria of (1) AUC > 0.7, (2) unadjusted and adjusted P-values <0.05. 
*Adjusted logistic models were adjusted by age, gender, smoking status, baseline FVC % 
predicted and DLCO % predicted. 
**Abbreviations: AUC=Area under the ROC curve based on biomarker threshold variable binary 
threshold version of biomarkers; OR: Odds ratio; VEGFsR2= soluble vascular endothelial 
growth factor receptor-2; LGMN=legumain; FCN2=ficolin 2; ICOS= inducible T cell 
costimulator; TRY3=trypsin 3; GRN=granulin; NACA= nascent polypeptide-associated complex 
subunit alpha. 
 
Determining analytes for scoring index 
 
The top 4 biomarkers used to predict progression in 2 complementary multivariable 
model paradigms are shown in Tables 4A-B, where biomarkers in Table 3A were selected using 
multivariable logistic regression model for 80-week progression status and biomarkers in Table 
Table 2) Biomarker Threshold Values in RFU, Corresponding Sensitivity and Specificity for Predicting 80-week 
Progression Status and Univariate Odds Ratios (Unadjusted and Adjusted) for Progression When Above Versus Below the 
Threshold.  
Biomarker Better 
Prognosis
Threshold 
Sensitivity Specificity AUC OR 95% CI P OR 95% CI P 
 (RFU)    (Unadjusted) (Adjusted*) 
VEGF sR2 >9559.30 0.71 0.80 0.74 0.11 0.03-0.39 0.001 0.07 0.01-0.33 0.001 
LGMN >5173.33 0.54 0.96 0.74 0.04 0.005-0.32 0.003 0.04 0.00-0.38 0.005 
FCN2 >2015.33 0.74 0.72 0.73 0.13 0.04-0.43 0.001 0.12 0.03-0.50 0.003 
Cathepsin S >1451.44 0.54 0.88 0.71 0.11 0.03-0.46 0.002 0.08 0.02-0.46 0.004 
ICOS <8031.61 0.77 0.64 0.71 6.00 1.93-18.68 0.002 13.5 2.88-62.88 0.001 
TRY3 <928.22 0.77 0.64 0.71 6.00 1.93-18.68 0.002 6.1 1.65-22.82 0.007 
Carbonic_an-
hydrase_XIII <8738.54 0.69 0.76 0.72 6.91 2.16-22.10 0.001 5.9 1.64-20.98 0.007 
GRN >32046.22 0.69 0.72 0.70 0.18 0.06-0.55 0.003 0.11 0.03-0.50 0.004 
NACA <17976.83 0.69 0.72 0.70 5.61 1.82-17.33 0.003 7.5 1.57-35.88 0.012 
Thresholds were chosen to maximize sensitivity plus specificity in separate ROC curve analyses.  Odds ratios greater than 1.0 
indicate higher risk of progression when above threshold; Odds ratios less than 1.0 indicate lower risk of progression when above 
threshold.  Nine biomarkers met screening criteria of (1) AUC > 0.7, (2) unadjusted and adjusted P-values <0.05. 
*Adjusted logistic models were adjusted by age, gend r, smoking status, baseline FVC % predicted and DLCO % predicted. 
**Abbreviations: AUC=Area under the ROC curve based on biomarker threshold variable binary threshold version of biomarkers; 
OR: Odds ratio; VEGFsR2= soluble vascular endothelial growth factor receptor-2; LGMN=legumain; FCN2=ficolin 2; ICOS= 
inducible T cell costimulator; TRY3=trypsin 3; GRN=granulin; NACA= nascent polypeptide-associated complex subunit alpha. 
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3B were selected using a multivariable Cox proportional hazards model for time to progression 
over the 80-week follow-up.  Logistic regression model identified the 4 best binary biomarkers 
as FCN2, VEGFsR2, Cath-S and TRY3.  Cox proportional hazard regression model also placed 
FCN2 and TRY3 in its model along with ICOS and LGMN.  Of the 6 unique biomarkers selected 
from the two multivariable progression model paradigms, values above identified thresholds 
were associated with lack of progression during the 80-week follow-up period in 4 cases (FCN2, 
VEGFsR2, Cath-S, LGMN) and progression in 2 cases (ICOS and TRY3).   
 
Table 4A: Best logistic regression model based on 4 binary biomarkers 
 Odds ratio 95% CI P 
FCN2 0.03 0.002-0.47 0.012 
VEGF sR2 0.02 0.001-0.30 0.005 
Cathepsin S 0.003 0.000-0.16 0.005 
TRY3 50.10 2.93-857.24 0.007 
 
 
Table 4B: Best Cox proportional hazard regression model based on 4 binary biomarkers 
 Hazard ratio 95% CI P 
LGMN 0.27 0.13-0.56 0.0003 
FCN2 0.49 0.22-1.08 0.076 
ICOS 2.32 1.02-5.24 0.044 
TRY3 2.32 1.03-5.20 0.042 
 
6-analytes created a weighted scoring index to predict IPF progression  
 
All 6 binary biomarkers identified for the scoring index had different time-to-progression 
profiles for the 80-week follow-up, suggesting different weights should be used for each in 
predicting progression within the index. Kaplan-Meier curves in Figure 39 display progression-
free survival for those above (black dashes) and below (red dashes) their corresponding threshold 
values.  ICOS, LGMN, FCN2 and TRY3 progression-free profiles diverged quickly following 
 138 
baseline threshold measurements, while differences in progression-free survival diverged later, 
after 40-weeks of follow-up, for those above and below Cath-S or VEGFsR2 thresholds at 
baseline.   Figure 40 shows progression-free survival curves for 3 biomarkers not selected for 
use in the index. 
 
Figure 39: Kaplan-Meier curves showing progression free survival for IPF patients related 
to markers of immune activation or angiogenesis.  
ICOS stands for inducible T cell co-stimulator, VEGF sR2 stands for soluble vascular 
endothelial growth factor receptor 2, TRY3 is trypsin 3 and LGMN is legumain 
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Figure 40: Kaplan-Meier curves showing progression free survival for IPF patients with 
baseline biomarker levels above or below the identified thresholds. 
Thresholds for analytes (A)Carbonic Anhydrase XIII, (B) Granulin(GRN) and (C) Nascent 
polypeptide-associated complex subunit alpha (NACA). 
 
Weighted index scores were created based on AUC.  Kaplan-Meier estimates for each 
biomarker were generated individually to calculate the restricted mean survival (AUC) by 571 
follow-up days, which was the minimum number of follow-up days for which we had data in 
different groups (Table 5).  Based on differences between AUC for each biomarker, a score was 
created to provide weight to each biomarker consistent with its AUC, and determined 
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assignments on the basis of the OR direction.  Therefore, the lowest AUC differences (Cath-S at 
58 days and VEGFsR2 at 69 days) were assigned a value of 1.  AUC differences for the next 
three biomarkers (ICOS, TRY3 and FCN2) were approximately 2-fold that of Cath-S and 
VEGFsR2, so those biomarkers were given a score of 2.   
Finally LGMN AUC difference was approximately 3-fold Cath-S and VEGFsR2, so that 
biomarker was given a score of 3 in the index.  For each patient a composite score was generated 
(scale of 0 to 11) based on whether their baseline values for the 6 biomarkers were above or 
below the identified thresholds.  Table 6A shows distribution of scores for progressors vs. non-
progressors.  Table 6B shows distribution of scores assigned to 3 unique groups.  Group level 1 
included scores 0-2.  Group level 2 consisted of scores 3-6.  Group level 3 contained scores 7-11.   
Analyzing the ROC curve for this model, we determined this scoring index has an AUC=0.91 
(Figure 41).  A score 3 on this index had 56% specificity and 97% sensitivity for predicting 
progression-free survival in IPF while a score of 7 had 66% sensitivity and 100% specificity for 
predicting progression-free survival in IPF.   
Figure 42 shows Kaplan-Meier curves for this scoring index by groups 1, 2 and 3. After 
adjusting for age, gender, smoking status, baseline FVC percent predicted and baseline DLCO 
percent predicted, Group 2 [scores 3-6] and Group 3 [scores 7-11] have 9.7 and 32.3 times the 
hazard of Group 1 [scores 0-2] (95% CI for Groups 2 vs 1: 1.2, 76.9;  p= 0.03; 95% CI for 
Groups 3 vs 1: 4.2, 250;  p= 0.0008).  A group level   2 [index score  3] had an adjusted 
hazard 18.7 times higher than group 1, (95% CI 2.5 -140.7), P=0.005.  Bootstrap distribution of 
area between Kaplan Meier curves for groups 2 and 3 compared to 1 is shown in Figure 37.   
There is an estimated 131 days (18.7 weeks) lived longer during the 590 days (84.3 weeks) of 
follow-up comparing Group1 to Group2 (95% CI: 48-215 days, P=0.002) and an estimated 246 
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days (35.1 weeks) lived longer during 589 days (84.1 weeks) of follow-up comparing Group1 to 
Group3 (95% CI: 168-325 days, P<0.001).  Bootstrap distribution of ROC curve shown in 
Figure 43, with our cohort’s observed ROC overlaid, is displayed in Figure 44. These results 
demonstrate the index performed well in these random sampling analyses. 
Table 5: Restricted mean survival (AUC) using Kaplan-Meier estimates for each 
biomarker individually over 571 days of follow up utilized to generate a standardized score.  
Biomarker Marker 
prognosis good 
Marker 
prognosis bad 
Difference Score 
LGMN 481 296 185 3 
FCN2 495 363 132 2 
TRY3 501 370 131 2 
ICOS 493 376 117 2 
VEGF sR2 456 387 69 1 
Cathepsin S 444 386 58 1 
 
 
Table 6A: Distribution of scores for patients meeting the definition for progressor or non-
progressor 
Frequency 
Row Pct 
Col Pct 
Score 
0 1 2 3 4 5 6 7 8 9 10 11 Total 
Non-progressor 5 
20 
100 
2 
8 
100 
7 
28 
87.5 
4 
16 
66.7 
4 
16 
80 
1 
4 
25 
2 
8 
28.6 
0 
 
0 
 
0 
 
0 
 
0 
 
25 
 
 
Progressor 0 
 
0 
 
1 
2.9 
12.5 
2 
5.7 
33.3 
1 
2.9 
20 
3 
8.6 
75 
5 
14.3 
71.4 
5 
14.3 
100 
7 
20 
100 
3 
8.6 
100. 
6 
17.1 
100 
2 
5.7 
100 
35 
 
 
Total 5 2 8 6 5 4 7 5 7 3 6 2 60 
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Table 6B: Distribution of group scores among progressors and non-progressors 
 
 
 
 
 
 
 
 
 
 
 
 
Frequency 
Row Pct 
Col Pct 
Score group 
1 2 3 
Total [0,2] [3,6] [7,11] 
Non-
progressor 
14 
56 
93.3 
11 
44 
50 
0 
 
25 
 
 
Progressor 1 
2.9 
6.7 
11 
31.4 
50 
23 
65.7 
100 
35 
 
 
Total 15 22 23 60 
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Figure 41: Receiver operating characteristic (ROC) curve using two prognostic index 
thresholds (corresponding to groups shown in Figure 42.   
Higher areas under the curve indicate better overall classification, where AUC = 0.5 indicates a 
useless classification tool and AUC=1.0 indicates a perfect classification tool. Our prognostic 
index score AUC = 0.91 indicates an extremely useful prognostic index score. 
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Figure 42: Kaplan-Meier curve showing progression free survival for patients according to 
the different groups in our weighted index score.   
In unadjusted analyses, A group level increasing by 1 using this index has a hazard ratio=4.02, 
(95%CI 2.28-7.10), P<0.0001 for predicting IPF progression by univariate Cox regression model.  
In adjusted analyses, a group level increasing by 1 using this index has a hazard ratio=4.27, 
(95%CI 2.30-7.96), P<0.0001 for predicting IPF progression by Cox regression model after 
being adjusted by age, gender, smoking status, baseline FVC percent predicted and baseline 
DLCO percent predicted 
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Figure 43: Sampling distribution of the number of progression-free weeks that group level 
1 lived longer than group levels 2 and 3 over 80 follow-up weeks.  
(Calculated via bootstrap methodology.) Our cohort estimates are superimposed in red. 
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Figure 44: Bootstrapped distribution of receiver operating characteristic (ROC) curves, 
with observed curve from our cohort superimposed in red. 
 
Discussion 
 
Blood-based biomarker analysis could be useful if it provides prognostic information for 
IPF patients.  IPF natural history can vary considerably with some patients experiencing relative 
disease stability, while others experience rapid progression (448).  While there are two FDA-
approved drugs available to treat IPF (pirfenidone and nintedanib), costs of these medications are 
prohibitive for many, and benefit is limited to slowing disease progression over an ~6 month 
time frame in patients with mild to moderate functional impairment (458, 459).  Thus, the ability 
 147 
to accurately predict patients who are likely to progress could help focus treatment to patients at 
highest risk for functional decline.  
Biomarkers may also determine aberrant signaling pathways associated with disease 
progression.  Interestingly, some of our predictive analytes are associated with processes already 
known to be aberrant in IPF, namely immune dysfunction, angiogenesis and proteolysis.  
Accumulating evidence suggests IPF is characterized by immunologic alteration, with studies 
showing either activated leukocytes or impaired immunologic responses.  Peripheral blood gene 
expression analysis demonstrated IPF patients are characterized by activated leukocyte 
phenotypes (333).  Similarly, CD4 T cells in IPF patients have activated phenotypes 
characterized by lower levels of CD28(53), but elevated levels of MHC class II , CD154 and 
oligoclonal Vβ gene expression (174).  Additionally, CXCR3+ CD8 cells which represent 
activated cytotoxic T cells also correlate with progression in IPF when found in increased 
percentages in peripheral blood (460).   A correlation between increased percentages of CD14hi, 
CD16hi monocytes in circulation and IPF progression in COMET IPF patients was previously 
shown (460) and these cells corresponded to intermediate monocytes(461).  Thus, it is interesting 
that 3 of the SOMAmer analytes identified have known roles in immunologic functions namely, 
ICOS, FCN-2 and Cath-S. 
ICOS is a CD28-superfamily costimulatory molecule upregulated on CD4+ T cells 
following antigenic stimulation.  This molecule intensifies CD28 signaling during established 
immune responses and induces T cell effector functions (462). ICOS may also regulate lung 
mucosal inflammatory responses (463).  In bleomycin-induced lung and skin fibrosis, ICOS-
deficiency attenuated fibrosis (464).  Conversely, in IPF peripheral blood mononuclear cells 
(PBMCs), decreased expression of ICOS, CD28 and lymphocyte-specific protein tyrosine kinase 
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(LCK) led to more severe IPF (333).  In our studies, elevated levels of ICOS measured in plasma 
correlated with worse IPF.  While seemingly contradictory, these human measurements were 
made in different compartments.  We tested if ICOS is shed from T cells after activation.  Figure 
45 demonstrates activation of murine T cells releaseed ICOS into supernatant, suggesting 
elevated ICOS in circulation could indicate leukocyte activation.  Certainly there is evidence for 
shedding of ICOS ligand induced by ICOS itself (465).  Thus, we hypothesize ICOS is released 
either by shedding or via exosomes upon cellular activation, and this may explain why lower 
levels of ICOS mRNA in PBMCs (333), but higher levels of ICOS in plasma could both be 
associated with IPF progression. 
 
Figure 45: ICOS is shed by activated T cells.   
A million CD4 positive splenocytes were stimulated with CD3 + CD28(T cell markers) then 
(TGFβ, 2ng/mL+ IL-6, 20ng/mL cytokines) or TH1 (IFNγ, 10ng/mL) for 24 hr. Cell free 
supernatants were collected and concentrated using Amicon Ultra Centrifugal filters (Millipore, 
Billerica, MA). Equal amounts of protein from each sample were separated on a 4-20% gradient 
SDS-polyacrylamide gel and transferred to a PVDF membrane (Amersham/GE Healthcare, 
Pittsburgh, PA). PVDF membrane was probed with rabbit monoclonal ICOS (Abcam). 
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Another factor believed to contribute to IPF pathogenesis is the presence of pathogens, 
both viral and bacterial.  Studies in both IPF patients and animal models have shown viral 
infections, particularly herpesviral infections may promote fibrogenesis [reviewed in (351)]; 
however, bacterial burden may also predict worse outcomes (134, 374).  FCN-2 reductions 
correlate with IPF progression.  Human L-Ficolin (FCN 2) is synthesized in liver and secreted 
into the bloodstream where it’s a major pattern recognition receptor (466). FCN2 can opsonize 
several species of bacteria, in a manner similar to mannose-binding lectin (MBL) (467). FCN2 
and MBL activate the lectin complement pathway and studies have linked this pathway to 
fibrotic organ manifestations in Scleroderma, including ILD (468).  Furthermore, FCN2-
deficiency may predispose patients to development of bronchiectasis (469).  Common variable 
immunodeficiency (CVID) patients with bronchiectasis also demonstrate low levels of FCN2 
(470).  FCN2 binds to S.pneumoniae activating the lectin pathway of complement (471) and 
mice lacking ficolin-A, the murine homolog of FCN2 showed increased mortality in a model of S. 
pneumoniae pneumonia (472, 473).  It is particularly noteworthy that microbiome analyses also 
conducted in COMET IPF patients suggest Streptococcus species are overabundant in 
progressive IPF patients (374).  Lower levels of FCN2 may contribute to overabundance of these 
bacterial species, which may, in-turn promote disease pathogenesis.  S. pneumoniae promotes 
fibrogenesis through pneumolysin-mediated destruction of lung epithelial cells in animal models 
(474), suggesting a mechanism whereby bacterial burden may promote lung injury and fibrosis.  
Cath-S is a single chain, non-glycosylated cysteine protease ubiquitously distributed in 
the lysosome. It is expressed mainly in lymphatic tissues and is characterized as a key enzyme in 
class II-mediated antigen presentation (475). LGMN is a cysteine peptidase existing in a number 
of mammalian tissues, such as kidney, placenta, spleen, liver and testis. Interestingly, LGMN 
 150 
acts as a primary regulator of cysteine cathepsins (476). Our study identified an association 
between high circulating levels of both proteases and improved progression free survival in IPF, 
suggesting impaired endo-lysosomal function may directly promote disease progression. Or, the 
lower levels of Cath -S in circulation could indicate IPF patients have defective antigen 
presentation or aberrant cell survival pathways.  Cath -S also promotes tumor cell invasion, 
metastasis and angiogenesis once secreted into the extracellular milieu it causes degradation of 
extracellular matrix proteins including laminin, fibronectin, elastin, and some collagens (477-
479).  Thus, it’s not surprising that Cath -S levels are reduced in progressive IPF patients. 
Additionally, LGMN was identified as a diagnostic and prognostic liver fibrosis biomarker (480).  
Our study is the first to correlate lower levels of LGMN with poor outcomes in IPF, and we 
speculate LGMN may be important for degrading provisional matrix following injury. 
TRY3/mesotrypsin is a serine protease, encoded by the PRSS3 gene. Mesotrypsin/PRSS3 
is overexpressed in human primary pancreatic cancer tissues and is associated with metastasis 
and poor prognosis of pancreatic (481), prostate, and non-small cell lung cancer (482, 483). 
Alternative splicing produces four isoforms of human trypsinogen protein.   How TRY3 
influences IPF is unknown. 
VEGF is a potent and specific endothelial cell mitogen that regulates blood and 
lymphatic vessel development and homeostasis. The VEGF receptor family consists of three 
members, VEGFR1 (FLT1), VEGFR2 (KDR/FLK1) and VEGFR3 (FLT4) (484). Among these, 
VEGFR1 binds strongly to VEGF, VEGFR2 binds more weakly, and VEGFR3 shows essentially 
no binding, although it does bind to other members of the VEGF family.  Soluble forms 
(VEGFsR1 and VEGsFR2) have been studied as potential biomarkers for a number of diseases 
but most of the data available is about VEGFsR1, not VEGFsR2 (485-487).  VEGFsR2 was first 
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reported as a truncated 160KDa protein detected both in mouse and human plasma (488). An 
inverse correlation between the levels of VEGFsR2 and increasing tumor size has been observed 
(489).  The SOMAmer reagent was selected against VEGFsR2 and our analysis indicates lower 
levels of this protein correlated with disease progression.  It is unknown how circulating 
VEGFsR2 may correlate with endothelial cell activation or protective vs. pathologic 
angiogenesis in IPF, but we speculate lower levels of circulating VEGFsR2 would predict less 
ability to inhibit VEGF actions, potentially enhancing angiogenesis associated with disease 
progression. 
Our study was the first to analyze IPF patients using SOMAmers, and a limitation is 
small sample size and the lack of a validation cohort.  Given the expense of Somascan validation,  
sensitivity and specificity of the index was addressed using a bootstrap analysis.  The index 
performed well across all 100 different bootstrap analyses performed (Fig. E4) implying the 
index should perform well in other patient cohorts.  Future studies are needed to determine 
whether smaller analyte panels could be cost-effective or if ELISA measurements for these 
markers show similar or divergent results.  Periostin levels were measured in the same patient 
samples using an ELISA developed by Abbott Pharmaceuticals.  There was a good correlation 
between measures made by SOMAmer and ELISA for this biomarker with a Spearman 
correlation of r=0.44, p<0.0001 (Figure. 46). 
Together, our results demonstrated a 6-analyte SOMAmer panel measuring circulating 
markers of immune function; proteolysis and angiogenesis could be used to create a simple index 
with excellent sensitivity and specificity for predicting progression-free survival in IPF.  Use of 
this index on easily-accessible plasma should be further validated to offer a simple way of 
predicting IPF patient outcomes. 
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Figure 46: Periostin levels in IPF patients correlate by SOMAscan and ELISA.   
The same plasma samples were run on a periostin ELISA developed by Abbot Pharmaceuticals 
and were compared to measures of periostin made by SOMAmer.  The correlation was 
significant, Spearman r=0.44; p<0.0001.
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Chapter 7: 
Conclusions 
 
Viral and Bacterial Exacerbation Studies 
 
 Previous work from our lab illustrated that either short term or long term γ-herpesvirus 
latency in the lung could significantly enhance the response to fibrotic challenge. It was 
demonstrated that latent HV-68 infection could augment a subsequent fibrotic challenge and 
that the worsened fibrosis was not associated with substantial reactivation of the lytic phase of 
the virus (346). Based on these observations we wanted to further expand our studies to examine 
whether the exacerbation of established fibrosis was only limited to γ-herpesvirus or whether 
other pathogens could also have a similar effect.  
 It was shown that HV-68 exacerbated bleomycin-induced fibrosis and stimulated 
collagen deposition. Once lung fibrosis was established, infection with Influenza (H1N1), CMV 
or the Gram-negative bacterium, P. aeruginosa did not exacerbate fibrosis at the doses tested. 
HV-68 augmented established fibrosis as previously published, and the use of the ORF-72 
mutant virus did not, further demonstrating that the ability of HV-68 to exacerbate bleomycin-
induced fibrosis and enhance collagen deposition required the ability of HV-68 to undergo 
reactivation from latency. 
 In addition, there was a cell-specific increase in susceptibility to TGF signaling post-
HV-68 infection with no observed difference in the active or total TGF in the lungs of 
bleomycin-treated mice infected with H1N1 or HV-68. Interestingly, herpesviruses have 
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received the most attention as either a causal or exacerbating agent of IPF [reviewed in 
(490)],but it was assumed that other agents which may be able to damage lung epithelium could 
have similar effects. Thus, it was very surprising that we did not see similar results in the 
infection studies with HV-68 and H1N1 infection after established fibrosis, since both viruses 
can infect epithelial cells. These results seem to suggest that the critical feature for the ability to 
exacerbate fibrosis by a pathogen is the ability to maintain replication and or sensitize AECs to 
the induction of apoptosis, a feature that was only seen following HV-68 infection in our studies.  
H1N1 infection can activate TGF signaling and increase apoptosis in AECs, yet in our model it 
caused no change in collagen deposition. Potentially, this could reflect dose differences or the 
intense pathogenicity of H1N1 in mice.  A 1000-fold lower dose of H1N1 was given to the mice 
to keep them alive long enough to analyze fibrotic outcomes.  When higher doses of H1N1 were 
given, the mice died of acute lung injury.  Extrapolating to humans, this would obviously be a 
severe exacerbation, but it is likely that patients (and rodents) in this case die of lung injury 
before the fibrotic response can be manifested (perhaps in an attempt to provide lung repair).  
Why murine CMV did not exacerbate may reflect the propensity of this virus to migrate to the 
CNS rather than establish robust infection in the respiratory tract. 
When put in the context of our other studies in this dissertation, it is interesting to speculate that 
HV-68 infection leads to epithelial cell apoptosis, recruitment of periostin-expressing fibrocytes 
and that fibrosis may propagate due to the paracrine effects of these cells on the resident 
fibroblasts. 
Fibrocyte and Periostin Studies 
 
Our laboratory and others have reported increased circulating levels of periostin in 
patients with IPF (258, 402). In our study high levels of periostin in plasma at diagnosis 
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predicted disease progression as defined by a relative change of 10% FVC, a 15% drop in DLCO, 
acute exacerbation, lung transplant or death in a 48 week follow-up (122).  In addition, 
circulating fibrocytes cultured from the peripheral blood of IPF patients expressed higher mRNA 
levels of periostin compared to normal volunteers (122). In our BM-chimera studies we showed 
that periostin production by both structural and hematopoietic cell types was critical for 
development of bleomycin-induced fibrosis (122). These observations propelled our studies to 
determine the contribution of fibrocytes and fibrocyte-derived periostin in the development of 
lung fibrosis. Our first thought was to generate a mouse where we could conditionally deplete 
fibrocytes. We generated a collagenIa2-Cre-DTR mouse (CD45.1), and used these mice as bone 
marrow donors into WT (CD45.2) mice to localize the transgene for deletion to just the 
circulating mesenchymal cells (i.e. fibrocytes) as opposed to using the full-body deletion which 
would also target resident and structural fibroblasts throughout the body. After full 
hematopoietic reconstitution mice were treated with bleomycin and then given diphtheria toxin 
via oropharyngeal aspiration. On day 21 we assessed the percentage of fibrocytes by comparing 
CD45.1 and CD45.2 positive cells; despite great reconstitution we were not successful at 
depleting fibrocytes regardless of whether we gave DT systemically or locally. The depletion of 
fibrocytes using our Col1a2-Cre-ROSA-DTR mice as donors was not very successful as there 
was an increase in recipient fibrocytes over time. The host continued to regenerate new 
fibrocytes while we were depleting donor-derived cells. These results may indicate that there is 
either a lung-resident stem cell that can regenerate circulating fibrocytes in addition to a bone 
marrow-derived stem cell or that there was a radio-resistant host-derived population that could 
be stimulated to proliferate following lung injury. 
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The role of fibrocytes in exacerbating bleomycin-induced fibrosis was further explored 
by performing adoptive transfer experiments with WT and periostin
-/- 
fibrocytes. It was shown 
that both WT and periostin
-/-
 fibrocytes are capable of effectively migrating to the lungs after 
transfer, as we saw no difference in the mRNA expression of the chemokine receptors CCR2 and 
CXCR4, suggesting no defect in trafficking of fibrocytes in the absence of periostin. 
Additionally, fibrocytes recruited to the lungs both in the presence and absence of periostin did 
not differentiate into other cell types as they maintained their CD45 expression over time. Thus, 
these studies showed that the ability of fibrocytes to augment bleomycin-induced fibrosis was 
through paracrine function.  Our studies corroborate another in vivo study suggesting that 
fibrocytes do not differentiate into myofibroblasts in the lung during fibrogenesis (401).  This is 
an important contribution to the literature in this field as the dominantly held belief in the lung 
fibrosis community has been that fibrocytes contribute to fibrogenesis via direct differentiation 
into myofibroblasts.  Further support for this view comes from work from Dr. Kim’s laboratory 
here at the University of Michigan showing that the ability of fibrocytes to produce collagen is 
irrelevant to the development of fibrosis, (200) again suggesting that paracrine functions other 
than collagen secretion and myofibroblast differentiation are critical. 
Using PCR array analysis, we assayed for the differences in gene expression in 
bleomycin-treated fibrocytes from WT and periostin
-/-
 mice. The data demonstrated that 
fibrocytes from perisotin
-/- 
mice had a significant decrease in mRNA expression of LOX and 
CTGF but no difference in PDGF mRNA expression. Conditioned medium collected from 
bleomycin-treated fibrocytes and added back to WT untreated fibroblasts caused an increase in 
SMA protein expression in fibroblasts that received supernatant from WT bleomycin-treated 
cells. Using ELISA we measured higher amounts of CTGF in the condition medium from WT 
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bleomycin-treated fibrocytes. Furthermore, using a MRTF inhibitor to block expression of CTGF 
in the WT untreated fibroblasts also resulted in less SMA production by fibroblasts after 
addition of conditioned medium.  This was the first data to demonstrate that production of one 
matricellular protein (periostin) could influence the production of other matricellular proteins 
like CTGF in circulating fibrocytes.  Given that fibrocytes are just one source of periostin in the 
lung, it is perhaps surprising that deletion of periostin just from hematopoietic sources or 
deletion of periostin from just the adoptively transferred fibrocytes could have such a large 
impact on fibrosis.  We speculate that this is likely because the fibrocytes have the ability via 
their chemokine receptors to migrate to the exact sites of tissue injury.  In this way, they may be 
uniquely positioned to deliver the paracrine signals to the injured epithelium and underlying 
mesenchymal cells. 
Targeting Inhibitor of Apoptosis Studies 
 
Work from Ajayi et al. showed that fibroblasts isolated from IPF patients express 
increased levels of the anti-apoptotic protein XIAP. To determine whether this anti-apoptotic 
protein is responsive to periostin stimulation, we treated normal lung murine mesenchymal cells 
with periostin and measured induction of XIAP by western blot. These results suggested that 
periostin may be partially responsible for changes in lung fibroblasts causing them to be resistant 
to apoptosis during the course of fibrogenesis. To further characterize the role of IAPs in 
promoting lung fibrosis, we assessed the effects of TGF on increasing the mRNA expression of 
IAPs (XIAP, cIAP1 and -2) and saw significant increases in the expression of these genes. 
Additionally, the  inhibition of IAPs using a bioavailable IAP anatgonist, AT-406, limited 
bleomycin-induced lung fibrosis but had no effect on inflammation. Therapeutic administration 
of AT-406, at day 10 after the initiation of lung fibrosis caused a decrease in the fibrotic outcome 
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by day 21 suggesting that AT-406 displayed anti-fibrotic effects independently of the early phase 
inflammation. This indicated that the beneficial effects occurred during the stage of disease 
associated with fibroblast accumulation.  It was also demonstrated that within 48hrs after in vivo 
AT-406 treatment, there was an increase in caspase-3 activity, in isolated murine lung 
mesenchymal cells. Taken together, these results indicate that IAPs play a role in the 
pathogenesis of lung fibrosis and that loss of one IAP, XIAP, was not sufficient to attenuate 
bleomycin-induced lung fibrosis. However, broad functional inhibition of IAPs may be an 
effective strategy for treatment of lung fibrosis by promoting mesenchymal cell apoptosis. 
Our overall results for these projects demonstrated that γ-herpesvirus but not H1N1, 
CMV or P. aeruginosa couls exacerbate bleomycin-induced fibrosis via effects on AECs and 
likely via induction of chemokines to recruit fibrocytes. In turn, the paracrine activity of 
fibrocytes was dependent on periostin and had direct effects on resident mesenchymal cells.   
Perisotin can upregulate anti-apoptotic genes such as XIAP in fibroblasts and through the 
upregulation of other profibrotic mediators such as CTGF can promote the differentiation of 
myofibroblasts and ultimately enhance the fibrotic response. The anti-apoptotic effects of XIAP 
can be inhibited through treatment with a bioavailable IAP antagonist AT-406. This drug had no 
effect on inflammation but caused changes in the fibroproliferative phase attenuating bleomycin-
induced lung fibrosis (Figure 47). 
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Figure 47: A model of how virus and recruited fibrocytes promote fibrosis. 
Damage to the lung epithelial cells by bleomycin or viral infection leads to production of 
cytokines/chemokines and profibrotic mediators such as TGFβ, periostin and CTGF. The 
profibrotic mediators cause fibroblast proliferation;  periostin causes upregulation of XIAP. 
XIAP expression in myofibroblasts leads the accumulation of apoptosis-resistant myofibroblasts 
leading to accumulation of ECM proteins and fibrosis. Therapeutic administration of AT-406 
(SMAC mimetic) blocks XIAP leading the attenuation of fibrosis. 
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IPF Biomarker Studies 
 
 Biomarkers in accessible compartments like peripheral blood that can predict disease 
progression in idiopathic pulmonary fibrosis (IPF) would be clinically useful regarding clinical 
trial participation or treatment decisions. For these studies we screened for biomarkers in the 
plasma of IPF patients.  Plasma from IPF patients was measured using an 1129 analyte slow off-
rate modified aptamer (SOMAmer) array and patient outcomes were followed over the next 80 
weeks. The ability of each continuous biomarker to predict IPF progression over an 80 week 
period was assessed. ROC curves were constructed and a biomarker threshold was chosen to 
maximize the combined sensitivity and specificity. An estimated AUC of 0.7 from the ROC 
analysis was chosen for further consideration of each biomarker. To further screen the biomarker 
threshold values, adjusted and unadjusted odds ratios were generated through logistic regression 
adjusting for age, gender, smoking status, baseline percent predicted FVC and baseline predicted 
DLCO.  To be considered for the IPF progression index, biomarker threshold variables had to 
maintain a statistical significance of 0.05 levels in both the adjusted and unadjusted analyses. 
In order to ensure independent prognostic ability of the biomarkers both multivariable 
logistic and COX regression models were investigated. Using a multivariable logistic regression 
predicting 80-week progression status and a multivariable COX proportional hazard regression 
predicting time to progression over the 80-week follow-up period, we identified six unique 
biomarkers with p values less than 0.05 for predicting either 80 week progression status or time 
to progression. Overall these biomarkers corresponded to changes in immune response, 
angiogenesis or protease activity. Using Kaplan-Meier estimates of progression-free survival for 
those above and below their threshold we showed that legumain, FCN2, VEGFsR2 and cathepsin 
S below threshold and ICOS and TRY3 above threshold predicted IPF progression over a 80 
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week follow-up.  In light of our murine data suggesting that infection can exacerbate fibrosis, 
and that recruitment of fibrocytes via the vasculature are important events to exacerbate fibrosis, 
we were gratified to find that the functional categories that these biomarkers represent seem to fit 
well with what we understand about the pathogenesis of lung fibrosis using our animal models. 
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Chapter 8: 
Final Thoughts and Future Directions 
 
In summary, we constructed a mouse model to further our understanding about some 
essential players in bleomycin-induced lung fibrosis. Our results demonstrate that only a DNA 
virus that can establish latency can augment established fibrosis. We speculate that the model 
could be explored further to better understand the specific cell types that are critical for the virus-
induced augmentation of lung fibrosis. Additionally, since this is a “two hit model”, we would 
like to explore the effects of infection with H1N1 or other pathogens before bleomycin treatment.  
We are interested in investigating if the damage induced by bleomycin before the viral infection 
caused defects in toll-like receptor (TLR) signaling. TLRs detect pathogens such as bacteria and 
viruses.  TLR3 is located in endosomal membrane compartments and recognizes dsRNA, an 
intermediate product from replicating RNA viruses such as Influenza (491).  The synthetic 
double stranded RNA (dsRNA) analog poly (I:C) has been shown to activate RhoA in small 
airway epithelial cells (492), suggesting a possibility  that influenza might be able to activate 
TGFβ through TLR3. We speculate that this might lead to downstream activation of an integrins 
that may be interacting with TGFβ but we have not explored these experiments yet. Also, it 
would be very interesting to isolate different cell types from bleomycin-treated H1N1 compared 
to HV-68 infected mice to understand the Th1 and Th2 cytokines in these microenvironments.  
Another potential reason why the H1N1 infections did not exacerbate bleomycin-induced 
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fibrosis may be that the bleomycin-injured epithelium was just too damaged to support robust 
H1N1 replication.  This is another reason why studying the response in the reverse order of 
exposure could be interesting.  As mentioned before, H1N1 infection at higher doses lead to 
animal death due to acute lung injury.  This is also a clinically relevant problem and future 
studies could attempt to understand exactly how H1N1 and γHV-68 differ in their induction of 
acute lung injury and could attempt to find therapeutic targets.  This could also improve 
outcomes for patients who develop influenza infections often with precipitous declines in lung 
function. 
Our description of the role of fibrocyte and fibrocyte-derived periostin in promoting lung 
fibrosis suggests that fibrocytes in the presence of periostin secrete other profibrotic mediators 
leading to increased myofibroblast differentiation as shown by the increase in SMA production. 
We also showed that TGF and periostin were coregulating each other and that perisotin binds to 
different integrins on fibrocytes compared to fibroblasts. 
It will be very interesting to test whether CTGF and periostin were coregulating each 
other in fibrocytes or if they can function independent of each other. Loss of periostin did not 
totally abolish the secretion of CTGF from the fibrocytes suggesting a necessary role for CTGF 
and the possibility that other mediators such as TGF could be contributing to the production of 
CTGF. Performing experiments with CTGF knockdown to see if it inhibits persiotin-dependent 
effects on fibrocytes or if knockdown of CTGF affects the ability of fibrocyte supernatant to 
induce myofibroblast differentiation are now warranted.   Furthermore, we could explore the 
impact of CTGF on proliferation in lung mesenchymal cells (fibroblasts and fibrocytes). Since 
beta 1 integrin is shown to be important for persiotin to interact with fibrocytes we want to 
identify the site on periostin that is binding to this integrin. These experiments can be performed 
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through the development of domain specific periostin mutants. Knowledge of this site would be 
an initial step towards developing specific drugs that block periostin during lung disease, while 
potentially preserving beneficial functions of periostin in other contexts (like prevention of 
myocardial infarction).  
Integrins are known to regulate collagen expression, usually by modulating members of 
the TGF1 signaling pathway. In our data we showed that blocking beta 1 integrin decreased 
collagen I mRNA expression in fibrocytes after treatment with periostin. One pathway linking 
activation of collagen expression involves increased activity of Rac1 (a small Rho GTPase) and 
ERK (493). Activation of ERK appears to be a common pathway for non-canonical expression 
of collagen 1. Fibrocytes would be treated with periostin with or without beta1 integrin blocking 
antibody then assessed for the presence of ERK phosphorylation by western blot. To determine 
the role of Rac, cell free supernatants will be collected from fibrocytes treated as mentioned 
above and Rac1 activity will be measured with a commercially available ELISA kit. We also 
know that there is a small molecule available that inhibits alphaVbeta1 function (301), and it 
would be interesting to assess the importance of alphaVbeta1 in fibrocyte function in vivo. In 
collaboration with Dean Sheppard’s group at University of California at San Francisco, we will 
incubate WT fibrocytes with this small molecule then adoptively transfer these cells into WT 
mice after bleomycin treatment to demonstrate an in vivo role for fibrocytes interacting with 
periostin to enhance the fibrotic response. Another formal possibility is that many alpha integrin 
partners may be able to interact with beta 1 to promote periostin effects on fibrocytes.  This 
would be best explored in the future through siRNA knock-downs of particular integrin chains. 
Several studies have documented a role for microRNAs in fibroblast biology [reviewed in 
(494)]. Conditioned medium from WT bleomycin-treated fibrocytes led to an increase in SMA 
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production by fibroblasts; some of which is accounted for by the presence of CTGF and periostin 
in these supernatants. However, the differential signaling of periostin in fibrocytes compared to 
fibroblasts suggests that microRNAs might be playing a role in the ability of fibrocytes to 
exacerbate lung fibrosis. MicroRNAs are small single stranded ribonucleic acids functioning as 
posttranscriptional regulators of gene expression (495). Many studies have characterized these 
small molecules as important regulators of cell proliferation and tissue repair, tissue development 
and differentiation (496, 497).  A number of microRNAs have been shown to be upregulated in 
IPF [(reviewed in (494)]. We would like to examine the microRNA profiling in fibrocytes from 
WT and periostin
-/-
 bleomycin-treated mice. Once different microRNAs have been identified we 
will perform studies directed at how these microRNAs promote the profibrotic response of 
fibrocytes to periostin.  It is also possible that the presence of periostin results in the release of 
exosomes containing different arrays of miRNA in fibrocytes from WT vs. periostin
-/- 
mice.  
Future studies could determine whether there are differential effects of fibrocyte exosomes from 
WT vs. periostin
-/-
 mice on fibroblasts. 
In the apoptosis studies we showed that loss XIAP alone was not sufficient to attenuate 
bleomycin -induced fibrosis but blockade of all IAPs with a small molecule early or late caused a 
decrease in the fibrotic outcome. Overall, these data suggest that in the absence of XIAP there is 
a compensatory effect by the other IAPs thus enhancing an anti-apoptotic response of lung 
mesenchymal cells during bleomycin-induced fibrosis. 
We did not evaluate how conditional deletion of XIAP expressing cells would affect 
bleomycin-induced fibrosis. It might be nice to create a transgenic mouse that could be induced 
to delete XIAP in the post-natal mouse.  This mouse may more faithfully recapitulate the 
phenotype of fibroblasts from IPF lung.  We would also like to investigate the role of apoptosis 
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in the exacerbation model of fibrosis by infecting XIAP conditionally- deficient mice or mice 
treated with AT-406 with HV-68, H1N1 or P. aeruginosa to assess inflammation and fibrosis. It 
is interesting that lung leukocytes isolated from XIAP deficient mice post-bleomycin treatment 
secreted higher levels of IL1 production but showed no difference in lung fibrosis. Even, 
though the role of IL1 in fibrosis is controversial, the increased production of IL1 could also 
suggest a role for inflammasomes, which we could also assess in this model.  It is likely that 
inflammasome activation could play a larger role in the pathogen-exacerbated fibrosis models 
than it does in the sterile bleomycin-injury model. 
 In the biomarker studies we used Slow Off-rate modified aptamer array to analyze 
plasma samples from 60 IPF patients. We identified 1129 analytes from these samples, 
constructed ROC curves for all candidate biomarker and chose a threshold to maximize 
sensitivity and specificity. Overall we identified a six-analyte panel that included legumain, 
FCN2, cathespin S, TRY3, VEGFsR2 and ICOS that correlated to progression of IPF. ICOS and 
TRY3 were above threshold, while legumain, Cathespin S, FCN2 and VEGFsR2 were below 
threshold. 
  To further assess the role of these proteins in lung fibrosis we would like to evaluate the 
role of legumain and FCN2 in our mouse model of bleomycin-induced fibrosis. Legumain has 
been shown to degrade fibronectin causing changes in the ECM in interstitial renal fibrosis (498). 
Legumain deficient mice showed worse fibrosis in unilateral ureteral obstruction (UUO)-induced 
renal fibrosis and significant accumulation of fibronectin (498). We would like to treat legumain 
deficient mice with bleomycin and assess inflammation and fibrosis post-bleomycin treatment. 
Additionally, we will validate our SOMAmer array data using ELISA to analyze our six analytes. 
Given that the SOMAmer array is prohibitively expensive and ELISA-based array measuring 
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these same factors could be more cost effective.  The most important future direction for our 
biomarker work in humans will be to repeat these analyses in a validation cohort of patients.  
Finally we will also assess the role of ficolin in bleomycin-induced fibrosis by instilling lung 
fibrosis in ficoln 2
-/- 
mice. FCN2 was recently shown to bind to Streptococcus, and it would be 
interesting to expand our studies to understand how different viral or bacterial pathogens affect 
the fibrotic response in ficolin 2 
-/- 
mice. 
Concluding Remarks 
 
We recognize that IPF is a multifactorial disease and that patients suffering from the 
disease may have alterations in genetic or environmental factors or both. Our mouse models have 
allowed us to investigate the potential of both environmental factors (infections) and host factors 
(periostin) that can contribute to lung fibrogenesis and have uncovered important signaling 
responses in both epithelial cells and fibroblasts.  We have also performed translational studies to 
determine whether biomarkers can be identified that provide prognostic information as well as 
insight into disease pathogenesis.  We hope that this work may help lead to new therapeutic 
interventions for patients suffering from this devastating disease. 
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